Efficacy and Safety of Continuous Infusion of Vancomycin in Critically Ill Adults: A Systematic Review

Author names

- **Katrin Viertel** (corresponding author)
  viertelk@kliniken-koeln.de
  Telephone: 0049 0221 8907 13439
  - Central Pharmacy, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Ostmerheimer Str. 200, 51109 Cologne, Germany
  - Institute of Hygiene, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Ostmerheimer Str. 200, 51109 Cologne, Germany
  - Division of Hygiene and Environmental Medicine, Department of Human Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany.
- **Elisabeth Feles**
- felese@kliniken-koeln.de
  - Central Pharmacy, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Ostmerheimer Str. 200, 51109 Cologne, Germany
  - Institute of Hygiene, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Ostmerheimer Str. 200, 51109 Cologne, Germany
  - Division of Hygiene and Environmental Medicine, Department of Human Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany.
- **Melanie Schulte**
- schulteme@kliniken-koeln.de
  - Central Pharmacy, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Ostmerheimer Str. 200, 51109 Cologne, Germany
- **Thorsten Annecke**
  annecket@kliniken-koeln.de
  - Department of Anaesthesiology and Intensive Care Medicine, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Ostmerheimer Str. 200, 51109 Cologne, Germany
- **Frauke Mattner**
  mattnerf@kliniken-koeln.de
  - Institute of Hygiene, Cologne Merheim Medical Centre, University Hospital of Witten/Herdecke, Ostmerheimer Str. 200, 51109 Cologne, Germany
  - Division of Hygiene and Environmental Medicine, Department of Human Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany.

Efficacy and Safety of Continuous Infusion of Vancomycin in Critically Ill Adults: A Systematic Review

Abstract:

Background:

Vancomycin is an antibiotic to empirically treat gram-positive infections in critically ill adults in the intensive care unit (ICU). For continuously administered vancomycin (CI), various target ranges have been used in the past, ranging from 15-20 mg/L to 30-40 mg/L.

Objectives:

To investigate the impact of steady-state serum concentration (Css) of CI on the safety and efficacy of therapy in adults in the intensive care unit: a systematic literature review.

Methods:

According to the PRISMA statement, relevant literature was identified by searching three electronic databases (MEDLINE through the PubMed interface, Cochrane Library and Google Scholar) from inception until March 2022, focussing on studies reporting measured steady-state serum concentration of vancomycin (Css) and treatment outcomes (mortality, nephrotoxicity) with CI. Due to the heterogeneity of the study designs and outcome measures, it was not possible to summarise the results in a meta-analysis. Therefore, a narrative synthesis of the evidence was performed.

Results:

Twenty-one publications were included with a total of 2,949 patients (pts) with CI. In two studies (n=388 pts) mortality rates were reported and cohorts with different Css compared. Mortality was higher with a Css <15 mg/L measured approximately 24 hours after initiation of therapy with CI (C24). An adequate loading dose appeared most important for maintaining higher C24. Acute kidney injury (AKI) in cohorts with different Css was described in four

studies (n=863 pts). In one study (n=129 pts), a mean Css throughout the duration of therapy

(Cmean) of >30 mg/L was found to predict AKI. No clear cutoff value for Css has been

identified in the other studies, but higher concentrations led to higher rates of AKI. We

calculated that a Css <25 mg/L was preferable compared to a concentration ≥25 mg/L for

reducing nephrotoxicity. Data on target attainment and Css was mentioned in eleven studies

(n=1,391 pts). We noticed higher target attainment rates in the studies if the defined target

ranges were lower and broader. No association between target attainment and effectiveness

(e.g. mortality) of therapy with CI has been observed so far. In two studies (n=101 pts) data

on clinical response was presented and compared in cohorts with different Css of which in

one study (n=40 pts) higher clinical cure was detected with a C24 >15 mg/L while in the other

study (n=61 pts), treatment success was reported at higher Cmean, with sparing out a clear

cutoff calculation.

Conclusion:

Despite sparse data availability, it seems that for continuous infusion of vancomycin the

mortality was increased if C24 was <15 mg/L, AKI may be reduced if Cmean was <25 mg/L,

clinical cure was more likely to occur at C24 >15 mg/L, while no relationship between target

attainment and efficacy has yet been established. In future research, vancomycin serum

concentration cohorts should be formed to allow evaluation of the impact of serum

concentration of CI on treatment outcomes.

Introduction

Infections in intensive care units (ICU) are highly prevalent. More than half of ICU patients

may become infected during their ICU stay [1] and between 8-22 % of infections are acquired

nosocomially. [1, 2] Infections with gram-positive pathogens regularly occur in critically ill

patients [3-5] causing one third (21-67 %) of all infections. [6] Available since the 1950s, the

glycopeptide vancomycin remains an important antibiotic for the treatment of infections with

gram-positive bacteria, particularly methicillin-resistant *Staphylococcus aureus* (MRSA),

coagulase-negative staphylococci (CoNS) and *Enterococcus faecium*. [7-11] It is also frequently

used in sepsis therapy as empirical treatment in combination with β-lactam antibiotics. [12]

Infections in the ICU lead to a substantial risk of in-hospital mortality and prolong the length

of stay. [1, 13] Current guidelines emphasize the importance of early as well as appropriate

antibiotic therapy. Especially, rapid achievement of sufficient drug concentrations at the

infection site is necessary. [14-21] Physiological changes caused by critical illness may often

lead to inappropriate drug levels. The volume of distribution (V_d) may increase due to

increased capillary permeability and endothelial dysfunction, altered regional organ blood

flow and protein binding, edema formation and vasodilatation. Impaired or renal

hyperfiltration result in a decrease or increase of renal clearance (CL). In addition, large

volume infusion therapy may escalate interstitial space. Vasopressor and extracorporal

treatments confound the CL as the V_d. [20, 22, 23] Renal insufficiency particularly affects drug

elimination and the attainment of therapeutic drug concentrations. [23] Acute kidney injury (AKI)

is common in ICU patients. 15-81 % of patients develop AKI during intensive care. [24, 25] In

addition, acute renal insufficiency worsens the outcome of the ICU stay. [26, 27] While critical

illness may lead to acute kidney failure, vancomycin itself can equally impair the renal

function by induction of an acute tubulointerstitial nephritis [28, 29] or acute tubular necrosis. [30]

The drug is predominantly excreted unchanged in the urine by glomerular filtration and the

drug's clearance is highly correlated with creatinine clearance (CrCl). [31-33] The appropriate

dosage of vancomycin in critical illness has therefore been under discussion for some time.

Vancomycin is administered via intermittent infusion (II) or continuous infusion (CI). CI

appears to hold several advantages over II. These include a lower potential risk of AKI, [34-38]

earlier or higher target attainment, [37-48] less variability in serum concentrations [39, 45, 47, 49] and

easier and less expensive monitoring of drug levels. [39, 42, 44, 47] In 2020, it was recommended

in the revised consensus guidelines on the administration of vancomycin in serious MRSA

infections to target the area under the curve over 24 hours to minimum inhibitory

concentration of the isolated strain ratio (AUC24/MIC) instead of the previously advised

trough level monitoring. [15] The trough level has been used in the past as a surrogate marker

for AUC24/MIC to facilitate dose adjustment, monitoring and management of therapy. [50] In

the current guideline update a pharmacokinetic/pharmacodynamic (PK/PD) aim of

AUC24/MIC of 400-600 for II is suggested to maintain vancomycin efficacy but reduce

nephrotoxicity compared with trough-only monitoring. [15, 51] At a MIC of 1 mg/L based on broth

microdilution methods, the proclaimed PK/PD target theoretically results in a vancomycin

steady-state serum concentration (Css) of 16.7-25 mg/L with CI. Several studies have been

published in the past with continuously administered vancomycin using different ranges for

target serum levels. These were 15-20 mg/L, [29, 44, 52-55] 15-25 mg/L, [42, 43, 45, 56-62] 20-25 mg/L,

[46, 47, 63-65] 20-30 mg/L, [33, 39, 66-75] 25-30 mg/L, [76] 20-40 mg/L [75] and 30-40 mg/L, [77] respectively.

As far as we are aware, there is a lack of a comprehensive comparative evaluation of the

influence of vancomycin serum concentration during continuous infusion of vancomycin on

therapeutic outcomes of efficacy (e.g. clinical and microbiological outcomes such as mortality

or cure) and safety (e.g. nephrotoxicity such as AKI) in critically ill adult patients. Therefore,

this review examines the current knowledge on the impact of Css on the efficacy and safety

of CI in critically ill adults in the ICU.

Materials and Methods

135 A systematic review was carried out in accordance with the PRISMA guidelines (preferred

136 reporting items for systematic review and meta-analysis). [78]

Selection Criteria

According to the PICOS questions (population, intervention, comparison, outcomes and

study design), enrollment of papers was performed as follows:

- **Population**: Adults (age ≥ 18 years) having been treated with vancomycin in an ICU.

- **Intervention**: Continuous infusion of vancomycin.

- **Comparison**: Vancomycin with or without intermittent infusion, chronic kidney injury

(CKD), renal replacement therapy (RRT), obesity or different dosing regimens.

- **Outcomes**: Vancomycin steady-state serum level (about 24 hours after the start of

therapy (C24), average serum level during the entire duration of therapy or at least

three days of therapy (Cmean), area under the serum concentration vs. time curve for

24 hours (AUC24)) and efficacy or safety. Efficacy was defined as clinical or

microbiological success (e.g. cure) or failure (e.g. mortality). Safety was defined as

occurrence of nephrotoxicity (e.g. AKI).

• **Study design**: Clinical trials and observational studies.

Studies with the following criteria were excluded: Nonhuman data, pediatric patients (age <

18 years), records without intravenous vancomycin application, records without continuous

infusion of vancomycin, non-ICU setting, lacking efficacy or safety data, omitted vancomycin

serum levels, case reports, comments, editorials, reviews and meta-analyses. In addition,

investigations with less than 30 patients with CI, studies with a duration of less than one year

and studies assessing fewer patient records than patients were included in the study were

excluded from our analysis. Exclusion based on the language of publication was not

performed.

Data Sources

A literature search from inception until March 2022 of three electronic databases (MEDLINE

through the PubMed interface, Cochrane Library and Google Scholar) was performed using

the combined search terms *"vancomycin"* and "*continuous*".

Study Selection

Initially, the exclusion of doubles was carried out. Thereupon, articles were selected based

on the information obtained from the title and abstract according to the inclusion criteria.

Pertinent articles or those not providing sufficient information via title or abstract were

evaluated in full text. Finally, the selected articles were critically read in total (Figure 1).

Quality Assessment

The quality of the studies selected for inclusion was rated using two tools: The Newcastle-

Ottawa Scale (NOS) for non-randomized studies developed by an ongoing collaboration

between the universities of Newcastle (Australia) and Ottawa (Canada) [79, 80] and the

Cochrane risk of bias tool for randomized trials (RoB 2). [81] Using the NOS a "star system"

described the suitability of the selection of the study groups (one star maximum each), the

comparability of the groups (two stars maximum) and the ascertainment of the exposure or

outcome of interest (one star maximum each). The total number of stars of each study was

interpreted as "good quality" at 8-9 stars, "fair quality" at 6-7 stars, "questionable quality" at

4-5 stars, "poor quality" at 2-3 stars and "serious risk of bias" at 0-1 stars. With the RoB 2

scale, risk of bias was categorized by "low risk", "high risk" or "some concerns", with "low

risk" of overall bias interpreted as "good quality," "high risk" as "serious risk," and "some

concern" as "questionable quality". Due to the heterogeneity of the study designs (e.g.

inclusion or exclusion of patients with chronic kidney disease) and outcome measures (e.g.

use of different definitions for AKI or mortality), it was not possible to summarize the results

in a meta-analysis. In accordance with the Cochrane Consumers and Communication

Review Group guideline [82], we therefore alternatively performed a narrative synthesis of the

evidence. To minimize the influence of seasonal variations in infection type and frequency on

study results (selection bias), investigations with a duration of less than one year or a

population number of less than 30 patients with CI were excluded from our analysis. Attrition

bias from publications that analyzed fewer patient records than were included in the study

was prevented by excluding them from our evaluation. Because of the inhomogeneous

coverage of potential factors affecting outcome, such as disease severity or concomitant

nephrotoxin use, some degree of performance and reporting bias was to be expected.

Language bias was avoided by including all languages of publication. The free internet

translation programme www.Deepl.com/Translator was used for translation where

necessary.

Data Extraction

The main characteristics of the included studies were outlined in five tables. In Table S1 the

design, type of study and main objective were summarised. In Table S2 characteristics of the

study population (number of patients, comparator, age, gender, comorbidities, type of ICU,

length of stay in the ICU, type of infection, treated microorganisms) were presented. In

Table S3 information regarding the treatment with vancomycin (dosage, target concentration,

therapeutic drug management, duration of therapy) was shown. The main findings in terms of

efficacy and safety are compiled in Table S4 and Table S5. "*Efficacy*" connotes clinical or

microbiological cure, improvement, persistence, progression, relapse or reinfection (further

definitions displayed in Table S11 in the supplementary material) mortality/survival and target

attainment, while "*safety*" stands for extrarenal but mainly nephrotoxic adverse events

(Table 1). Some of the values given have been calculated by us in the presence of sufficient

numerical data.

Analysis

The reported average vancomycin steady-state serum concentrations were primarily divided

into three categories: Vancomycin serum level on the second day, i.e. approximately 24

hours after initiation of CI therapy (C24), mean vancomycin serum level during the entire

duration of CI therapy or at least three days of CI therapy (Cmean) and area under the curve

of vancomycin serum concentration versus time for a period of 24 hours during CI (AUC24).

The mortality rate was differentiated into "in-hospital", "ICU", "infection-related," "x-days" (e.g.

28-days), "end of therapy" or "not reported" if no specific type of mortality had been listed.

Likewise, nephrotoxicity in the form of AKI was classified according to Table 1 in "AKIN",

"KDIGO", "RIFLE", "Rybak2009", "Rybak2020", "RRT" or "other". To compare the reported

steady-state vancomycin serum concentrations, in cases where no mean but only the

median was reported, the mean and standard deviation were calculated according to the

method described by Wan et al.: *mean = (median + lower quartile + upper quartile)/3*. [83] In

order to use only one value per study for the comparison, weighted means of serum

concentration, mortality, nephrotoxicity or target attainment rates were calculated if values

were given only for subgroups but not the entire CI population of a study. Because individual

values of the study population were not available, no relationship between the variables

could be tested by regression analysis. But to give an impression of interdependence,

average Css, i.e. C24, Cmean, AUC24, were plotted against the corresponding percentage

rates of clinical failure (mortality, persistence or progression of infection symptoms), clinical

success (cure, improvement of infection symptoms), microbiological failure (persistence,

escalation, relapse), microbiological success (cure), AKI or target attainment, respectively.

Additionally, scatterplots were created comparing rates of target attainment to mortality or

AKI, mortality to AKI and target attainment to target range. For comparison of the different

cohorts and based on the parameters identified as significant predictors for outcomes in the

included studies (Table 3), the dosing (planned loading dose (pLD) and planned

maintenance dose (pMD), actually applied loading dose (aLD) and actually applied

maintenance dose (aMD)), length of therapy with vancomycin (LOT), age, gender

distribution, body weight (BW), kidney status at baseline (serum creatinine (SCr), creatinine

clearance (CrCl)), amount of patients with sepsis, severity of illness at start of CI (APACHE II

score (Acute Physiology and Chronic Health Evaluation score), SAPS II (Simplified Acute

Physiology Score), SOFA score (Sepsis-related Organ Failure Assessment score)), amount

of patients with mechanical ventilation and concomitant reported nephrotoxics were added to

the scatterplots. The relative risk, its confidence interval, z-value and p-value for AKI at an

Css above or below 25 mg/L were calculated by the formulas described by Altman et al. [84]

and displayed in a forest plot. The collected data were summarized and graphically plotted

using Microsoft Excel (2016) and the *ggplot2* and *epitools* packages of the R Statistical

Software (v4.2.0; R Core Team 2021).

Results

Bibliographic Search

Across the various databases, 1,668 articles were identified (857 from PubMed, 264 from

Cochrane databases, 438 from Google Scholar and 109 from a manual search in the

reference lists of related publications). 452 duplicate studies were excluded, leaving 1,216

records for further investigation. A total of 1,097 publications were classified as inappropriate

according to the PICOS criteria after inspection of the title and abstract, mainly because of

the absence of intravenous or continuous use of vancomycin. Of the remaining 119 full-text

articles, twenty-one were evaluated for data extraction and inclusion in this systematic

review. Eighteen reported efficacy data and sixteen presented safety data. Figure 1 shows

the selection process of studies included in this systematic review.

Quality of Included Studies

258 The methodological quality of the studies included in this review varied, but did not influence

259 inclusion in the analysis. The detailed results of the risk of bias assessment are shown in

260 Table S8 and Table S9 in the supplementary material.

Characteristics of Included Studies

262 The characteristics of the included studies were very heterogeneous as can be seen from the

263 following descriptions.

Design

265 Only two randomized controlled trials met the inclusion criteria. [47, 62] Two of the included

266 studies were multicenter investigations. [47, 61] One-third (n=8) had a prospective design. [47, 56,

267 62, 67, 68, 70, 85, 86]

Time and place

269 The majority of the studies (16/21) was performed in Europe, [33, 46, 47, 58, 59, 61-63, 67, 68, 70, 71, 73, 75,

270 85, 87] three in North America, [56, 57, 64] one in South America, [86] one in Australia. [72] The studies

271 were conducted between 2001 and 2020.

Comparison

In two-thirds of the studies a comparison of different patient groups was included. [46, 47, 57-59, 61,

62, 64, 68, 71, 75, 85, 87] Equally, in thirteen studies only patients on CI were included, [33, 56-58, 61, 63, 67,

68, 70-73, 86] In one study the effect of vancomycin in obese (body mass index (BMI) >35 kg/m²)

and non-obese (BMI <30 kg/m²) patients was compared, [57] whilst in one study the two

comparators consisted of patients with a CrCl at baseline above or below 50 mL/min. [58] In

two studies patients with or without AKI were compared. [61, 71]

Demographics

In total 2,949 patients treated with CI were enrolled in the trials. The mean age of CI patients

in the studies ranged from 40 years [64] to 71 years. [58] The gender distribution of CI patients

varied between 52 % men [61] and 91 % men. [64]

ICU

Interdisciplinary ICU occupancy was present in twelve studies, [33, 47, 56, 58, 62, 67, 68, 70, 71, 73, 75, 87]

two studies took place in a medical-only ICU [59, 85] and three studies in a surgical-only ICU. [46,

[57, 64] In four studies no description of the type of ICU was provided. [61, 63, 72, 86] Three studies

took place in a special setting: Burn patients, [64] cardiac surgery patients, [46] central nervous

system (CNS) patients. [86] In two studies, the rate of mechanical ventilation was 100 %. [57, 68]

Kidney function

The Cockcroft-Gault formula [88] was used most often to calculate creatinine clearance (n=7),

[46, 47, 57, 58, 64, 68, 71] while the CKD-EPI formula (Chronic Kidney Disease Epidemiology

Collaboration) [63, 89] and the MDRD formula (Modification of Diet in Renal Disease) [62, 90] were

each only used once. In three studies patients with CKD were excluded. [46, 62, 68] In two

studies information on patients with augmented renal clearance (ARC) was provided. [63, 68]

Seven studies were conducted also with patients who required RRT prior to initiation of

vancomycin therapy. [56, 57, 59, 63, 70, 72, 73]

Severity of illness

The APACHE II score and the SOFA score were used most frequently (9/21) to qualify

severity of illness (APACHE II: [33, 56, 57, 62, 67, 70-73], SOFA: [33, 62, 63, 67, 70-73, 87]). The SAPS II was

mentioned eight times. [46, 47, 58, 61, 63, 68, 75, 85] Comorbidities were described in two-thirds of the

studies. [33, 46, 47, 59, 61, 63, 67, 70, 71, 73, 75, 86] The length of stay (LOS) of the patients in the ICU or

hospital was given in half of the studies. [33, 46, 56, 62, 63, 68, 70-73, 75] The duration in the ICU ranged

from 7 ± 8 days [63] to 32 ± 31 days [56]

 Type of infection

 The type of (presumed) infection was not reported in four studies. [56, 59, 75, 87] In two fifth of the

 studies only patients with sepsis were included, [33, 58, 67, 68, 70-73, 85] where different definitions

 were used. [91-94] One study each was conducted with patients treated with vancomycin only

 for CNS infection [86] or pneumonia. [71]

 Microbiology

 In 20 % of the studies no microbiological information was provided. [56, 59, 68, 72] In almost half of

 the studies information on the number of positive cultures was given, [33, 61, 63, 67, 70, 71, 73, 75, 85, 86]

 which ranged from 6 % to 100 %. In two studies it was specialized in infections caused by

 betalactam-resistant pathogens such as MRSA or methicillin-resistant CoNS (MRCoNS). [47, 62]

 Measured MICs of the respective pathogens were reported in only two studies. [47, 64]

 A summary of the variables and results of the twenty-one included studies can be found in

 Table 2 or in more detail in the supplementary material in Table S1 and Table S2.

 Characteristics of Vancomycin Treatment

 In general, the vancomycin therapy consisted of a loading dose (LD) and a maintenance

 dose (MD). The specific therapy protocols were described as follows. Additionally, the

 parameters for treatment with vancomycin are depicted in Table 2 as well as in Table S3 in

 the supplementary material.

 Loading dose

 In two studies it was not mentioned whether a LD was required in the protocol. [64, 87] In one

 third of studies a fixed LD was described with 500 mg [85] or 1,000 mg [75] used in one study

 each and 1,000-1,500 mg used in five studies. [58, 59, 62, 63, 68] In contrast, in two thirds of the

 studies a weight-based LD of either 15 mg/kg (7/21), [33, 47, 61, 71-73, 85] 20 mg/kg (1/21), [46] 25

 mg/kg (1/22), [56] 30 mg/kg (2/21) [57, 86] or a maximum of 35 mg/kg (2/21) [67, 70] actual body

 weight was implemented. In one study the results of a constant versus a weight-based LD

 were compared. [85] In one third of the studies, the applied LD was not reported. [46, 47, 61, 64, 75, 86]

330 Mean LD ranged from 500 mg [85] to 2,894 mg [57] and from 8 mg/kg [85] to 35 mg/kg [67] body

331 weight.

Maintenance dose

In two studies, no MD was specified in the treatment protocol. [63, 87] In two studies a constant

MD of 2,000 mg per day [75] or 3,000 mg per day [64] was standardized. In one third of the

studies a purely body weight-based MD [46, 47, 61, 68, 70, 72, 73, 86] was reported, ranging from 14

mg/kg per day [70] to 60 mg/kg per day. [86] Considering kidney function, the MD was chosen to

be body weight-based in five studies [33, 56, 67, 71, 85] or constant in four studies. [57-59, 62] A method

of adjusting dosing to measured vancomycin levels was described in half of the studies. [33, 47,

57, 61, 62, 67, 71-73, 75] In one fifth of the studies no information on the measured average MD was

provided. [47, 61, 85, 86] With the rest, the average daily MD ranged from 396 mg/d or 5 mg/kg/d [58]

to 3,039 mg/d or 42 mg/kg/d. [57] A total dose throughout the course of therapy was reported in

five studies and ranged from 3.6 g to 14 g. [58, 62, 71, 75, 87]

Duration of therapy

344 In seventeen studies the average duration of vancomycin therapy was reported. [33, 46, 47, 56-59,

345 61-64, 70, 71, 73, 75, 86, 87] It ranged from 3 days [70] to 15 days [61] (mean 6 days, IQR 5-9 days).

Target definition

347 In most studies (7/21) it was aimed for a vancomycin steady-state serum concentration of 20-

348 30 mg/L, [33, 67, 68, 70-73] six studies settled on a range of 15-25 mg/L, [56-59, 61, 62] in four studies the

349 range of 20-25 mg/L was designated as the target value. [46, 47, 63, 64] Other targets were

350 20 mg/L [85] and 20-40 mg/L. [75] No target concentration was reported in two studies. [86, 87] In

351 addition, a target AUC24/MIC of ≥400 was only reported in three studies. [58, 64, 70]

Therapeutic drug monitoring (TDM)

In half of the studies details on the method of the first drug level measured were provided [33,

56, 57, 63, 64, 67, 70, 85-87] and in three-quarters regular measurements of drug levels were depicted.

[33, 46, 47, 56-59, 61-64, 67, 68, 70, 71, 73] In 57 % of the studies in which a TDM method was reported, a

daily measurement was performed. [33, 46, 47, 61-63, 67, 68, 70, 71, 73]

Drug levels

Mean vancomycin serum concentrations were presented by thirteen studies, [33, 46, 47, 56-58, 62, 64,

68, 71-73, 85] while in eight studies median values were used, [59, 63, 67, 68, 70, 75, 86, 87] Only Baptista et

al. mentioned both. [68] In half of the studies, an average C24 was reported. [33, 56, 57, 63, 67, 68, 70-73,

85] In two thirds of the studies, Cmean were stated or could be calculated. [33, 46, 47, 56, 59, 61, 62, 64,

71, 73, 75, 86, 87] In four studies, both C24 and Cmean were available. [33, 56, 71, 73] In fourteen studies

that reported Css, the method for determining serum vancomycin levels was described. [33, 46,

47, 57, 58, 61-63, 67, 70, 72, 73, 85, 86] Different kinds of immunoassays were used for measurement,

which measured the total vancomycin amount in the serum. In seven studies an average

AUC24 value was presented, [46, 47, 57, 58, 67, 70, 86] but only in one study data on AUC24 instead

of C24 or Cmean was exclusively reported. [58] While in two studies the calculation of the AUC

was not explained, [58, 86] in the others a (log-) trapezoidal rule was used [46, 47, 67, 70] or linearity

in steady-state was assumed and therefore the serum concentration of vancomycin with 24

hours multiplied. [57] The distribution of the mean C24 was as follows: Two levels were

between 15-<20 mg/L, [71, 85] nine levels were between 20-<25 mg/L. [33, 56, 57, 63, 67, 68, 70, 72, 73] No

study had an average C24 <15 mg/L or ≥25 mg/L (Figure S6a). The distribution of the mean

Cmean was as follows: three levels were between 15-<20 mg/L, [59, 62, 87] six levels were

between 20-<25 mg/L, [33, 47, 56, 64, 71, 75] two levels were between 25-<30 mg/L, [46, 73] one level

was ≥30 mg/L [86] (Figure S6b). Mean AUC24(/MIC) data ranged from 477 mg*h/L [58] to

788 mg*h/L [86] (Figure S6c). Only Spadaro et al. reported AUC24/MIC values. [58]

Additional nephrotoxins

Additional use of nephrotoxins was described in about two fifth of the publications. [46, 47, 58, 61,

63, 71, 75, 87] Aminoglycosides were listed most frequently (7/8), [46, 47, 58, 61, 63, 71, 75] followed by

angiotensin converting enzyme inhibitors/angiotensin receptor blockers (5/8), [58, 61, 63, 71, 75] iv

contrast (5/8), [46, 47, 63, 71, 75] vasopressors (5/8), [46, 58, 61, 71, 75] diuretics (4/8) [46, 63, 71, 75] and

nonsteroidal anti-inflammatory drugs (3/8). [61, 63, 71]

Characteristics of Outcome Parameters

Efficacy and safety of CI were analyzed. The outcome parameters are displayed in Table 2

as well as Table S4 and Table S5 in the supplementary material.

Efficacy

Efficacy was mentioned in eighteen studies and could be divided into clinical or

microbiological treatment failure or success (n=2,648 patients (pts)) (Table 2 or in the

supplementary material Table S4, Table S10 or Table S11). [33, 46, 47, 56-58, 61-64, 67, 70-73, 75, 85, 87]

Clinical failure ranged from 8 % to 63 % (18/18). ICU mortality was most frequently studied

(11/18) and ranged from 21 % to 59 %. [33, 46, 47, 58, 63, 70, 71, 73, 75, 85, 87] *Microbiological failure*

rates ranged from 3 % up to 54 % (3/18). [47, 63, 64] *Clinical success* rates in the form of "*cure*"

or "*improvement*" were in the range of 64 % and 93 % (5/18). [46, 47, 62, 63, 85] *Microbiological*

success rates varied between 46 % and 91 % (3/18). [47, 62, 63] *Target attainment* was

considered a treatment success in eight studies (n= 1,116 pts) and ranged from 24 % to 92

%. [33, 56-58, 63, 67, 70, 73] Further analysis of drug level target attainment can be viewed below.

Only for C24 <15 mg/L could a significant association with in-hospital mortality be shown by

(multivariate) regression analysis (Table 3). [58] Other links between Css and clinical or

microbiological success or failure were not detected. Omuro et al. associated *ICU mortality*

with the occurrence of AKI in univariable analysis (Table 3). [75] Cianferoni et al. also found a

higher ICU mortality rate in patients with AKI (AKI: 40 % mortality, no AKI: 18 % mortality). [71]

Five studies compared cohorts with different Css and treatment effectiveness. Mohammedi

et al. (n=40 pts) used a constant loading dose (500 mg = 7.5±1.5 mg/kg) and a weight-based

approach (15 mg/kg = 1,147±317 mg). [85] This resulted in different Css of 14.9±5 mg/L and

18.5±6 mg/L. Differences in mortality (50 % vs. 35 %, p=not significant) and clinical cure (56

% vs. 93 %, p<0.02) were noticed, arguing for the higher dose and resulting higher C24

(Figure 2a). Spadaro et al. (n= 348 pts) studied patients with creatinine clearance above (A)

and below (B) 50 mL/min. [58] They reported a significant correlation between subtherapeutic

levels at first measurement (C24 target: 15-25 mg/L) and in-hospital mortality (OR 2.1,

p=0.003) (Table 3). Additionally, they found lower AUC24/MIC with also numerically lower

ICU mortality (M) in group A (A: 468±79, M: 21.4 %; B: 490±84, M: 23.9 %). Lin et al. (n= 52

pts) distinguished between obese (o; BMI > 35 kg/m²) and non-obese (no; BMI < 30 kg/m²)

patients. [57] No statistically significant differences were noticed between groups in respect to

mean Css and mortality (C24: o/no: 20±4 mg/L; AUC24: o: 488±92 mg*h/L, no:

481±91 mg*h/L; M: o: 19.2 %, no: 15.4 %). In a subset analysis, Akers et al. (n= 90 pts)

distinguished between patients with gram-positive bacteremia (1), patients with sepsis

without proven gram-positive bacteremia (2) and patients with pneumonia (3) (Cmean: 1:

19±3 mg/L, 2: 21±4 mg/L , 3: 22±4 mg/L). [64] A slight numerical difference in serum levels was

observed, which was not associated with in-hospital mortality (1: 16 %, 2: 70 %, 3: 35 %) and

was not studied in relation to the impact on microbiological failure (Cmean overall:

20±4 mg/L; failure overall: 18 %). Wysocki et al. (n=61 pts) associated a Cmean of

23±4 mg/L or AUC24 of 596±159 mg*h/L with treatment success and a Cmean of 25±5 mg/L

or AUC24 of 685±260 mg*h/L with treatment failure. [47]

Target Attainment

In half of the studies a target achievement rate was reported (n=1,391 pts). [33, 56-58, 63, 64, 67, 68,

70, 72, 73] Additionally, in one third each the rate of subtherapeutic (7/21) and supratherapeutic

(6/21) levels was described. [33, 56, 59, 64, 70, 72, 73] Target attainment was most frequently reported

in the C24 group (9/21), with rates ranging from 24 % to 92 % (Figure 3a). [33, 56, 57, 63, 67, 68, 70,

72, 73] In the Cmean group (4/21), rates ranged from 31 % to 80 % (Figure 3b) [33, 56, 64, 73] and in

the AUC24 group (1/21), rates ranged from 44 % to 57 %. [58] Significant predictors for target

attainment were identified in five studies (n=664 pts) by univariate and multivariate

regression analysis (Table 3). [33, 63, 67, 70, 73] In no study a dependence of target attainment on

Css per se was described, but a higher vancomycin dose increased target attainment. [33, 73]

We noticed that a lower and wider target range was achieved more often (Figure 3). In no

study the *time within* the target range was reported, but in three studies a *time required to*

reach the target serum concentration was stated. It took 16 hours (target range 20-25 mg/L),

[46] 36 hours (target range 20-25 mg/L) [47] and 48 hours (target range 20-30 mg/L). [33]

Safety

The safety of treatment with vancomycin was discussed in sixteen studies (n=2,383 pts)

(Table 2 or Table S5 in the supplementary material). While in five studies symptoms such as

hearing loss due to ototoxicity, fever, infusion reactions (e.g. Red man syndrome, phlebitis)

or platelet counts due to bone marrow toxicity were mentioned in the context of vancomycin

safety, [47, 56, 57, 64, 68] the majority of fifteen publications (n=2,331 pts) dealt with "nephrotoxicity"

in the form of AKI. [46, 47, 57-59, 61-64, 68, 71, 75, 85-87] Different definitions were used to describe AKI

and the frequency of AKI varied from 0 % [57, 62, 85] to 60 % [63] (Table 1). Higher vancomycin

serum levels (especially >30 mg/L) and higher Cmean were identified as a significant

predictor of AKI occurrence by multivariate regression analysis (Table 3). [61, 71] In contrast,

Spadaro et al. found no relationship between AKI and Css >15 mg/L. [58] Furthermore,

Cianferoni et al. found no correlation of daily vancomycin dose and the onset of AKI. [71] In

four studies (n=863 pts) vancomycin serum concentration-dependent nephrotoxicity was

described, the incidences of which varied widely: Spadaro et al. (n=348 pts) saw no

nephrotoxicity at Css of 25-30 mg/L and an incidence <8 % (<28/348) when the Css

exceeded 30 mg/L. [58] Cianferoni et al. (n=207 pts) described an increasing incidence the

higher the Css, with a maximum of 38 % (25/66) above a level of 25 mg/L. [71] Perin et al.

(n=179 pts) noted a rate of 55 % (72/131) with a Css <25 mg/L versus 77 % (34/44) with a

Css >25 mg/L. [63] Spapen et al. (n=129 pts) demonstrated an increase in AKI the higher the

Css: 4,5 % (3/68) with a Css <25 mg/L, 31 % (9/29) with a Css of 25-30 mg/L and 81 %

(26/32) with a Css >30 mg/L. [61] Comparing the information from the latter three studies (the

only ones that provided patient numbers with concentration-dependent AKI rates), there

appeared to be an advantage in terms of AKI occurrence when the target concentration was

<25 mg/L (Figure 5, Table S7 in the supplementary material). The definition of AKI was

rather similar within these studies and differed only in the inclusion or omission of urine

output (Table S6 in the supplementary material). Cianferoni et al. (n= 207 pts) established a

link between Css, the onset of AKI and mortality. As mentioned above, they observed a

higher rate of AKI with increasing vancomycin concentration, as well as an equally rising

mortality rate. However, it cannot be ruled out that the escalated serum concentrations were

only a marker for a declining glomerular filtration and did not cause AKI per se. [71] Css ranged

from 18.7 mg/L (C24) and 21.2 mg/L (Cmean) with no AKI and ICU mortality of 18 % to

24.5 mg/L (C24) and 27.2 mg/L (Cmean) with early AKI and ICU mortality of 46 %. Omuro et

al. (n=119 pts) also reported higher mortality in patients with AKI who were additionally

treated with inotropics. [75] However, they did not present the Css of these patients. The

duration of AKI was only considered in two studies. Spapen et al. (n= 129 pts) reported a

return of serum creatinine to baseline at discharge in 67 % of patients who suffered AKI. [61]

Cianferoni et al. (n= 207 pts) noted higher serum creatinine levels one month after initiation

of vancomycin therapy in patients who had experienced AKI (p = 0.04). Apart from the

distinction between early (= within 48 h from the start of CI) and late (>48 h from the start of

CI) AKI by Cianferoni et al. (early AKI: 28/50, late AKI: 22/50) no author reported the

measurement of the time of onset of renal injury. [71] Therapy management for AKI, such as

reducing the vancomycin dose or switching to alternative therapeutics, has not been

described anywhere.

Discussion

Although vancomycin has been used for decades in the therapy of infections with gram-

positive pathogens, it has not yet been conclusively clarified what serum concentration of the

drug should be aimed for during CI. To determine what Css should be targeted when

administered continuously to achieve effective yet tolerable therapy, studies were elicited in

which data on vancomycin concentration and therapeutic outcome were published.

Numerous studies were found, but overall they provided little data on the serum

concentration to be targeted.

Efficacy

An assessment of the reported mortality data was difficult. Mortality seemed to depend on numerous factors and was not only influenced by the vancomycin serum concentrations $C24$, $Cmean$ or $AUC24$. Furthermore, there was very little comparative concentration and mortality data. Higher $C24$ resulted in lower mortality rates, with a concentration above 15 mg/L found to be favorable by Spadaro et al. and Mohammedi et al.. [58, 85] A target concentration for $Cmean$ or $AUC24$ leading to lower mortality was not evaluated in any of the studies included in this review. When looking at the plotted available datasets of each study's average serum concentration and mortality rate we also noticed an association of ICU mortality with $C24$ ($R^2 = 0.7435$), but not with $Cmean$ ($R^2 = 0.0057$) or $AUC24$ ($R^2 = 0.0009$) (Figure 2a-c). Mohammedi et al. emphasized the need for sufficient LD to maintain high $C24$ and reduce mortality. [85] We observed the importance of sufficient LD as well (Table S3 in the supplementary material). Additionally, a higher MD seemed to result in lower mortality in the $C24$ cohort (Table S3 in the supplementary material). Reaching high therapeutic levels as early as possible at the beginning of anti-infective therapy is in accordance with general recommendations. [14, 16-21] However, sufficient dosing in critically ill patients is challenging. [20] The increased volume of distribution with impaired capillary barrier function as well as the probable losses through renal function and renal replacement procedures can be the reason for this. [23] The difficulty of appropriate dosing may also be the reason for the heterogeneity of doses applied in the studies included in this review. From our diagrams (Figure 2a-c), it could be deducted that dialysis was a predictor of mortality in the $C24$, $Cmean$ and $AUC24$ cohorts. The higher mortality of dialysis patients compared to people of the same age with normal kidney function is well known and therefore in line with our observations. [95] We also found that the initial severity of illness may have influenced mortality (Table S2 in the supplementary material). Since the scores applied (APACHE II, SAPS II and SOFA) are generally used to predict the probability of survival of patients in an intensive care unit, this observation seemed conclusive. Only Mohammedi et al. compared Css and clinical cure in two cohorts and concluded that a higher $C24$ value led to higher clinical success. [85] A

comparison of Css and microbiological efficacy in different CI cohorts was not performed in

any study. Stepan et al. and Wysocki et al. reported Cmean for clinical and microbiological

success. [47, 62] While the lower concentration resulted in a lower outcome rate for clinical

success, in line with the results of Mohammedi et al., the case was reversed for

microbiological success (Table S10 in the supplementary material). However, it must be kept

in mind that Wysocki et al. based their microbiological evaluation on the result after five days

of CI, whereas Stepan et al. performed the microbiological evaluation after the treatment was

completed. With intermittent use of vancomycin (II), higher trough levels or AUC24/MIC

values resulted in better clinical *and* microbiological cure. [96-98] Seemingly contradictory were

also the findings of Wysocki et al. that higher as opposed to lower Cmean and AUC24 led to

more frequent treatment failure. [47] However, this could be explained by the fact that they also

measured higher SCr on day 10 of vancomycin therapy in those (CI+II) who failed therapy.

They hypothesised that an increase in SCr could be a marker of treatment failure. Thus, an

increase in Css would automatically follow.

Target attainment

Target attainment was considered to be the effectiveness of a dosing regimen, without

eliciting in advance whether and how meaningful this target was. Therefore, many different

target ranges were used in the studies. Furthermore, when investigating the achievement of

defined target ranges, researchers have typically focused on evaluating new dosing

protocols [57, 68, 70] or comparing different dosing modalities. [37, 38] The literature did not provide

associations between target attainment and Css. When plotting the target attainment rate

and Css of each trial, higher target achievement was observed with higher LD, but MD did

not appear to influence target attainment (Figure 3a/b). In studies with sepsis patients, lower

target attainment rates were found. Physiological changes during sepsis may have played a

role in this. [20, 22, 23] It should be noted, however, that in the studies different definitions of

sepsis were used, making it difficult to compare patients and sepsis rates. Akers et al. only

studied burn patients, which may explain the comparatively low target attainment rate due to

physiological changes (e.g. capillary leakage or oedema) in this population compared to the

other cohorts in the plot (Figure 3b). [64] The temporal differences (16-48 h) to reach target

Css could be due to another dosing regimen where target concentrations were reached more

quickly with higher vancomycin doses. [33, 46, 47]

Safety

The nephrotoxicity of vancomycin is known. [28-30] Due to the poor tissue penetration, [99] the

therapy with vancomycin is limited because the dose cannot be increased arbitrarily. The

upper limit of serum concentration of vancomycin that keeps the impairment of renal function

within acceptable limits, weighing the benefits and harms, is much debated. For intermittent

infusion, a trough level upper limit of 20 mg/L was established and recently corrected to the

recommendation of an upper value of AUC24/MIC = 600.[15, 100] For CI, an upper limit of

28 mg/L in outpatients and 30 mg/L in ICU patients was described, above which a significant

increase in nephrotoxicity rates was observed. [61, 101] At steady-state, the upper AUC24 value

of 600 mg*h/L (if MIC=1 mg/L) corresponds to a concentration of 25 mg/L. This parallels with

the preferable concentration calculated by us. However, due to a lack of data, we were

unable to compare 25 mg/L with other concentrations such as 30 mg/L, 28 mg/L or 20 mg/L.

An increased risk of AKI in CI has also been reported with raised AUC levels. [100] Ma et al.

reported a nephrotoxic risk at an AUC24 of 535 mg*h/L and no nephrotoxic risk at an AUC24

of 360 mg*h/L in a cohort of ICU and non-ICU patients. [52] Definitions of reported acute kidney

injury varied. As Hutschala et al. and Koeze et al. showed, this had implications for the

reported incidence, timing and outcome of AKI in critically ill patients. [25, 46] Newer definitions

such as AKIN (Acute Kidney Injury Network) [102] or KDIGO (Kidney Disease Improving Global

Outcomes) [103] are more sensitive, resulting in higher reported rates of AKI. Published meta-

analyses comparing the nephrotoxicity of II versus CI have not paid attention to this fact and

compared AKI rates without hindrance. [34-38] In our comparison, we stratified by AKI definition

and related only similar definitions. Cianferoni et al. and Hanrahan et al. identified in multiple

regression a longer duration of therapy with CI as a trigger for a higher number of

nephrotoxic events (Table 3). [71, 87] In dataset plots of C24, Cmean or AUC24 against AKI rate

of each trial, we also found that higher Css and longer duration of therapy increased the rate

of AKI ([Figure 4](#)). AKI per se (vancomycin-independent) has been associated with worse

treatment outcome in the past in a large prospective multicenter study. Mortality and long-

term reduced renal function were consequences of AKI. [27] In addition, increased length of

ICU stay and hospitalization, as well as increased costs to the healthcare system, have been

associated with AKI. [104-106] Cianferoni et al. and Spapen et al. also noted longer-lasting

deterioration in renal function after AKI and Omuro et al. and Cianferoni et al. described

increased mortality in patients who developed acute renal dysfunction with CI. [61, 71, 75] AKI

with CI has negative consequences and should consequently be avoided. To distinguish

vancomycin-induced nephrotoxicity from the naturally high rate of AKI in ICU patients, a

comparison group would have been needed in all studies to assess the impact of

vancomycin on the AKI rate. However, only Omuro et al. used a control group, but the

included patients were randomly selected and no matching was done. [75] The studies

included in this review did not report the treatment management affecting vancomycin

application after detection of AKI. Teng et al (n=10 pts) described the possibility of continuing

therapy of II with adjusted dosing after the occurrence of AKI. [107] In their study, in all patients

serum creatinine had normalized or significantly reduced at discharge. Carreno et al.

conducted a RCT in patients with risk factors for AKI to investigate the impact on AKI rates of

early change from II to alternatives such as linezolid, daptomycin or ceftaroline. No benefit of

switching was found. [108] Nevertheless, in idiosyncratic vancomycin-induced renal injury,

treatment cessation is still recommended. [109] The best course of action for acute renal injury

on CI remains to be determined.

Limitations

Several limitation should be considered when interpreting the results. First, of the twenty-one

included studies, only two were randomized controlled trials; most of the others were

retrospective or observational studies. Allocation bias, selection bias and various types of

other confounding factors may influence the results of our report due to the observational

design of these studies. Publication bias is to be expected, since publications that

demonstrate an effect are more likely to be published. Second, no raw data was available for

calculation. Instead, our plotting of datasets of the study results was performed with means

and medians. Thus, the preparation of a meta-analysis or the calculation of cut-off values for

efficacy was not possible. Furthermore, the use of mean Css may lead to a bias of

interpretation. Third, the forest plot we created included data only from the studies that

provided information on the number of patients with concentration-dependent AKI in their

publication. Inclusion of data from the other twelve studies that reported incidences of

nephrotoxicity may change the result of our calculation. Fourth, the characteristics of the

studies included in this review were very heterogeneous, which limited the comparison of

parameters. For example, it could not be determined which dosage, whether a constant

amount or weight- or kidney-adapted, led to a better outcome. Thus, no statement regarding

the best dosage was possible. Fifth, only few AUC24 and only one AUC24/MIC value were

presented in the included studies, so that conjectures about the influence of AUC24 on

treatment outcome with CI were very limited and on AUC24/MIC were not possible at all.

Rybak et al. argue that it is sufficient to aim for AUC24 rather than AUC24/MIC because the

MIC distribution is generally narrow at about 1 mg/L or less, MIC values are not measured

very accurately, assay methods vary widely and MIC values are not readily available. [15] This

may be a reason why only Spadaro et al. reported AUC24/MIC values [58] and only Akers et al.

and Wysocki et al. presented measured MIC values. [47, 64] Nevertheless, it is important to

determine MIC values and to include them in the therapy evaluation, since higher therapy

failure has been described for MIC >1 mg/L. [110] Finally, in accordance with clinical TDM

routine, only the total amount of vancomycin in serum (bound + free vancomycin) was

measured in the studies. However, rather the active agent that is not bound to plasma

proteins is active. [111, 112] Variations in the protein binding of vancomycin between <10 % and

82% have been described. [112-115] Because albumin concentration varies widely in critically ill

patients, [20] the active concentration of vancomycin also differs widely. Berthoin et al. reported

a poor correlation of total and free vancomycin concentration ($R^2 = 0.55$). [116] Therefore, they

concluded that free rather than total vancomycin concentration should be determined in

patients with less susceptible organisms to reduce the rate of treatment failure. The extent to

which determination of free vancomycin concentration is also preferable in sensitive germs is

unclear. Therefore, it has to be clarified whether the evaluation of a correlation between total

vancomycin concentration and efficacy or safety parameters applicable to a broader

intensive care patient population is at all possible. Maybe, the formulation of a total

vancomycin serum concentration target range adaptable to the individual protein

concentration represented an option if the determination of free vancomycin is not possible in

clinical routine. However, to our knowledge, such modification of the vancomycin target

range is not currently performed in practice.

Conclusions

Despite currently sparse data availability, it appeared that for continuous infusion of

vancomycin (CI) the mortality was reduced and clinical cure increased with C24 above

15 mg/L and AKI may be reduced with Css below 25 mg/L. Target attainment is time-

dependent. As the available data included either C24 or Cmean, the effectiveness of the

therapy may not have been measurable using only the current compilation of data. The

range of 15-25 mg/L to aim for in CI needs to be validated by direct comparison with other

concentration ranges to achieve a safe (i.e. least damaging effect on the kidneys) and

simultaneously most effective (i.e. therapeutically successful) therapy. To this end, future

research should always sort patients by vancomycin serum concentration groups. Large

prospective controlled studies are needed for this purpose.

Definition of nephrotoxicity

Table 1: Compilation of all definitions of acute renal insufficiency (AKI) used in the included publications.

	Serum creatinine (SCr)		CrCl/eGFR$_{MDRD}$	Urine output (UO)		AKI range	Reference
Consensus Recommendation from AHSP/IDSA/SIDP on Therapeutic Monitoring of Vancomycin (2009) (Rybak2009) [50]:						5 %	[58]
	SCr ↑ ≥1.5 x baseline SCr	<u>or</u> SCr ↑ ≥0.5 mg/dL					
	for ≥2 consecutive measurements after several days of vancomycin therapy and in absence of alternative explanation						
KDIGO (2012) [103]						60 %	[63]
1	SCr ↑ 1.5-1.9 x baseline SCr (7 d)	<u>or</u> SCr ↑ ≥0.3 mg/dL (48 h)		<0.5 mL/kg/h for 6-12 h			
2	SCr ↑ 2.0-2.9 x baseline SCr			<0.5 mL/kg/h for ≥12 h			
3	SCr ↑ ≥3.0 x baseline SCr	<u>or</u> SCr ↑ ≥4.0 mg/dL	<u>or</u> initiation of RRT	<0.3 mL/kg/h for ≥24 h	<u>or</u> anuria for ≥12 h		
AKIN criteria (2007) [102]						20-50 %	[46, 61, 75, 86]
1	SCr ↑ 1.5-2.0 x baseline SCr (7 d)	<u>or</u> SCr ↑ ≥0.3 mg/dL (48 h)		<0.5 mL/kg/h for >6 h			
2	SCr ↑ 2.0-3.0 x baseline SCr	<u>or</u> SCr ↑ ≥0.5 mg/dL		<0.5 mL/kg/h for >12 h			
3	SCr ↑ >3.0 x baseline SCr	<u>or</u> acute SCr ↑ ≥0.5 mg/dL if SCr is ≥4 mg/dL	<u>or</u> initiation of RRT	<0.3 mL/kg/h for ≥24 h	<u>or</u> anuria for ≥12 h		
RIFLE category (ADQI) (2004)						25-37 %	[46, 87]
Risk	SCr ↑ ≥1.5 x baseline SCr		<u>or</u> eGFR ↓ >25% from baseline	<0.5 mL/kg/h for 6-12 h			
Injury	SCr ↑ ≥2.0 x baseline SCr		<u>or</u> eGFR ↓ >50% from baseline	<0.5 mL/kg/h for ≥12 h			
Failure	SCr ↑ ≥3.0 x baseline SCr	<u>or</u> acute SCr ↑ ≥0.5 mg/dL if SCr is ≥4 mg/dL	<u>or</u> eGFR ↓ >75% from baseline	<0.3 mL/kg/h for ≥24 h	<u>or</u> anuria for ≥12 h		
Loss	Persistent acute renal failure (AFR): complete loss of kidney function for >4 weeks (requiring dialysis)						
ESRD	Complete loss of kidney function for >3 months (requiring dialysis)						
Other							
	Increase in SCr by >0.3 mg/dL on ≥2 consecutive days					6 %	[68]
	Increase in SCr by 50 % from baseline until the end of treatment					16 %	[47]
	Increase in SCr by 0.5 mg/dL or ≥50 % from baseline over 2 consecutive SCr values					0 %	[57]
	Increase in SCr by 0.5 mg/dL or ≥50 % from baseline to end of treatment; CVVH: daily urine output <0.3 mL/kg					20 %	[64]
	Increase in SCr by 0.3 mg/dL or ≥50-100 % from baseline over 2 consecutive days during and within 72 h after VCM discontinuation and/or daily urine output <0.5 mL/kg/h					24 %	[71]
	Increase of SCr					0 %	[62]
	Reduction of CrCl					0 %	[62]
	Hemodialysis upon discharge from hospital					0 %	[57]
	Start of RRT					7 %	[59]
	Alterations in renal function					0 %	[85]

ADQI: Acute Dialysis Quality Initiative, AHSP: American Society of Health-System Pharmacists, AKIN: Acute
Kidney Injury Network, CrCl: creatinine clearance, eGFR: estimated glomerular filtration rate, ESRD: End Stage
Renal Disease, IDSA: Infectious Diseases Society of America, KDIGO: Kidney Disease Improving Global
Outcomes, MDRD: Modification of Diet in Renal Disease, ND: not described , PIDS: Pediatric Infectious Diseases
Society, RRT: renal replacement therapy, SCr: serum creatinine, SIDP: Society of Infectious Diseases
Pharmacists

Flowchart

Figure 1: Flowchart of the study selection.

Overview

Table 2: *Overview of the main characteristics of the twenty-one included studies with continuous infusion of vancomycin.*

Reference	Country	Design	Time Course	ICU	Total Number of Patients	Comparison of Patient Groups	Specialty of study	Definition Css [mg/L] AUC24/MIC	Measured Value Css [mg/L] AUC24 [mg*h/L]		Definition	Results
Akers 2012 [64]	USA	Retrospective single-center cohort study	2009/12-2006/01	Surgical (burn)	90		Burn patients (100 %)	Css: 20-25	**Overall therapy:** 20.0±3.8 Gram-positive bacteremia: 19.3±3.2 Sepsis without proven gram-positive bacteremia: 21.2±4.2 Pneumonia: 22.0±3.9	ECF	Mortality (in-hospital, 14-day, 28-day)	In-hospital mortality: All: 32.2 % (29/90) Non-CVVH: 19.1 % (13/68) Gram-positive bacteremia: 16 %, 4/25 / 4.4 %, 4/90 Sepsis without gram-positive bacteremia: 70 %, 14/20 / 15.6 %, 14/90 Pneumonia: 35 %, 7/20 / 7.8 %, 7/90 14-d mortality: All: 10 % (9/90) 28-d mortality: All: 18.9 % (17/90)
										EMF	Recurrence of gram-positive bacteremia after beginning of CI	MSSA: (2 of an unknown quantity); MRSA: (2 of an unknown quantity); Enterococci: (3 of an unknown quantity) CI+II: 17.5 % (10/57)
								AUC24: ≥ 400	Lack of postinfusion peak data prevented actual calculation of AUC	SR	Non-CVVH: Increase in SCr by ≥0.5 mg/dL or at least 50 % increase from start to end of vancomycin therapy CVVH: Urine output <0.3 mL/kg/d	All (CVVH + Non-CVVH): ≥ 50 % SCr increase: 7.8 % (7/90) ≥0.5 mg/dL SCr increase at end of therapy: 6.7 % (6/90) ≥0.5 mg/dL SCr increase at any time during therapy: 20 % (18/90) Non-CVVH: ≥ 50 % SCr increase: 10.4 % (7/68) ≥0.5 mg/dL SCr increase at end of therapy: 8.8 % (6/68) ≥0.5 mg/dL SCr increase at any time during therapy: 22.1 % (15/68)
										SNR	Bone marrow toxicity: Difference in leukocytes, neutrophils and platelets at the beginning and end of CI	Leukocytes (x1000/µL): Start of CI 10.6 (8.4-17.5); End of CI: 12.2 (8.4-18.8) (p=0.22) Neutrophils (x1000/µL): Start of CI: 9.1 (6.7-14.8); End of CI: 9.9 (6.4-16.5) (p=0.33) Platelets (x1000/µL): Start of CI: 176 (101-271); End of CI: 236 (108-417) (p=0.001)
Baptista 2014 [68]	Portugal	Retrospective /Prospective single-center cohort study	A (MD 30 mg/kg/d): 13 months; B (MD nomogram): ND	Medical: A: 39.2 % B: 20 %; Surgical: A: 60.8 % B: 80 %	104	A (MD 30 mg/kg/d): 79 B (MD nomogram): 25	Augmented renal clearance (77 %) Mechanical ventilation (100 %) Sepsis (100 %)	Css: 20-30	**24 h:** A: 21.5±6.4 B: 24.5±5.2	SR	Increase in SCr by >0.3 mg/dL on ≥2 consecutive days	A (MD 30 mg/kg/d): 6.3 % B (MD nomogram): 4.0 %
										SNR	Red-man-syndrome	ND
Beumier 2013 [70]	Belgium	Prospective single-center cohort study	2012/05-2011/01	Medical: 69 % Surgical: 31 %	32		CRRT (100 %) Mechanical ventilation (78 %) Sepsis (100 %)	Css: 20-30 AUC24: >400	**24 h:** 24.3±9.3 679±150	ECF	Mortality (ICU)	57 % (18/32)
										ECS	Target attainment	Target: 12 h: 69 % 24 h: 63 % Subtherapeutic: 12 h: 3 % 24 h: 19 % Supratherapeutic: 12 h: 28 % 24 h: 19 %
Cianferoni 2013 [71]	Belgium	Retrospective single-center cohort study	2009/12-2008/01	Medical: All: 59 % No AKI: 59 % AKI: 62 % (Early AKI: 60 % Late AKI: 63 %) Surgical: All: 41 % No AKI: 41 % AKI: 38 % (Early AKI: 40 % Late AKI: 37 %)	207	No AKI: 157 AKI: 50 (Early AKI: 28 Late AKI: 22)	Mechanical ventilation (69 %) Sepsis (100 %);	Css: 20-30	**Overall therapy:** All: 22.3±7.0 No AKI: 21.2±6.8 AKI: 25.8±6.6 (Early AKI: 27.2±5.1 Late AKI: 24.1±7.8) **24 h:** All: 19.7±8.5 No AKI: 18.7±7.0 AKI: 22.5±9.6 (Early AKI: 24.5±7.8 Late AKI: 20.2±11.1)	ECF	Mortality (ICU)	All: 23 % (48/207); No AKI: 18 % (28/157) AKI: 40 % (20/50) Early AKI: 46 % (13/28) Late AKI: 32 % (7/22)
										SR	Daily urine output <0.5 ml/kg/h and/or increase of SCr ≥0.3 mg/dl or 50-100 % increase from baseline (=VCM on first day of therapy) on at least two consecutive days during and within 72 h after VCM discontinuation Early AKI: Occurrence within first 2 days of therapy; Late AKI: Occurrence after 2 days of therapy; Severe AKI: Need for CRRT or HD within VCM therapy or up to 3 days after drug discontinuation	Total: 24 % (50/207); Early AKI: 56 % (28/50) VCM level Late AKI: 44 % (22/50) <15 mg/L: 6 % (2/34) CRRT/HD: 15-20 mg/L: 11 % (5/47) No AKI: 2 % (3/157 patients needing CRRT 9/11/13 d 20-25 mg/L: 30 % (18/60) after VCM discontinuation) 25-30 mg/L: 38 % (15/39) AKI: 18 % (9/50) during VCM therapy >30 mg/L: 37 % (10/27)
Covajes 2013 [73]	Belgium	Retrospective single-center cohort study	2010/12-2008/01	Medical: 69 % Surgical: 31 %	85		CRRT (100 %) Mechanical ventilation (84 %) Sepsis (100 %);	Css: 20-30	**24 h:** 24.7±9.0 **48 h:** 26.0±8.1 **72 h:** 27.7±9.3	ECF	Mortality (ICU)	59 % (50/85)
										ECS	Target attainment	Target: 24 h: 51 % 48 h: 56 % 72 h: 67 % Subtherapeutic: 24 h: 29 % 48 h: 22 % 72 h: 8 % Supratherapeutic: 24 h: 20 % 48 h: 21 % 72 h: 26 %
Cristallini 2016 [67]	Belgium	Prospective single-center cohort study	2013/05-2012/01	Medical: 36 % Surgical: 64 %	107		Mechanical ventilation (54 %) Sepsis (100 %)	Css: 20-30 AUC24: ND	**12 h:** 26.0±8.3 **24 h:** 23.0±6.8 **48 h:** 26.0±6.0 780±180	ECF	Mortality (ICU)	22 % (24/107)
										ECS	Target attainment	12 h: 56 % 24 h: 54 % 48 h: 73 %
Hanrahan 2014 [87]	UK	Retrospective single-center cohort study	2009/08-2004/12	Medical Surgical	653		ND	Css: ND	**Overall therapy:** 18.4±4.2	ECF	Mortality (ICU all-cause; within 72 h of last recorded VCM dose)	ICU: 26.3 % (172/653) Within 72 h of last VCM: 19.9 % (130/653) Mortality or nephrotoxicity within 72 h of cessation: 38.7 % (253/653)
										SR	AKI (RIFLE [117])	24.7 % (161/653) Nephrotoxicity or mortality within 72 h of cessation: 38.7 % (253/653)
Hutschala 2009 [46]	Austria	Retrospective single-center cohort study	2005/12-2001/01	Surgical (cardiosurgical)	119		Cardiosurgery (100 %) CKD (0 %; SCr >1.5 mg/dL))	Css: 20-25 AUC24: ND	**Overall therapy:** 25.0±4.0 Time to target: 16±8 h 529±98	ECF	Mortality (ICU, in-hospital)	ICU: 21 % (25/119); In-hospital: 30.3 % (36/119) Timing of death in course of VCM administration: 9±3.3 d (1-20)
										ECS	Improvement (= Reduction of CRP; leukocytes)	CRP: -66.4±41.6 % ((before CS: 3,7±5,1 (0.5-25.1) at start of VCM: 22.64±10.1 (7.3-55); on 10th day of VCM: 7.6±5.69 (0.7-32.1))
										SR	AKI (AKIN [102] and RIFLE [117])	AKIN 49.6 % (59/119) RRT: 23.5 % (28/119) AKIN: 1: 29.4 %; 2: 11,8 %; 3: 8.4 % Necessity to administer diuretics

Reference	Country	Design	Time Course	ICU	Total Number of Patients	Comparison of Patient Groups	Specialty of study	Definition Css [mg/L] AUC24/MIC	Measured Value Css [mg/L] AUC24 [mg*h/L]		Definition	Results
												RIFLE: 37 % (44/119) (furosemide): 12.6 % (15/119)
												RIFLE: R: 30.3 % **I:** 4.2 % **F:** 2.5 %
Lin 2016 [57]	USA	Retrospective single-center cohort study	2015/01-2013/01	Surgical	52	Obese (BMI >35 kg/m²): 26 Non-obese (BMI <30 kg/m²): 26	CVVH (35 %) Differentiation obese/non-obese Mechanical ventilation (~100 %)	Css: 15-25	**24 h:** All: 20.32±3.72 Obese: 20.3±3.81 Non-obese: 20.03±3.8 CVVH: Obese: 19.8±3.05 Non-obese: 21.6±3.02 Preserved renal function: Obese: 20.6±4.21 Non-obese: 19.6±4.41	ECF	Mortality (in-hospital)	50 % (7/14)
										ECS	Target attainment	**24 h:** CVVH Obese: 92.3 % Obese: 100 % Non-obese: 88.5 % Non-obese: 100 %
								AUC24: ND	Obese: 488±91.5 Non-obese: 480.9±91 CVVH: Obese: 474±73.2 Non-obese: 517±48.6 Preserved renal function: Obese: 496±101 Non-obese: 471±106	SR	Not requiring CVVH: Increase in SCr by 0.5 mg/dL or at least 50 % increase from baseline over two consecutive SCr values Hemodialysis upon discharge from hospital	AKI: 0 %; Hemodialysis: 0 %
										SNR	Hearing loss	Hearing loss: 0 %
Mohammedi 2006 [85]	France	Prospective single-center cohort study	12 months	Medical	40	A (LD 500 mg): 20 B (LD 15 mg/kg): 20	Mechanical ventilation (90 %) Sepsis (100 %)	Css: 20	**24 h:** A: 14.9±5.4 B: 18.5±6.4	ECF	Mortality (ICU)	A (LD 500 mg): 50 % (10/20) B (LD 15 mg/kg): 35 % (7/20)
										ECS	Cure (in patients with proven infection)	A (LD 500 mg): 56 % (10/18) B (LD 15 mg/kg): 93 % (14/15)
										SR	Alterations in renal function	0 %
Ocampos-Martinez 2012 [33]	Belgium	Retrospective single-center cohort study	2009-2008	Medical: 59.8 % Surgical: 40.2 %	261		Mechanical ventilation (71 %) Sepsis (100 %)	Css: 20-30	**24 h:** 20.4±8.9 **48 h:** 24.1±9.1 **72 h:** 25.5±10.1 Time to target: 2 d (1-3)	ECF	Mortality (ICU)	29 % (77/261)
										ECS	Target attainment	*Target:* *Subtherapeutic:* *Supratherapeutic:* **24 h:** 47 % **24 h:** 42 % **24 h:** 11 % **48 h:** 67 % **48 h:** 14 % **48 h:** 19 % **72 h:** 86 % **72 h:** ND **72 h:** ND
Omuro 2021 [75]	Germany	Retrospective single-center cohort study	2019-2012	Medical: 30.3 % Surgical: 68.9 % Neurolog.: 0.8 %	119		CKD (8 %) Mechanical ventilation (87 %)	Css: 20-40	**Overall therapy:** 20.7±7.9	ECF	Mortality (ICU)	CI: 25.2 % (30/119) (VCM-AKI (CI+II): 48 % Non VCM-AKI (CI+II): 16.8 %)
										SR	AKI (AKIN [102])	20,2 % (eventually higher rate of AKI in medical patients (CI/II: surgical: 25,7 %; medical: 42,6 %))
Perin 2020 [63]	France	Retrospective single-center cohort study	2018/12-2016/01	No data on type of ICU provided	179 Primary outcome: 176 Finished follow-up: 131 (follow-up = 15 consecutive days after VCM initiation)		Augmented renal clearance (4 %) Mechanical ventilation (85 %) RRT (27 %)	Css: 20-25	**24-48 h:** 20.3±6.8	ECF	Mortality (ICU, in-hospital, 28-day)	**28-day:** D2/3 VCM level 20-25 mg/L: 19 % (8/42) All: 26 % (46/178) D2/3 VCM level <20/>25 mg/L: 28 % (37/132)
										ECF	Persistence or progression of baseline signs and symptoms of infection after ≥ 2 d of treatment, consistent with active infection Requirement for additional antibacterial treatment	Failure without identification: 13 % (23/179)
										ECS	Target attainment	**24-48 h:** 24 %
										ECS	Cure (= Resolution of clinical signs and symptoms compared with baseline, no requirement for antibiotic escalation)	65 % (116/179) (test of cure could not be assessed in 13 % (23/179))
										EMF	Relapse (= Finding of same pathogen); Reinfection (= Presence of another pathogen)	Relapse: 3 % (5/179); Reinfection 7 % (12/179);
										SR	AKI (KDIGO [103] (measured on D1-4; D10; D15))	During VCM administration: VCM <25 mg/L at d2/3: 60 % (107/179) VCM 55 % (72/131) With RRT: 27 % (49/179); ≥25 mg/L at d2/3: 77 % (34/44) With RRT 25 % (33/131) With RRT: 36 % (16/44);
Saugel 2013 [59]	Germany	Retrospective single-center cohort study	2008/12-2004/01	Medical	164		Mechanical ventilation (54 %) RRT (43 %)	Css: 20-30	**Overall therapy:** 19.7±14.7	SR	Start of RRT	7.3 %
Sin 2018 [56]	USA	Prospective single-center	2017/01-2014/11	Surgical: 65.4 % Medical: 34.6 %	52		CVVH (100 %)	Css: 15-25	**24 h:** 20.1±4.7 **48 h:** 20.7±3.7	ECF	Mortality (in-hospital)	63.5 % (33/52)

					Study Population with CI			Target Vancomycin Level		Outcome			
Reference	Country	Design	Time Course	ICU	Total Number of Patients	Comparison of Patient Groups	Specialty of study	Definition Css [mg/L] AUC24/MIC	Measured Value Css [mg/L] AUC24 [mg*h/L]		Definition	Results	
		cohort study							**72 h**: 21.9±3.5	ECS	Target attainment	*Target:* **24 h**: 82.7 % **48 h**: 81.8 % **72 h**: 75 %	*Sub ther ape utic:* **24 h:** 3.8 % **48 h:** 6.1 % **72 h:** 8.3 % / *Supratherapeutic* **24 h**: 13.5 % **48 h**: 12.1 % **72 h**: 16.7 %
										SNR	Infusion reaction; Ototoxicity	0 %	
Spadaro 2015 [58]	Italy	Retrospective single-center cohort study	2013/07-2010/03	Medical: CrCl >50 mL/min: 57 % ≤50 mL/min: 50 % Surgical: CrCl >50 mL/min: 43 % ≤50 mL/min: 50 %	348	CrCl >50 mL/min: 210 CrCl ≤50 mL/min: 138	CKD (40 % CrCl ≤50 mL/min) Differentiation in CrCl ≤/>50 mL/min	Css: 15-25 AUC24: >400	Not described CrCl >50 mL/min: 468±79 (AUC/MIC) CrCl ≤50 mL/min: 490±84 (AUC/MIC)	ECF ECS	Mortality (ICU) Target attainment	>50 mL/min: 21.4 % (45/210) **24 h:** >50 mL/min: 44 % ≤50 mL/min: 57 %;	≤50 mL/min: 23.9 % (33/138) **48 h:** >50 mL/ min: 41 % ≤50 mL/ min: 40 % / **72 h:** >50 mL/min: 41 % ≤50 mL/min: 41 %
										SR	AKI (Consensus Recommendation from AHSP/IDSA/SIDP on Therapeutic Monitoring of Vancomycin (2009) [50])	CrCL >50 mL/min: 2.4 % CrCL ≤50 mL/min: 9.4 %	VCM level 25-30 mg/L: 0 % VCM level >30 mg/L: <8 %
Spapen 2011 [61]	Belgium	Retrospective two-center cohort study	2009/11-2008/01	No data on type of ICU provided	129	AKI: 38 No AKI: 91	CKD (0 %; SCr >1.5 mg/dL))	Css: 15-25	**Overall therapy:** VCM level <25 mg/L: No AKI: 95.6 % (65/68) (71.4 %, 65/91) AKI: 4.4 % (3/68) (7.9 %, 3/38) VCM level 25-30 mg/L: No AKI: 69.0 % (20/29) (22.0 %, 20/91) AKI: 31.0 % (9/29) (23.7 %, 9/38) VCM level >30 mg/L: No AKI: 18.8 % (6/32) (6.6 %, 6/91) AKI: 81.3 % (26/32) (68.4 %, 26/38)	ECF	Mortality (no differentiation between "infection-related" or "AKI-induced")	AKI: 53 % (20/38)	No AKI: 20 % (18/91)
										SR	AKI (AKIN [102] 1)	Total: 29.5 % (38/129) Distribution according to VCM level: VCM level <25 mg/L: 7.9 % (3/38) VCM level 25-30 mg/L: 23.7 % (9/38) VCM level >30 mg/L: 68.4 % (26/38) No AKI: 95.5 % (65/68) (71.4 %, 65/91) AKI: 4.5 % (3/68) (7.9 %, 3/38)	VCM level 25-30 mg/L: No AKI: 69 % (20/29) (22 %, 20/91) AKI: 31 % (9/29) (23.7 %, 9/38) VMC level >30 mg/L: No AKI: 18.8 % (6/32) (6.6 %, 6/91) AKI: 81.3 % (26/32) (68.4 %, 26/38) Return of SCr to baseline at discharge (surviving): 66 % (12/18)
Stepan 2009 [62]	Czech Republic	Prospective single-center randomized controlled trial	2008/05-2004/05	Medical and Surgical	33		ND	Css: 15-25	**Overall therapy:** 19.0±4.3	ECF ECF ECS	Mortality (infection-related) Persistence of symptoms; Increase of symptoms Cure (= Vanishing of all symptoms of an infection); Improvement (= Reduction of symptoms of infection; LOS; LOV; LOT; Reduction of leukocytes; Reduction of CRP)	18 % (6/33) Not described Cure/improvement: 64 % (21/33) LOS: 26 d (12.8-40.3) LOV: 25 d (10.5-39.3)	LOT: 9 (7-10) Leukocytes: d0: 13.4 (9,7-18.9) end: 10.9 (8.6-17.9) (-18.7 %) CRP: d0: 192.0±98.1 end: 123±83.1 (-35.9 %)
										EMF EMS	Persistency; Superinfection; Relapse Cure (=Eradication; Suspected eradication)	Not described 76 % (25/33)	
										SR	Increase of SCr; Reduction of CrCl	0 %	
Tuon 2021 [86]	Brazil	Prospective single-center cohort study	2020/09-2018/01	No data on type of ICU provided	33		CNS infection (100 %)	Css: ND AUC24: ND	**Overall therapy:** 33.8±16.0 788±384	SR	AKI (AKIN [102])	Total: 21 % (7/33)	AKIN 1: 3 % (1/33) AKI N 2: 6 % (2/3 3) / AKI AKIN 3: 12 % (4/33)
Udy 2013 [72]	Australia	Retrospective single-center cohort study	2010/12-2008/01	No data on type of ICU provided	81	CVVH: 41 CVVHDF: 40	CRRT (100 %) Mechanical ventilation (85 %) Sepsis (100 %)	Css: 20-30	**24 h:** 24.6±9.2	ECF	Mortality (not specified)	58 % (47/81)	
Wysocki 2001 [47]	France	Prospective multicenter cohort study	36 months	Medical and Surgical	61		Mechanical ventilation (79 %)	Css: 20-25	**Overall therapy:** 24±8 Success: 23±4 Failure: 25±5	ECF	Mortality (infection-related: 10-day; end of treatment; overall: 10-day; end of treatment; ICU)	**Infection-related:** D10: 8 % (5/61) End of treatment: 10 % (6/61)	**Overall:** D10: 8 % (5/61) End of / ICU: 37 % (21/61)

Reference	Country	Design	Time Course	ICU	Study Population with CI		Specialty of study	Target Vancomycin Level		Outcome		
					Total Number of Patients	Comparison of Patient Groups		Definition Css [mg/L] AUC24/MIC	Measured Value Css [mg/L] AUC24 [mg*h/L]		Definition	Results
								AUC24: ND	Time to target: 36±31 h 577±120 Failure: 685±260 Success: 596±159	ECF	Persistency or impairment of clinical, laboratory, radiological statuses	D10: 21 % (13/61) — End of treatment: 21 % (13/61) — treatment: 18 % (11/61)
										ECS	Cure; Improvement	78.7 % (48/61)
										EMF	Presence of *Staphylococcus spp.* or other species in specimen on day 5	*Staphylococcus*: 39 % (24/61) — Other species: 15 % (9/61) — Bacteremia: 28 % (17/61)
										EMS	Cure (= Eradication of *Staphylococcus spp.* In specimen on d5)	46 % (28/61)
										SR	50 % increase of SCr from D0 until end of treatment	16.4 % (10/61) Dialysis: 9.8 % (6/61)
										SNR	Phlebitis/fever	3 % (2/61)

691
AKI: acute kidney injury, AKIN: Acute Kidney Injury Network, AHSP: American Society of Health-System Pharmacists, AUC24: vancomycin area under the serum concentration
versus time curve for 24 hours, CI: continuous infusion of vancomycin, CrCl: creatinine clearance, Css: steady-state serum concentration, CKD: chronic kidney disease, CNS:
central nervous system, CVVH: continuous veno-venous hemofiltration, CVVHDF: continuous veno-venous hemodiafiltration, d: day, D10: day 10 after initation of vancomycin
therapy, ECF: failure of clinical effectivity, ECS: success of clinical effectivity, EMF: failure of microbiological effectivity, EMS: success of microbiological effectivity, h: hour, ICU:
intensive care unit, IDSA: Infectious Diseases Society of America, II: intermittent infusion of vancomycin, KDIGO: Kidney Disease Improving Global Outcomes, LD: loading dose,
LOS: length of stay, LOT: length of therapy, LOV: length of ventilation, MD: maintenance dose, MIC: minimum inhibitory concentration, ND: not described, RIFLE: Risk, Injury,
Failure, Loss, End Stage Renal Disease, (C)RRT: (continuous) renal replacement therapy, SNR: non-renal safety, SCr, Serum creatinine, SR: renal safety, SIDP: Society of
Infectious Diseases Pharmacists, VCM: vancomycin.

Table 3: *Significant predictors for the outcomes "acute kidney injury", "mortality" and "target attainment" identified by univariate and multivariate regression analysis in the studies.*

701 **Significant predictors of outcomes**

Univariate	Multivariate
Target attainment (TA) • Loading dose (↑ dose → ↑ TA) [33] • Daily vancomycin dosage (↑ dosage → ↑ TA) [73] • Serum creatinine (↑ SCr → ↑ TA) [33] • Creatinine clearance (↓ CrCl → ↑ TA) [33] • CRRT intensity (↓ intensity → ↑ TA) [70, 73] • Age (↓ age → ↑ TA) [73] • Body weight (↑ body weight → ↑ TA) [67, 70] • Gender (male → ↓ TA) [33] • Prolonged ICU stay before initiation of vancomycin (↑ stay → ↓ TA) [63] • SOFA score (↑ score → ↑ TA) [33] *ICU mortality* • AKI (AKI → ↑ mortality) [75] *Acute kidney injury (AKI)* • Diabetes mellitus (diabetes → ↑ AKI) [61] • Shock (shock → ↑ AKI) [61]	*Target attainment (TA)* • Daily vancomycin dosage (↑ dosage → ↑ TA) [73] • Creatinine clearance (↓ CrCl → ↑ TA) [33, 67] • CRRT intensity (↓ intensity → ↑ TA) [73] • Age (↓ age → ↑ TA) [73] • Body weight (↑ body weight → ↑ TA) [67] • Body mass index (↑ BMI → ↑ TA) [67] • Gender (male → ↓ TA) [33] • Prolonged ICU stay before initiation of vancomycin (↑ stay → ↓ TA) [63] *In-hospital mortality* • C24 <15 mg/L (↓ C24 → ↑ mortality) [58] • SAPS II score (↑ score → ↑ mortality) [58] *Acute kiney injury (AKI)* • Cmean (day 1-3) (↑ Cmean → ↑ AKI) [71, 87] • Vancomycin level (esp. >30 mg/L) (↑ level → ↑ AKI) [61] • Duration of therapy (at time of highest SCr (risk/injury)) (↑ duration → ↑ AKI) [71, 87] • CrCl at ICU admission [58] • Body weight (↑ lean body weight → ↑ AKI) [61] • SAPS 3 score (↑ score → ↑ AKI) [61] *Early AKI* • Bacteremia (bacteremia → ↑ AKI) [71] • Cmean day 1-3 (↑ Cmean → ↑ AKI) [71] • Daily vancomycin dosage (day 1-3) (↓ dosage → ↑ AKI) [71] *Late AKI* • Diabetes (diabetes → ↑ AKI) [71] • Duration of therapy (↑ duration → ↑ AKI) [71]

702 AKI: acute kidney injury, BMI: body mass index, C24: mean steady-state vancomycin serum concentration about
703 24 hours after initiation of therapy, Cmean: mean steady-state vancomycin serum concentration during the entire
704 duration of therapy or at least three days of therapy, CrCl: creatinine clearance, CRRT: continuous renal
705 replacement therapy, ICU: intensive care unit, SAPS: Simplified Acute Physiology Score, SCr: serum creatinine,
706 SOFA score: Sepsis-related Organ Failure Assessment score, TA: target attainment

Figure 2: *Scatterplots of mean vancomycin steady-state serum concentrations (Css) plotted against each cohort's mortality rate. The dashed lines represent the regression lines (RL) of ICU mortality (▲ filled black triangle) in studies without 100 % dialysis patients. **a)** Studies in which Css approximately 24 h after initiation of therapy with continuous infusion of vancomycin (C24) were reported (n=10). RL: n=4 studies representing 615 patients; R²=0.7435. **b)** Studies in which Css during the entire duration of therapy with continuous infusion of vancomycin or at least three days of therapy (Cmean) were reported (n=10). RL: n=6 studies representing 1,420 patients; R²=0.0057. **c)** Studies in which mean vancomycin areas under the serum concentration vs. time curve for 24 h for continuously administered vancomycin (AUC24) were reported (n=6). RL: n=4 studies representing 635 patients; R²=0.0009.*

709
710

711   Filled black circle: mortality at the end of treatment with vancomycin, filled black triangle: ICU mortality, bordered
712   cross: in-hospital mortality, X: x-day mortality (e.g. 10-day, 28-day, 30-day), non-filled circle: mode of mortality not
713   reported, non-filled square: infection-related mortality.
714   CKD: chronic kidney disease, (C)RRT: (continuous) renal replacement therapy, CVVH: continuous veno-venous
715   hemofiltration, ICU: intensive care unit, SCr: serum creatinine.

Target attainment

Figure 3: *Scatterplots of mean vancomycin steady-state serum concentrations (Css) plotted against each cohort's rate of target attainment.* ***a)*** *Studies in which Css approximately 24 h after initiation of therapy with continuous infusion of vancomycin (C24) were reported (n=9 studies representing 953 patients).* ***b)*** *Studies in which Css during the entire duration of therapy with continuous infusion of vancomycin or at least three days of therapy (Cmean) were reported (n=4 studies representing 488 patients).*

Filled square: Css target range of 20-30 mg/L, filled circle: Css target range of 15-25 mg/L, filled triangle: Css target range of 20-25 mg/L,

aLD: applied average loading dose, aMD: applied average maintenance dose, Sepsis: proportion of patients with sepsis in the study population

Nephrotoxicity

*Figure 4: Scatterplots of mean vancomycin steady-state serum concentrations (Css) plotted against each cohort's rate of acute kidney injury (AKI) (= Nephrotoxicity). The dashed lines represent the regression lines calculated from the data of all cohorts of a respective Css class. **a)** Studies in which Css approximately 24 h after initiation of therapy with continuous infusion of vancomycin (C24) were reported (n=5 studies representing 582 patients; R²=0.0242). **b)** Studies in which Css during the entire duration of therapy with continuous infusion of vancomycin or at least three days of therapy (Cmean) were reported (n=9 studies representing 1,479 patients; R²=0.1174). **c)** Studies in which mean vancomycin areas under the serum concentration vs. time curve for 24 h for continuously administered vancomycin (AUC24) were reported (n=5 studies representing 613 patients;*

Filled black diamond: AKIN, filled black square: KDIGO, squared triangle: other definition of AKI, star: RIFLE, non-
filled triangle: RRT, non-filled diamond: Rybak2009
AKIN: Acute Kidney Injury Network, KDIGO: Kidney Disease Improving Global Outcomes, LOT: length of therapy
with continuously administered vancomycin, RIFLE: Risk, Injury, Failure, Loss, End Stage Renal Disease, RRT:
renal replacement therapy, Rybak2009: Consensus Recommendation from AHSP/IDSA/SIDP on Therapeutic
Monitoring of Vancomycin (2009) (AHSP: American Society of Health-System Pharmacists, IDSA: Infectious
Diseases Society of America, SIDP: Society of Infectious Diseases Pharmacists).

Figure 5: Forest plot comparing the influence of vancomycin steady-state serum concentration below or above 25 mg/L on acute kidney injury (AKI) (n=3 studies representing 515 patients). Overall risk ratio = 0.535 (95 % confidence interval 0.432-0.662; z = -5.745; p = <0.0001).

770 Risk ratio <1 indicates a lower risk of acute kidney injury at a vancomycin serum concentration of <25 mg/L as
771 opposed to >25 mg/L. The dark grey diamond represents the overall risk ratio.

773 Supplementary Material

774 Study Design

775 **Table S1**: *Overview of study designs, number of patients, inclusion and exclusion criteria and primary purpose of studies. Thirty-eight studies were identified in the initial full-text*
776 *selection process that presented data of steady-state serum concentrations of continuously administered vancomycin (CI) and efficacy (clinical or microbiological success (e.g.*
777 *cure) or failure (e.g. mortality)) or safety (e.g. acute renal failure). Only twenty-one studies made it into the final analysis. Studies excluded from the final selection because of an*
778 *increased risk of bias (e.g. unspecified time course or time course of less than 12 months or a CI study population of less than 30 patients) are written in italics.*

Reference	Country	Design	Time Course	Study Population — Total Number of Patients	Total Number of CI Patients	Comparison	Inclusion Criteria	Exclusion Criteria	Main Purpose
Akers [64]	USA	Retrospective single-center cohort study	2009/12-2006/01	171	90	CI: 90; II: 81	≥1 VCM serum level (Css or trough); Burn injury; With/without high-dose CVVH; Contribution of data of patients only once	≤1 VCM level; Pediatric patients; Pregnancy; Admission for other than a primary thermal burn injury	Determination of serum vancomycin levels resulting from CI vs II in critically ill burn patients with or without CRRT
Albanèse [74] Excluded due to number of patients <30 and unspecified length of time course	*France*	*Prospective single-center cohort study*	*Not described*	*13*	*13*	*Bacterial meningitis: 7; Other infection: 6*	*Infection with VCM-sensitive bacteria; Mechanical ventilation for acute respiratory failure*	*Renal dysfunction; Expected hospital stay <72 h; Pediatric patients*	*Evaluation of CSF penetration and PK of VCM after CI in mechanically ventilated patients*
Baptista [68]	Portugal	Prospective single-center cohort study	A (MD 30 mg/kg/d): 13 months; B (MD nomogram): Not described	104	104	A (MD 30 mg/kg/d): 79; B (MD nomogram): 25	A: Mechanical ventilation; Adult (≥18 years); Severe sepsis or septic shock; Empirical or directed treatment with VCM; B: Administration of LD + MD per protocol; Evaluation of 8 h CrCl the day of initiation of VCM; Interval between LD and TDM >12 h + <24 h; Stable renal function;	SCr >1.3 mg/dL; CKD; RRT; Pediatric patients (<18 years); Pregnancy; ICU stay <48 h	Development of a dosing nomogram for administration of VCM by CI for the first 24 h of therapy based on the measured urinary CrCl (8 h CrCl)
Beumier [70]	Belgium	Prospective single-center cohort study	2012/05-2011/01	32	32	32	Sepsis; CRRT	VCM therapy in previous 48 h	Evaluation of the adequancy of a new CI VCM regimen in septic patients undergoing CRRT; description of impact of CRRT intensity on drug concentrations; assessment of correlation between AUC/MIC and VCM concentration during CI
Carricajo [76] Excluded due to number of patients <30 and unspecified length of time course	*France*	*Prospective single-center cohort study*	*Not described*	*22*	*22*	*Microbiological identification in 12 patients*	*CrCl >50 mL/min*	*-*	*Evaluation of an administration protocol (LD 30 mg/kg; MD 30 mg/kg/d) for VCM using CI in patients with CrCl > 50 mL/min*
Cianferoni [71]	Belgium	Retrospective single-center cohort study	2009/12-2008/01	207	207	No AKI: 157; AKI: 50; (Early AKI: 28; Late AKI: 22)	VCM therapy ≥48 h; VCM levels (daily); No RRT (CRRT or HD) at time of VCM initiation; Sepsis;	VCM therapy within the week prior to present episode; RRT; ESRD chronically treated	Evaluation of the occurrence of renal failure during CI of VCM in critically ill patients with sepsis; identification of risk factors and time course (early vs late) of development of AKI; long-term (1 month ±7 d)

Reference	Country	Design	Time Course	Study Population			Inclusion Criteria	Exclusion Criteria	Main Purpose
				Total Number of Patients	Total Number of CI Patients	Comparison			
							TBW noted in data file;	with HD; Missing data on SCr, urine output and/or concomitant nephrotoxins	consequences of CI on renal function
Covajes [73]	Belgium	Retrospective single-center cohort study	2010/12-2008/01	85	85	85	VCM therapy ≥48 h; VCM level (daily); CRRT; Sepsis according to standard criteria	Previous administration of VCM by II (within 48 h of start of CI); Residual urine output >500 mL/d; Pregnancy; Burn; Cystic fibrosis	Determination of the application of VCM by CI in septic patients receiving CRRT
Cristallini [67]	Belgium	Prospective single-center cohort study	2013/05-2012/01	107	107	107	VCM monotherapy or combination with other antibiotics; Adult (≥18 years); Sepsis	VCM application in the previoius 48 h; RRT; ECMO	Validation of a dosing regime of VCM given by CI to septic patients
Di Filippo [77] Excluded due to number of patients <30 and time course of only 7 months	Italy	Retrospective single-center cohort study	7 months	25	11	CI: 11; II: 14	VCM therapy ≥5 d; Documented MRSA/MRCoNS infection; Clinical cure	History of hypersensitivity to glycopeptides; Severe renal failure (=SCr >5 mg/dL); Pediatric patients; Pregnancy; AIDS	Verification of the therapeutic response/efficacy of VCM in MRS (MRSA/MRCNS) administered by CI vs II
Duszynska [44] Excluded due to number of patients <30	Poland	Prospective single-center cohort study	2014/04-2012/05	42	21	CI: 21; II: 21	Adult (≥18 years); Microbiologically confirmed gram-positive infection; Non-MRSA infection	History of intolerance to glycopeptides; CKD requiring HD; AKI already treated by CRRT; Pregnancy; Burn Cystic fibrosis	Evaluation of the effectivity and safety of VCM in treatment of gram-positive pathogens other than MRSA + determination of optimal AUC/MIC and VCM concentration for treatment of septic patient with non-MRSA gram-positive infection
Eldemiry [53] Excluded due to number of patients <30	Egypt	Prospective single-center cohort study	2012/09-2009/11	40	20	CI: 20; II: 20	SCr >1.4 mg/dL; Oliguria <0.5 mL/kg/h for 6 h	SCr ≥4 mg/dL; RRT; Critical illness potentially resulting in renal dysfunction (e.g. septic shock, cardiac arrest); Systolic blood pressure <90 mmHg	Comparison of CI vs II in renally impaired critically ill patients
Hanrahan [87]	UK	Retrospective single-center cohort study	2009/08-2004/12	1430	653	CI: 653; II: 390; Mixed Infusion: 221; Unknown Mode of Infusion: 166	First episode of VCM treatment	No VCM serum level, dosing amount, SCr; Incomplete SOFA score availability	Evaluation of VCM dose, trough and dosing strategy on evolution of AKI in critically ill patients
Hong [39] Excluded due to time course of only 9 months	USA	Retrospective single-center cohort study	2014/06-2013/10	130	65	CI: 65; II: 65	≥1 VCM serum level (Css or trough); CrCl≥20 mL/min	Change between II/CI; CrCl (CG/MDRD) <20 mL/min; Dialysis: HD, PD, RRT; Postoperative prophylaxis; Pregnancy; Prisoner	Evaluation of target plasma level attainment and safety (nephrotoxicity) in neurosurgical ICU patients receiving CI vs II VCM
Hutschala [46]	Austria	Retrospective single-center cohort study	2005/12-2001/01	149	119	CI: 119; II: 30	Adult (>19 years); SCr ≤1.5 mg/dL; ICU-admission after elective CS (open heart); Presumed or documented hospital acquired gram-positive infection; Preoperative no period of AKI or CKD; no preoperative RRT	VCM therapy 72 h before elective CS; Verified betalactam allergy; SCr >1.5 mg/dL; Necessity of RRT; Intraoperative: prolonged extracorporeal circulation; Preoperative: clinical signs of infection, SIRS; Increased body temperature > 37.5 °C; bleeding (>4 red packed cells), hemofiltration on CPB; perioperative and/or postoperative: AKI in accordance	Comparison of the nephrotoxic impact of VCM during CI vs II

Reference	Country	Design	Time Course	Study Population			Inclusion Criteria	Exclusion Criteria	Main Purpose
				Total Number of Patients	Total Number of CI Patients	Comparison			
								with AKIN classification, hemodynamic instability, increased vasopressor support, norepinephrin dosage > 0.5 µg/kg*min, epinephrin dosage >0.2 µg/kg*min, dobutamin dosage >5 µg/kg*min, increased inotropic support, hypotension, urine production <0.5 mL/kg*h, necessity of additional administration of proven nephrotoxic drugs (immunosuppressive drugs), ≥ 2 organ failures (MOD Score ≥9), SAPS II >70 on ICU admission	
Lin [45] Excluded due to number of patients <30	*USA*	*Retrospective single-center cohort study*	*2014/08-2011/01*	*54*	*14*	*CI: 14; II: 45*	*VCM 24 h serum level; CVVH*	*First dose of VCM received ≥ 6 h prior to initiation of CVVH; Residual renal function during CVVH; Average urine output >0.5 mL/kg/h for 6 consecutive hours; ECMO (concomitantly)*	*Comparison of VCM administration during CVVH by II vs CI*
Lin [57]	USA	Retrospective single-center cohort study	2015/01-2013/01	52	52	Obese (BMI >35 kg/m²): 26; Non-obese (BMI <30 kg/m²): 26	VCM level 24 h after initiation of therapy; BMI ≥35 kg/m²	VCM application within 48 h prior to start of CI	Evaluation of difference in the weight-based maintenance dose required to reach a therapeutic VCM concentration at 24 hours when given as a CI in obese versus non-obese critically ill patients
Ma [52] Excluded due to inclusion of ICU and non-ICU patients in analysis	*Canada*	*Retrospective multicenter cohort study*	*2016/12-2010/01*	*292*	*146*	*CI: 146; II: 146*	*VCM therapy ≥48 h; ≥1 VCM serum level (Css or trough); ≥2 SCr levels (1 before VCM initiation + 1 either during or within 2 weeks after VCM therapy)*	*Start of VCM at non-study hospital; Rise in SCr within first 48 h of VCM initiation; RRT at baseline or immediately before initiation of VCM*	*Comparison of the nephrotoxicity with CI vs II when the target concentration ranges were the same*
Mohammedi [85]	France	Prospective single-center cohort study	12 months	40	40	A (LD 500 mg): 20; B (LD 15 mg/kg): 20	Presumed or proven gram-positive sepsis	History of prior allergy to VCM	Determination of the better loading dose of VCM in critically ill patients with suspected gram-positive infection
Ocampos-Martinez [33]	Belgium	Retrospective single-center cohort study	2009-2008	261	261	261	VCM therapy ≥48 h; VCM levels (daily); Diagnosis of sepsis according to standard criteria (2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference); TBW available in the medical file	Pediatric patients; CKD requiring dialysis; CRRT; Pregnancy; Burns; Cystic fibrosis; Previous II VCM administration (within 48 h of the start of CI);	Evaluation of the efficacy of CI in septic patients by evaluation of the VCM concentrations within the first 24-48 h of therapy in patients receiving CI + of the determinant of early insufficient VCM concentration in this population
Omuro [75]	Germany	Retrospective single-center cohort study	2019-2012	578	119	CI: 119; II: 147; Control: 312	VCM therapy ≥48 h; Adult (≥18 years); SCr levels (up to 72 h after cessation of VCM); Urinary time volume (up to 72 h after cessation of VCM)	VCM therapy within previous 7 days; RRT at VCM initiation; ESRD requiring dialysis	Evaluation of the incidence of AKI and identification of predictors of AKI in CI vs II VCM
Perin [63]	France	Retrospective single-center cohort study	2018/12-2016/01	179	179	Primary outcome: 176; Finished follow-up: 131 (follow-up = 15 consecutive days after VCM initiation)	Adult (≥18 years); ICU stay; Clinical indication for CI according to physician in charge	Ongoing VCM treatment; II of VCM; No iv infusion of VCM; >14 d treatment with VCM (e.g. endocarditis); Decision over withdrawing care would be decided in the next 48	Assessment of the proportion of ICU patients with VCM serum concentration between 20-25 mg/L after 24-48 h

Reference	Country	Design	Time Course	Study Population			Inclusion Criteria	Exclusion Criteria	Main Purpose
				Total Number of Patients	Total Number of CI Patients	Comparison			
								h; No VCM level; Chronic renal failure with previous RRT; Pediatric patients (<18 years); Pregnancy; Previous participation in the present study; Expression of refusal to participate in study	
Ricard [118] Excluded due to number of patients <30 and unspecified length of time course	*France*	*Prospective multicenter cohort study*	*Not described*	*14*	*14*	*14*	*Adult (>18 years); Presumed or proven pneumococcal meningitis; D2/3: 2nd lumbar puncture*	*Not described*	*Determination of the VCM concentration in serum and CSF of patients with suspected or proven pneumococcal meningitis receiving dexamethasone to assess the penetration of VCM into CSF during steroid therapy*
Saugel [69] Excluded due to time course of only 9 months	*Germany*	*Prospective single-center cohort study*	*2013/02-2012/06*	*34*	*34*	*34*	*VCM LD + MD according to study protocol*	*Not described*	*Evaluation of a dosing algorithm for CI administration in ICU patients*
Saugel [59]	Germany	Retrospective single-center cohort study	2008/12-2004/01	239	164	CI: 164; II: 75	-	Not described	Evaluation of CI in ICU patients
Schmelzer [60] Excluded due to number of patients <30 and unspecified length of time course	*USA*	*Prospective single center randomized controlled trial*	*Not described*	*55*	*28*	*CI: 28; II: 27*	*VCM therapy ≥48 h; VCM levels obtained; Adult (>18 years); Trauma; Suspected VAP after BAL; Double inclusion if patient met the inclusion criteria on later occasion again*	*History of prior allergy to VCM; Pediatric patients; Abnormal renal function (CrCl <60 mL/min); Pregnancy; Ascites;*	*Comparison of CI vs II in VAP trauma patients*
Sin [56]	USA	Prospective single-center cohort study	2017/01-2014/11	52	52	52	Adult (≥18 years) CVVH due to acute or chronic renal failure with minimal or no urine output; Critical illness; Switch from II possible	No level drawn 24 h after CI initiation; Urine output >0.5 mL/kg/h while undergoing CVVH; ECMO	Evaluation of a CI dosing nomogram that incorporates CVVH intensity
Spadaro [58]	Italy	Retrospective single-center cohort study	2013/07-2010/03	348	348	CrCl >50 mL/min: 210; CrCl ≤50 mL/min: 138	VCM therapy ≥48 h; Empiric or targeted sepsis treatment	CRRT; Pregnancy	Estimation of the efficacy of a VCM dosing protocol in target attainment in critically ill patients with or without kidney dysfunction to analyse which factors are related to subtherapeutic VCM levels
Spapen [61]	Belgium	Retrospective two-center cohort study	2009/11-2008/01	129	129	AKI: 38; No AKI: 91	VCM therapy ≥5 d; Adult (≥18 years) SCr (baseline) <1,5 mg/dL; Microbiologically documented gram-positive pneumonia/bacteremia; Neutrophil count ≥1000/µL	VCM/SCr data missing; Polymicrobial infection; Meningitis Cystic fibrosis; Bronchiectasis; iv contrast (within 7 d of VCM initiation);	Determination of the incidence and risk factors of AKI during CI
Stepan [62]	Czeck Republic	Prospective single-center randomized controlled trial	2008/05-2004/05	65	33	CI: 33; II: 32	VCM therapy ≥4 d; Gram-positive infection indicated for VCM administration	SCr >2.3 mg/dL; Pregnancy;	Comparison of the clinical and microbiological efficacy and safety of CI vs II in critically ill patients
Tiede [119] Excluded due to number of patients <30	*Germany*	*Retrospective single-center cohort study*	*2017/03-2016/01*	*11*	*11*	*11*	*Ventriculitis secondary to subarachnoid hemorrhage (with insertion of EVD to manage hydrocephalus/monitor intracranial pressure --> source of infection)*	*Infection due to other sources than external ventricular drains*	*Individualized dosing strategy for continuous meropenem + VCM + TDM to optimized antimicrobial exposure in ventriculitis patients*
Tuon [86]	Brazil	Prospective single-center	2020/09-2018/01	33	33	33	Presumed or documented EVD infection (meningitis/ventriculitis);	History of hypersensitivity to VCM;	Evaluation of CI (high-dose) in patients with nosocomial ventriculitis + utility of a

Reference	Country	Design	Time Course	Study Population			Inclusion Criteria	Exclusion Criteria	Main Purpose
				Total Number of Patients	Total Number of CI Patients	Comparison			
		cohort study					ICU stay	Pediatric patients (<18 years); Inability to obtain informed consent	commercial kit used to measure serum VCM concentration in cerebrospinal fluid (CSF) sample
Udy [72]	Australia	Retrospective single-center cohort study	2010/12-2008/01	81	81	CVVH: 41; CVVHDF: 40	VCM therapy ≥48 h; ≥ 1 VCM level; Adult (>18 years); Sepsis according to standard criteria; CRRT	Previous administration of VCM by II within 48 h of start of CI; Urine output >500 mL/d; Pregnancy; Burns; Cystic fibrosis	Conduction of a population PK analysis in septic patients undergoing CRRT + determination of parameters associated with inadequate VCM concentration
van de Vijsel [54] Excluded due to number of patients <30	*Canada*	*Retrospective single-center cohort study*	*2008/06-2003/01*	*24*	*No*	*24*	*VCM therapy ≥24 h; ≥2 VCM serum levels (peak + trough; 2 post-dose Css); Adult (≥18 years); Concurrent CVVHD*	*Unclear nursing notes as to when VCM had been administered or serum sampling was conducted; Burns*	*Development of a practical recommendation for initial dosing of VCM in critically ill patients undergoing CVVHD*
van den Heever [55] Excluded due to number of patients <30	*South Africa*	*Prospective single-center cohort study*	*2011/02-2010/02*	*10*	*No*	*10*	*Severe infection caused by gram-positive organism (MRSA; CoNS; enterococci)*	*Continued empirical use for infection; Children <12 y; Renal failure with RRT; Hypersensitivity to VCM; Selective bowel decontamination; Eradication of MRSA colonization; Primary treatment of Clostridioides difficile colitis; Topical application or irrigation of VCM; CNS infection; Endocarditis; Pregnancy; Neutropenia; Thrombocytopenia; Concurrent use of nephrotoxic drugs*	*Testing of a feasible regimen for adjusting the maintenance dose in critically ill patients in order to reach therapeutic levels*
Vazquez [68] Excluded due to number of patients <30	*Uruguay*	*Prospective single-center cohort study*	*12 months*	*25*	*No*	*25*	*Documented gram-positive infection; Severe sepsis; Septic shock;*	*Not described*	*Test of the usefulness of a multi-compartment model in order to understand the rapid changes that occur in critically ill patients during CI therapy*
Wysocki [47]	France	Prospective multicenter cohort study	36 months	119	61	CI: 61; II: 58; (Therapy success: 95; Therapy failure: 24)	Presumed or documented MRS infection acquired 72 h after admission; Direct microbiologic examination showing gram-positive cocci; Adult (≥18 years); SCr ≤2.3 mg/dL; Neutrophil count >1000/µL; ≤3 Organ failures according to organ system failure score; Only first course of VCM therapy is counted	VCM administration 72 h before current infection; Betalactam allergy; Participating currently in another protocol;	Comparison of CI vs II in regard to microbiological and clinical outcomes, safety, pharmacokinetics, ease of treatment adjustment, cost
Wysocki [120] Excluded due to number of patients <30	*France*	*Prospective single-center cohort study*	*1986/11-1983/05*	*26*	*13*	*CI: 13; II: 13*	*Expected VCM therapy ≥5 days; Documented MRSA infection; SCr ≤3.6 mg/dL on initiation of VCM therapy; Neutrophil count ≥1000/µL*	*Not described*	*Evaluation of the efficacy and nephrotoxicity of CI vs II*
Yamada [42] Excluded due to number of patients <30	*Brazil*	*Prospective single-center cohort study*	*2019/07-2018/01*	*23*	*11*	*CI: 11; II: 12*	*Presumed or documented gram-positive infection*	*History of hypersensitivity to VCM; Pediatric patients; SCr≥2.5 mg/dL or eGFR ≤40 mL/min; Life expectancy ≤48 h; Inability to obtain informed consent*	*Comparison of the PK characteristics between II vs CI in critically ill patients admitted to ICU*

CG: Cockcroft-Gault formula, CI: continuous infusion of vancomycin, CKD: chronic kidney disease, CNS: central nervous system, CoNS: coagulase-negative staphylococci, CrCl:
creatinine clearance, (C)RRT: (continuous) renal replacement therapy, CS: cardiosurgery, Css: concentration at steady state, CVVHD: continous veno-venous hemodialysis,
eGFR: estimated glomerular filtration rate, ESRD: end-stage renal disease, EVD: external ventricular drain, HD: hemodialysis, ICU: intensive care unit, II: intermittent infusion of

vancomycin, LD: loading dose, MD: maintenance dose, MRCoNS: methicillin-resistant coagulase-negative staphylococci, MRDR: modification of diet in renal disease, MRS:
methicillin-resistant staphylococci, MRSA: methicillin-resistant *Staphylococcus aureus*, PD: peritoneal dialysis, Pediatric patients: age <18 years; SCr: serum creatinine, TBW: total
body weight, VCM: vancomycin.

Study population

Table S2*: Overview of the study population. Thirty-eight studies were identified in the initial full-text selection process that presented data of steady-state serum concentrations of*
continuously administered vancomycin (CI) and efficacy (clinical or microbiological success (e.g. cure) or failure (e.g. mortality)) or safety (e.g. acute renal failure). Only twenty-one
studies made it into the final analysis. Studies excluded from the final selection because of an increased risk of bias (e.g. unspecified or time course of less than 12 months or a CI
study population of less than 30 patients) are written in italics.

Reference	Study Population with Continuous Infusion									
	Number of Patients	**Age [years]**	**Gender**	**Comorbidities**	**ICU**	**Specialty**	**Severity Score**	**ICU Length of Stay [days]**	**Type of infection**	**Microbiology**
Akers [64]	90 (out of 171)	40.8±19.8	Male: 91.1 % Female: 8.9 %	Not described	Surgical (burn)	Burn patients (100 %)	Not described	Not described	Gram-negative bacteremia or candidemia (18.9 %, 17/90); Gram-positive bacteremia (27.8 %, 25/90); Pneumonia (22.2 %, 20/90); Sepsis without confirmed gram-positive bacteremia (22.2 %, 20/90);	*MSSA; MRSA; CoNS; E. faecium; E. faecalis; Enterococcus spp.; Streptococcus pneumoniae; Streptococcus viridans; Streptococcus agalactiae; Nonenterococcal Group D Streptococci; Streptococcus mutans*
Albanèse [74] ***Excluded due to number of patients <30 and unspecified length of time course***	*Total: 11 Bacterial meningitis: 7; Other infections: 6*	*25-58*	*Male: 50 % Female: 50 %*	*Primary pathologies: medical coma (27 %); subarachnoid hemorrhage (18 %); stroke (9 %)*	*No data on type of ICU*	*Mechanical ventilation (100 %); CNS infection (100 %)*	*Not described*	*Not described*	*Infection due to VCM sensitive bacteria; Bacterial meningitis: 53.8 %, 7/13 Other CNS infection (46.2 %, 6/13)*	*Staphylococcus aureus (23 %, 3/13); Staphylococcus epidermidis (46 %, 6/13); Streptococcus pneumoniae (15 %, 2/13); Enterococcus faecalis (8 %, 1/13); Corynebacterium (8 %, 1/13)*
Baptista [68]	Total: 104 A (MD 30 mg/kg/d): 79; B (MD nomogram): 25	A: 57.8±15.5; B: 59.9±17.2	A: Male 66 % Female: 34 %; B: Male: 68 % Female 32 %	Not described	Medical: A: 39.2 %; B: 20 %; Surgical: A: 60.8 %; B: 80 %	Augmented renal clearance (76.7 %); Mechanical ventilation (100 %); Sepsis (100 %)	SAPS II: A: 39 (34-50); B: 43 (37-46)	A: 19 (9-29); B: 23 (18-30)	Sepsis (100 %, 104/104)	Not described
Beumier [70]	32	55 (47-64)	Male: 53.1 % Female: 46.9 %	COPD/asthma (9 %); Cardiopathy (41 %); Diabetes (19 %); Chronic haemodialysis (9 %); Liver cirrhosis (19 %); Cancer (13 %); Corticosteroids (1 %); Other immunosuppression (19 %); Organ transplantation (16 %)	Medical: 69 %; Surgical: 31 %	CRRT (100 %); Mechanical ventilation (78 %); Sepsis (100 %);	APACHE II (on admission): 21 (17-25); SOFA (on start of CI): 14 (11-17)	14 (9-29)	Sepsis (100 %, 32/32) Pneumonia (46.9 %, 15/32); Abdomen (18.8 %, 6/32); Catheter-related (12.5 %, 4/32); Urogenitary (3.1 %, 1/32); Other site (18.8 %, 6/32)	Positive cultures*: 16 % (5/32) *MRSA (40 %, 2/5); MRSE (40 %, 2/5); Enterococcus faecium (60 %, 3/5)*
Carricajo [76] ***Excluded due to number of patients <30 and unspecified length of time course***	*Total: 22 Microbiological identification in 12 patients*	*59.8 (40-76)*	*Not described*	*Not described*	*Medical: 25 %; Surgical: 75 %*	*Augmented renal clearance (32 %); CKD (0 %); CrCl <50 mL/min)*	*SAPS II: 42.4 (22-64)*	*Not described*	*Bacteremia; Pneumonia; SSTI*	*Staphylococcus aureus (83 %, 10/12): MIC 0.5-3; CoNS (17 %, 2/12); CrCl< 120 mL/min: microbiological evaluation 57.1 % (8/14); CrCl≥120 mL/min: 42.9 % (6/14)*
Cianferoni [71]	Total: 207 No AKI: 157; AKI: 50; (Early AKI: 28; Late AKI: 22)	All: 60±15; No AKI: 60±15; AKI: 61±14; (Early AKI:	All: Male: 62.8 % Female: 37.2 %; No AKI: Male 62.4 % Female: 37.6 %; AKI: Male: 64.0 % Female: 36.0 %;	All: Asthma/COPD (25 %); Hypertension (38 %); Cardiopathy (27 %); Diabetes (26 %); Liver cirrhosis (8 %); Cancer (31 %); Thromboembolic venous disease (6	Medical: All: 59 %; No AKI: 59 %; AKI: 62 %; (Early AKI: 60 %; Late AKI: 63 %)); Surgical: All: 41 %;	Mechanical ventilation (69 %) Sepsis (100 %);	APACHE II (on admission): All: 20 (16-27); (No AKI:19 (15-25); AKI: 24 (18-30);	All: 10 (6-18); No AKI: 10 (5-18); AKI: 12 (8-21); (Early AKI: 11 (8-19); Late AKI:	Sepsis (100 %, 207/207) Abdomen (21 %, 44/207); Bacteremia (all: 18 %, 37/207; no AKI: 16 %, 26/157; AKI: 22 %, 11/50; early AKI: 32 %, 9/28; late AKI: 9 %, 2/22); Pneumonia (50 %, 103/207) ; Urogenitary (13 %, 27/207)	Positive cultures*: 65 % (112/207); *MSSA (27 %, 30/112); MRSA (20 %, 22/112); CoNS (27 %, 30/112); Enterococcus (19 %, 21/112); Others (8 %, 9/112)*

Reference	Study Population with Continuous Infusion									
	Number of Patients	Age [years]	Gender	Comorbidities	ICU	Specialty	Severity Score	ICU Length of Stay [days]	Type of infection	Microbiology
		62±13; Late AKI: 59±15	(Early AKI: Male: 64.3 %; Female: 35.7 %; Late AKI: Male: 59.0 % Female: 41.0 %)	%); Smoking (19 %); Alcohol (17 %);	No AKI: 41 %; AKI: 38 %; (Early AKI: 40 %; Late AKI: 37 %)		early AKI: 24 (19-29); late AKI: 21 (16-29)); SOFA (on admission): All: 8 (5-11); (No AKI:7 (3-10); AKI: 9 (4-12); early AKI: 10 (6-13); late AKI: 8 (6-11))	12 (8-19)		
Covajes [73]	85	65±15	Male: 65.9 % Female: 34.1 %	Asthma/COPD (22 %); Hypertension (24 %); Cardiopathy (49 %); Diabetes (27 %); Liver cirrhosis (14 %); Cancer (15 %); Immunosuppresion (26 %); Thromboembolic disease (5 %)	Medical: 69 %; Surgical: 31 %	CRRT (100 %); Mechanical ventilation (84 %) Sepsis (100 %);	APACHE II (on admission): 24 (20-29); SOFA (on start of CI): 11 (7-14)	12 (6-20)	Sepsis (100 %, 85/85) Septic shock (82 %, 70/85); Abdomen (32 %, 27/85); Bacteremia (33 %, 28/85) Pneumonia (46 %, 39/85);	Positive cultures*: 55 % (47/85); MSSA (14.9 %, 7/47); MRSA (25.5 %, 12/47); CoNS (38.3 %, 18/47); Enterococcus spp. (21.3 %, 10/47)
Cristallini [67]	107	59 (48-71)	Male: 72 % Female: 38 %	Asthma/COPD (18 %); Cancer (16 %); CKD (29 %); Corticosteroids (32 %); Diabetes (21 %); Hearth disease (22 %); Liver cirrhosis (6 %); Organ transplantation (16 %); Other immunosuppression (23 %);	Medical: 36 %; Surgical: 64 %	Mechanical ventilation (54 %); Sepsis (100 %)	APACHE II (on admission): 19 (13-25); SOFA (on admission, daily): 6 (4-9)	Not described	Sepsis (100 %, 107/107) Septic shock (53 %, 57/107); Abdomen (11 %, 12/107); Bacteremia (17 %, 18/107); Catheter-related (6 %, 7/107); CNS (5 %, 5/107); Pneumonia (44 %, 47/107); SSTI (7 %, 8/107); Urogenitary (7 %, 8/107)	Positive cultures*: 79 % (84/107) MRSA (12 %, 10/84); MRSE (12 %, 10/84); Enterococcus faecium (5 %, 4/84) Gram-negative bacteria (71 %, 60/84)
Di Filippo [77] Excluded due to number of patients <30 and time course of only 7 months	11 (out of 25)	70±14	Male: 81.8 % Female: 18.2 %	Cardiogenic shock (27 %); head trauma (18 %); multitrauma (9 %); new acute COAD (9 %); polyneuropathy (9 %); pulmonary embolism (18 %)	No data on type of ICU	MRSA/MRCoNS (100 %)	SAPS II: 50±9; SOFA: Before start of CI: (6.6±2.2); End of CI: (4.37±3.5) (-33.8 %)	13±4	Bacteremia (27.3 %, 3/11); Pneumonia (72.7 %, 8/11)	Clinical sample: bronchial sputum, BAL, blood culture; Methicillin-resistant staphylococcal: MRSA; MRCoNS; Mixed infection: MRS + Klebsiella pneumoniae (n=2); MRS + Pseudomonas spp. (n=2)
Duszynska [44] Excluded due to number of patients <30	21 (out of 42)	62±14	Male: 76,5 % Female: 33,5 %	Not described	Surgical	Mechanical ventilation (100 %); Non-Staphylococcus aureus (100 %); Sepsis (100 %)	APACHE II: 21±6	36 (15-65)	Abdomen (Peritonitis) (29 %, 6/21); Catheter-related (19 %, 4/21); CNS (19 %, 4/21); Others (5 %, 1/21); Pneumonia (HAP/VAP) (14 %, 3/21); Septic shock (43 %, 9/21); SSTI (14 %, 3/21)	CoNS (71 %, 14/21); Enterococcus faecium (24 %, 5/21); Streptococcus pneumoniae (5 %, 2/21)
Eldemiry [53] Excluded due to number of patients <30	20 (out of 40)	Not described	Not described	Not described	No data on type of ICU	Pneumonia (100 %); CDK (100 %; SCr >1.4 mg/dL)	APACHE II: 14.2±4.6; SAPS; SOFA	-	Pneumonia (100 %, 40/40)	Positive cultures*: 60 % (12/20) Staphylococcus aureus
Hanrahan [87]	653 (out of 1430)	59 (44-69)	Male: 63.9 % Female: 36.1 %	Not described	Medical; Surgical	Not described	SOFA (on admission): 7 (5-9)	Not described	Not described	MRSA (9.8 %, 64/653)
Hong [39] Excluded due to time course of only 9 months	65 (out of 130)	56±15.5	Male: 53.8 % Female: 46.2 %	Reason for admission: stroke (16 %); ICH (60 %); CNS tumor (6 %); epidural abscess (8 %); seizure (3 %); meningitis (5 %); spinal cord injury (3 %); suicide attempt (3	Surgical (neurosurgical)	CNS patients (100 %); CKD (0 %; CrCl <20 mL/min)	Not described	Not described	SIRS criteria; Bacteremia (0 %, 0/65); CNS (Meningitis) (4.6 %, 3/65); Empiric (41.5 %, 27/65); Epidural abscess (9.2 %, 6/65); Pneumonia (69.2 %, 45/65)	Positive cultures* (with MIC): 23 % (15/65) MSSA (66.7 %, 10/15); MRSA (7 %, 1/15); MRSE (13 %, 2/15); CoNS (7 %, 1/15); Enterococcus (7 %, 1/15)

Reference	Study Population with Continuous Infusion									
	Number of Patients	Age [years]	Gender	Comorbidities	ICU	Specialty	Severity Score	ICU Length of Stay [days]	Type of infection	Microbiology
				%)						
Hutschala [46]	119 (of 149)	59±14 (19-86); >75 years: 22.7 %	Male: 61 % Female: 39 %	COPD (17 %); Acute liver failure (2 %); Extracardiac arteriopathy (12 %); Disseminated intravascular coagulation (4 %)	Surgical (cardiosurgical)	Cardiosurgery (100 %); CKD (0 %; SCr >1.5 mg/dL))	SAPS II: 37±13 (13-70)	15±13 (1-78)	Bacteremia (14 %, 17/119); Catheter-related (15 %, 18/119); Mediastinitis (7 %, 8/119); Pneumonia (HAP) (18 %, 21/119); Septic shock (0.9 %, 1/119); Severe sepsis (5 %; 6/119); SSTI (30 %, 36/119); Sternal infection (16 %, 19/119)	MRSA (22 %, 26/119); CoNS (11 %, 13/119)
Lin [45] Excluded due to number of patients <30	*14 (out of 54)*	*60.64±17.91*	*Male: 64.2 % Female: 35.8 %*	*Not described*	*Medical: 91.6 %; Surgical: 8.4 %*	*CKD (43 %); CVVH (100 %); Mechanical ventilation (100 %)*	*APACHE II (on admission): 26.42±8.01; SOFA (on start of CI): 14.5±2.28*	*Not described*	*Not described*	*Not described*
Lin [57]	Total: 52 Obese (BMI >35 kg/m²): 26; Non-obese (BMI <30 kg/m²): 26	Obese: 54.2±16.8; Non-obese: 55.4±16	Obese: Male: 69.2 % Female: 30.8 %; Non-obese: Male: 80.8 % Female: 19.2 %	Not described	Surgical	CVVH (35 %) Differentiation obese/non-obese; Mechanical ventilation (~100 %)	APACHE II (on admission): Obese: 20.3±9.24; Non-obese: 18.7±8.46	Not described	Abdomen (obese: 12 %, 3/26, non-obese: 8 %, 2/26); Bacteremia (obese: 8 %, 2/26, non-obese: 0 %, 0/26); Pneumonia (obese: 62 %, 16/26, non-obese: 73 %, 19/26); SSTI (obese: 8 %, 2/26, non-obese: 12 %, 3/26); Unknown (obese: 12 %, 3/26; non-obese: 8 %, 2/26)	MSSA (obese: 8 %, 2/26, non-obese: 12 %, 3/26); MRSA (obese: 23 %, 6/26, non-obese: 27 %, 7/26); CoNS (obese: 15 %, 4/26, non-obese: 12 %, 3/26); Enterococcus (obese: 0 %, 0/26, non-obese: 4 %, 1/26); Streptococcus spp. (obese: 8 %, 2/26, non-obese: 12 %, 3/26); Other (obese: 26 %, 12/26, non-obese: 35 %, 9/26)
Ma [52] Excluded due to inclusion of ICU and non-ICU patients in analysis	*146 (out of 292)*	*56.3±18.5*	*Male: 60.2 % Female: 39.8 %*	*Asplenia (1 %); CHF (4 %); COPD (3 %); Diabetes (17 %); Haematological malignancy (3 %); Immunosuppression (11 %); Any comorbidity or immunosuppression (32 %)*	*No data on type of ICU + general ward*	*Not described*	*APACHE II (≥20) (ICU); Pitt bacteraemica score (≥4) (ward)*	*Not described*	*Abdomen (1 %, 2/146); Bacteraemia (2 %, 3/146); BJI (65 %, 95/146); Cardiovascular (2 %, 3/146); Catheter-related (2 %, 3/146); CNS (10 %, 14/146); CNS abscess (3 %, 4/146); Pneumonia (1 %, 2/146); SSTI (13 %, 19/146); Urogenitary (0 %, 0/146); Unknown (1 %, 1/146)*	*MSSA (6 %, 9/146); MRSA (16 %, 24/146); CoNS (42 %, 62/146); other Staphylococcus spp (1 %, 1/146); E. faecium (3 %, 5/146); E. faecalis (10 %, 14/146); other Enterococcus spp (1 %, 1/146); Streptococcus spp. (7 %, 10/146); Other gram-positive bacteria (29 %, 23/146); Gram-negative bacteria (29 %, 43/146); Acid-fast bacilli (1 %, 1/146); Fungal (1 % 1/146)*
Mohammedi [85]	Total: 40 A (LD 500 mg): 20; B (LD 15 mg/kg): 20	A: 62.2; B: 61.2	A: Male: 70 % Female: 30 %; B: Male. 75 % Female: 25 %	Not described	Medical	Mechanical ventilation (90 %); Sepsis (100 %)	SAPS II: A: 59±17; B: 57±17	Not described	Bacteremia (A. 25 %, 5/20; B: 30 %, 6/20); Catheter-related (A: 15 %, 3/20; B: 10 %, 2/10); Others (A: 10 %, 2/20; B: 10 %, 2/20); Pneumonia (A: 50 %, 10/20; B: 50 %, 10/20) Sepsis (simple (A: 35 %, 7/20; B: 40 %, 8/20), severe (A: 30 %, 6/20; B: 30 %, 6/20), shock (A: 35 %, 7/20; B: 30 %, 6/20))	Positive cultures*: A: 90 % (18/20); B: 75 % (15/20); MSSA (A: 17 %, 3/18; B: 33 %, 5/15); MRSA (A: 67 %, 12/18; B: 40 %, 6/15); MRCoNS (A: 11 %, 2/18; B: 33 %, 5/15)
Ocampos-Martinez [33]	261	60±15	Male: 61.7 % Female: 38.3 %	Asthma/COPD (24 %); Cancer (23 %); CKD (13 %); Diabetes (25 %); Heart disease (30 %); Hypertension (36 %); Immunosuppres-sion (16 %); Liver cirrhosis (10 %); Smoking (18	Medical: 59.8 %; Surgical: 40.2 %	Mechanical ventilation (71 %) Sepsis (100 %)	APACHE II (on admission): 22 (17-28); SOFA: 8 (5-11)	10 (6-18)	Sepsis (100 %, 261/261); Septic shock (42 %, 112/261); Abdomen (23 %, 60/261); Pneumonia (49 %, 128/261)	Positive cultures*: 50 % (131/261); MSSA (29 %, 38/131); MRSA (18 %, 24/131); CoNS (31 %, 40/131); Enterococcus ssp (21 %, 27/131); Corynebacterium spp (1.5 %, 2/131)

Reference	Study Population with Continuous Infusion									
	Number of Patients	Age [years]	Gender	Comorbidities	ICU	Specialty	Severity Score	ICU Length of Stay [days]	Type of infection	Microbiology
				%); Alcohol (16 %); Thromboembolic disease (5 %);						
Omuro [75]	119 (out of 578)	59 (48-75)	Male: 60.5 % Female: 39.5 %	Cancer (10 %); Cardiopathy (43 %); CKD (8 %) Diabetes (15 %); Hypertension (50 %); Liver cirrhosis (4 %); Venous thrombosis (6 %);	Medical: 30.3 %; Surgical: 68.9 %; Neurological: 0.8 %	CKD (8 %); Mechanical ventilation (87 %)	SAPS II (on admission): 37 (31-48)	26 (16-39)	Not described	Positive cultures*: 23.5 % (28/119)
Perin [63]	Total: 179 (Primary outcome: 176; Finished follow-up: 131 (follow-up = 15 consecutive days after VCM initiation))	67 (59-75)	Male: 66 % Female: 34 %	Cancer (6 %); Cardiac insufficiency (7 %); Coronaropathy (10 %); Diabetes (19 %); Hypertension (30 %); Liver cirrhosis (4 %); Peripheral arterial disease (16 %); Single kidney (3 %)	No data on type of ICU	Augmented renal clearance d1 or d2 (4 %); Mechanical ventilation (85 %); RRT (27 %)	SAPS II (at ICU admission); SOFA (at d1-4, d10, d15)	ICU: 6 (3-13); Hospital: 23 (14-47)	Sepsis or septic shock (61 %; 110/179); Abdomen (37 %, 53/143); Bacteremia (20 %, 29/143); Bone (6 %, 9/143); Meningitis (2 %, 3/143); Pneumonia (17 %, 25/143); Skin (6 %, 9/143); Urogenitary (10 %, 15/143)	Positive cultures*: 80 % (143/179); (identification and analysis of isolated pathogens let to cessation of VCM therapy: 53 %, 94/179) MSSA (15 %, 21/143); MRSA (5 %, 7/143); CoNS (15 %, 21/143); E faecalis (15%, 22/143); E. facium (16 %, 23/143); Other gram-positive bacteria (10 %, 15/143); Enterobacterales (50 %, 71/143); Pseudomonas aeruginosa/Acinetobacter baumannii (13 %, 18/143); Other gram-negative bacteria (7 %, 10/143); Anaerobes (9 %, 13/143); Yeast (12 %, 17/143); Others (1 %, 2/143);
Ricard [118] Excluded due to number of patients <30 and unspecified length of time course	14	52±20 (19-83)	Male: 57.1 % Female: 42.9 %	Not described	Medical	CNS infection (100 %); Mechanical ventilation (71 %)	SAPS II: 43±20; Glasgow coma: 7±3	Not described	Presumed or proven pneumococcal meningitis (100 %) S. pneumonia bacteremia (57.1 %, 8/14)	Gram-positive cocci in CSF (1st lumbar puncture: 93 %, 13/14; 2nd lumbar puncture: 7); Streptococcus pneumoniae (1st lumbar puncture: 86 %, 12/14; 2nd lumbar puncture: 0 %, 0); Neisseria meningitides (7 %, 1/14)
Saugel [69] Excluded due to time course of only 9 months	34	62 (49-71)	Male: 62 % Female: 38 %	Not described	Medical	Mechanical ventilation (76 %)	APACHE II: 30 (21-36); SOFA: 13 (10-16); TISS: 18 (18-23); MODS: 1 (7-12)	Not described	Presumed or proven infection; Sepsis (44 %, 15/34)	Gram-positive bacteria
Saugel [59]	164 (out of 239)	65.1±13.1	Male: 61 % Female: 39 %	Diabetes (18 %)	Medical	Mechanical ventilation (54 %); RRT (43 %)	Not described	Not described	Not described	Not described
Schmelzer [60] Excluded due to number of patients <30 and unspecified length of time course	28 (out of 55)	40.3±16.4	Male: 89.2 % Female: 11.8 %	COPD; ischemic heart disease; diabetes; cancer	Surgical (trauma)	CKD (0 %; CrCl <60 mL/min) Trauma patients (100 %); VAP (100 %)	Injury Severity Score: 26.7±11.5	Not described	VAP (100 %, 28/28); Presumed VAP after BAL; Documented gram-positive pneumonia	Gram-positive bacteria; MRSA (< 10 %)
Sin [56]	52	60.1±15.5	Male: 73.1 % Female: 27.9 %	Not described	Surgical: 65.4 %; Medical: 34.6 %	CVVH (100 %)	APACHE II (upon ICU admission): 25.3±7.8	32.4±30.9	Not described	Not described

Reference	Study Population with Continuous Infusion									
	Number of Patients	Age [years]	Gender	Comorbidities	ICU	Specialty	Severity Score	ICU Length of Stay [days]	Type of infection	Microbiology
Spadaro [58]	Total: 348 CrCl >50 mL/min: 210; CrCl ≤50 mL/min: 138	CrCl >50 mL/min: 63±11.2; CrCl ≤50 mL/min: 70.6±9.9	CrCl >50 mL/min: Male: 73 % Female: 37 %; CrCl ≤50 mL/min: Male: 69 % Female: 31 %	Not described	Medical: CrCl >50 mL/min: 56.7 %; CrCl ≤50 mL/min: 50%; Surgical: CrCl >50 mL/min: 43.3 %; CrCl <50 mL/min: 50 %	CKD (40 %; CrCl ≤50 mL/min); Differentiation in CrCl ≤/>50 mL/min	SAPS II (first 24 h): CrCl >50 mL/min: 40.3±8.0; CrCl ≤50 mL/min: 46.2±7.7	Not described	Abdomen (>50 mL/min: 20.5 %, 43/210/≤50 mL/min: 31.8 %, 44/138); Bacteremia (>50 mL/min: 14.3 %, 30/210/≤50 mL/min: 4.3 %, 6/138); Pneumonia (>50 mL/min: 48.6 %, 102/210/≤50 mL/min: 36.2 %, 50/138); Sepsis (>50 mL/min: 30 %, 63/210; ≤50 mL/min: 26 %, 36/138); SSTI (>50 mL/min: 10.9 %, 23/210/≤50 mL/min: 27.5 %, 38/138); Others (>50 mL/min: 5.7 %, 12/210/≤50 mL/min: 0 %, 0/138)	*Staphylococci spp.* (CrCl >50 mL/min: 63.3 %/CrCl ≤50 mL/min: 62.3 %); *Enterococci spp.* (CrCl >50 mL/min: 35.2 %/CrCl ≤50 mL/min: 37.7 %); *Streptococci spp.* (CrCl >50 mL/min: 1.4 %/CrCl ≤50 mL/min: 0 %)
Spapen [61]	Total: 129 AKI: 38; No AKI: 91	No AKI: 60.8±14.6; AKI: 62.6±15.9	No AKI: Male: 51.6 % Female: 48.4 %; AKI: Male: 60.5 % Female: 39.5 %	Diabetes (No AKI: 54 %; AKI: 79 %) Shock (No AKI: 59 %; AKI: 87 %)	No data on type of ICU	CKD (0 %; SCr >1.5 mg/dL))	SAPS 3	Not described	Gram-positive bacteremia (29.5 %, 38/129); Pneumonia (60.5 %, 78/129); Bacteremia + Pneumonia (10.1 %, 13/129)	Positive cultures*: 100 % (129/129) *MRSA* (63.6 %, 82/129); *MRCoNS* (31 %, 40/129); *Enterococcus spp* (5.4 %, 7/129)
Stepan [62]	33 (out of 65)	56±14.6	Male: 69.7 % Female: 30.3 %	Not described	Medical; Surgical	Not described	APACHE II: 23.4±9.1; SOFA: 9.97±4.1	26 (12.8-40.3)	Gram-positive infection: Abdomen (39.3 %, 13/33); Bacteremia (54.4 %, 18/33); BJI+SSTI (0 %, 0/33); Pneumonia (6.3 %, 2/33); Urogenitary (0 %, 0/33);	*Staphylococci* (56.3 %, 18/33); *Staphylococcus aureus* (9.1 %, 3/33); *Staphylococcus epidermidis* (15.6 %, 5/33); *Staphylococcus haemolyticus* (3.1 %, 1/33); *CoNS* (28.1 %, 9/33); *Enterococci* (37.5 %, 12/33); *Enterococcus faecalis* (18.8 %, 6/33); *Enterococcus faecium* (15.6 %, 5/33); *Enterococcus spp.* (3.1 %, 1/33); Polymicrobial infection (staphylococci + streptococci) (9.4 %, 3/33); MIC (Etest): 0.5 (9.1 %), 1.0 (42.4 %), 2.0 (48.5 %); CI: 1 (1-2); II: 2 (1-2)
Tiede [119] Excluded due to number of patients <30	*9*	*53 (29-84)*	*Male: 78 % Female: 22 %*	*Not described*	*No data on type of ICU*	*CNS infection (100 %)*	*Not described*	*Not described*	*CNS (Ventriculitis) (100 %, 9/9)*	*-*
Tuon [86]	33	54 (40-61)	Male: 57 % Female: 43 %	Cancer (21 %) CKD + dialysis (6 %); COPD (3 %); Dementia (3 %); Diabetes (18 %); Hypertension (36 %);	No data on type of ICU	CNS infection (100 %)	Not described	Not described	CNS (Ventriculitis (nosocomial)) (100 %, 33/33)	Positive cultures*: 6 % (2/33); Repeated sampling after 5.5 d (4-8) *MRSA* (3 %, 1/33); *CoNS* (3 %, 1/33)
Udy [72]	CVVH: 41; CVVHDF: 40	61.0±15.6	Male: 65.4 % Female: 34.6 %	Not described	No data on type of ICU	CRRT (100 %); Mechanical ventilation (85.2 %) Sepsis (100 %)	APACHE II: 24.5±8.4; SOFA: 10.9±4.0	12 (16-19)	Presumed or documented gram-positive infection; Sepsis (100 %; 81/81)	Not described
van de Vijsel [54] Excluded due to number of patients <30	*24*	*64.3±15 (36-88)*	*Male: 79 % Female: 21 %*	*Not described*	*Medical; Surgical (cardiovascular)*	*CVVHD (100 %)*	*APACHE II (upon admission): 24.2±8.8 (12-46)*	*54±51 (7-189)*	*Abdomen (4 %, 1/24); Bacteremia (54 %, 13/24); CNS (4 %, 1/24); Pneumonia (13 %, 3/24); Urine (8 %, 2/24)*	*Positive cultures*: 63 % (15/24) MSSA (28 %, 7/25); blood (12 %, 3/25); sputum (12 %, 3/25); urine (4 %, 1/25)) MRSA (0 %) CoNS (40 %, 10/25); blood (36 %, 9/25); CSF (4 %, 1/25)) E. faecalis (12 %, 3/25); E. faecium (0 %); Streptococcus mitus (4 %, 1/25); Streptococcus anginosus-milleri (4 %, 1/25); Streptococcus oralis (4 %, 1/25)*

Reference	Study Population with Continuous Infusion									
	Number of Patients	Age [years]	Gender	Comorbidities	ICU	Specialty	Severity Score	ICU Length of Stay [days]	Type of infection	Microbiology
van den Heever [55] *Excluded due to number of patients <30*	10	44.2±17.3 (19-70)	Male: 50 % Female: 50 %	Not described	Medical; Surgical	CKD (10 %) Sepsis (100 %)	Not described	Not described	Sepsis (100 %, 10/10)	Not described
Vazquez [65] *Excluded due to number of patients <30*	25	Not described	Not described	Not described	No data on type of ICU	CKD (16 %) Sepsis (100 %)	Not described	Not described	Severe sepsis; Septic shock; MRSA-infection	MRSA (documented infection)
Wysocki [47]	61 (out of 119) (Therapy success: 48; Therapy failure: 13)	64±13	Male: 69 % Female: 31 %	Diabetes (12 %)	Medical; Surgical	Mechanical ventilation (79 %)	SAPS: 14±5; (Total CI+II: Therapy success: 13±4; Therapy failure: 16±4)	Not described	Presumed or documented MRS infection acquired 72 h after admission; Bacteremia (40 %, 25/61); Catheter-related (20 %, 12/61); CNS (20 %, 12/61); Endocarditis (2 %, 1/61); Mediastinitis (6 %, 4/61); Pneumonia (43 %, 26/61); Septicemia (11 %, 7/61); Others (18 %, 11/61)	*MRSA* (80 %, 49/61); *CoNS* (20 %, 12/61); MIC: 0.5 (14 %, 3/61), 1 (36 %, 8/61), 2 (50 %; 11/61); Disk agar; 40 strains additionally on Mueller-Hinton agar
Wysocki [120] *Excluded due to number of patients <30*	13 (of 26)	61±17	Male: 77 % Female: 23 %	Not described	No data on type of ICU	MRSA (100 %)	SAPS: 17±5	Not described	Severe MRSA infection; Bacteraemia (54 %, 7/13); Pneumonia (46 %, 6/13)	MRSA (100 %, 13/13)
Yamada [42] *Excluded due to number of patients <30*	11 (of 23)	49 (42.5-64)	Male: 63 % Female: 37 %	Not described	No data on type of ICU	CKD (0 %, eGFR ≤40 mL/min)	APACHE II	Not described	Abdomen (18.2 %, 2/11); Catheter-related (9.02, 1/11); CNS (18.2 %, 2/11); Pneumonia (45.5 %, 5/11); SSTI (9.05 %; 1/11); Others (0 %, 0/11)	Not described

APACHE: Acute Physiology And Chronic Health Evaluation score, BAL: bronchoalveolar lavage, BJI: bone and joint infection, CKD: chronic kidney disease, CNS: central nervous
system, COAD: chronic obstructive airway disease, CoNS: coagulase-negative staphylococci, CSF: cerebrospinal fluid, ICH: intracranial hemorrhage, ICU: intensive care unit, LD:
loading dose, MD: maintenance dose, MRCoNS: methicillin-resistant coagulase-negative staphylococci, MRSA: methicillin-resistant *Staphylococcus aureus*, MRSE: methicillin-
resistant *Staphylococcus epidermidis*, SAPS: Simplified Acute Physiology Score, SOFA: Sepsis-related Organ Failure Assessment score, SSTI: skin and soft tissue infection, TISS:
Therapeutic Intervention Scoring System, VAP: ventilator associated pneumonia.
* Sum of positive cultures with gram-positive pathogens

Characteristics of Continuously Administered Vancomycin Therapy

799 **Table S3**: *Overview of the characteristics of the continuous infusion of vancomycin. Thirty-eight studies were identified in the initial full-text selection process that presented data of*
800 *steady-state serum concentrations of continuously administered vancomycin (CI) and efficacy (clinical or microbiological success (e.g. cure) or failure (e.g. mortality)) or safety (e.g.*
801 *acute renal failure). Only twenty-one studies made it into the final analysis. Studies excluded from the final selection because of an increased risk of bias (e.g. unspecified or time*
802 *course of less than 12 months or a CI study population of less than 30 patients) are written in italics.*

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
Akers [64]	Not described	3000 mg/d	Not described	29.5±11.8 mg/kg/d; 2500±720 mg/d; CVVH: Initially 31.7±10.4 mg/kg/d	20-25	≥400	**Overall therapy:** 20.0±3.8; Gram-positive bacteremia: 19.3±3.2; Sepsis without proven gram-positive bacteremia: 21.2±4.2; Pneumonia: 22.0±3.9	Lack of postinfusion peak data prevented actual calculation of AUC	Non-CVVH (n=68): 30.7±19.9 %; *Subtherapeutic:* 50.0±26.7 %; *Supratherapeutic:* 19.3±21.7 %; CVVH (n=22): 30.0±20.3 %; *Subtherapeutic:* 45.1±29.6 %; *Supratherapeutic:* 24.9±24.1 %	First: 24 h after initiation of CI Regular: Not described	Gram-positive bacteremia: 12.4±11.8; Sepsis without proven gram-positive bacteremia: 8.7±5.9; Pneumonia: 13.5±11.1
Albanèse [74] Excluded due to number of patients <30 and unspecified length of time course	*15 mg/kg (2 h)*	*50-60 mg/kg/d*	*Not described*	*62±17 mg/kg/d*	*20-30*	*Not described*	*Overall therapy: 32±8 (range: Meningitis: 11.6-46.8; Without meningitis: 14.6-36.1)*	*Not described*	*Not described*	*First: 1st day: 2:00, 2:30, 3:00, 4:00, 5:00, 6:00, 8:00 pm, midnight; 2nd day: 6:00 am; 12:00 noon, 2:00 pm, midnight; 3rd day: 6:00 am, 2:00 pm; Regular: Daily at 6:00 am*	*13±7*
Baptista [68]	≤70 kg: 1000 mg; >70 kg: 1500 mg	A: 30 mg/kg/d; B: nomogram	A: 14.3 mg/kg (12.8-17.6); 1000 mg/d (1000-1500); B: 18.8 mg/kg (16.7-21.4); 1500 mg/d (1000-1500)	A: 1920 mg/d (1512-2400); B: 2072 mg/d (1750-2622)	20-30	Not described	**24 h:** A: 20.6 (16.7-26); B: 24.5 (22.2-27.4)	Not described	A: 51 %; B: 84 %	Daily at 7:00 am	Not described
Beumier [70]	35 mg/kg (4 h) (Adapted from Roberts, 2011. [121])	14 mg/kg/d	2750 mg (2250-3150)	1100 mg/d (975-1270)	20-30	>400	**24 h:** 23 (19-31)	652 (596-789)	**12 h:** 69 %; **24 h:** 63 %; *Subtherapeutic:* **12 h:** 3 %; **24 h:** 19 %; *Supratherapeutic:* **12 h:** 28 %; **24 h:** 19 %	First: End of LD (T1); 12 h after initiation of CI (T2); 24 h after initiation of CI (T3); Regular: daily at 8:00 am	3 (2-7)
Carricajo [76] Excluded due to number of patients <30 and unspecified length of time course	*30 mg/kg (1 h)*	*30 mg/kg/d*	*Not described*	*Not described*	*25-30*	*≥350*	*24 h: All: 21.33±7.64 (14.1-25.4); < 120 mL/min: 25.8±6.37 (21.9-27.3); ≥ 120 mL/min: 13.45±1.98 (12.6-14.7)*	*AUC24/MIC: All: 548.3±300.3 (325.3-568.9); <120 mL/min: 679.25±357.9 (371.8-667.0); ≥120 mL/min: 286.5±93.75 (264.8-345.3)*	*Css: All: 27.3 %; <120 mL/min: 42.9 %; ≥120 mL/min: 0 %; Subtherapeutic: All: 59.1 %; <120 mL/min: 35.7 %; ≥120 mL/min: 100 %; Supratherapeutic: All: 13.6 %; <120 mL/min: 21.4 %; ≥120 mL/min: 0 %;*	*First: 24 h after initiation of CI; Regular: Not described*	*Not described*

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
									AUC/MIC: *All: 66,7 %;* *<120 mL/min: 87,5 %;* *≥120 mL/min: 25 %*		
Cianferoni [71]	15 mg/kg (1-1.5 h)	According to renal function 20-30 mg/kg/d (TBW); VCM level <20 mg/L: Bolus (500 mg) + increase of daily dose by 500-1000 mg/d; VCM level >30 mg/L: Stop for ≥4 h + reduction of daily dose by 500-1000 mg/d	1000 mg (1000-1500)	All: 2000 mg/d (1697-2500); No AKI: 2000 mg/d (1800-2642); AKI: 1940 mg/d (1431-2212); (Early AKI: 1747 mg/d 1206-2000); Late AKI: 2050 mg/d (1714-2691)) Total dose All: 8.1 g (6-13.5); No AKI: 9.45 g (7-14); AKI: 11.5 g (7.5-16.9)	20-30	Not described	**Overall therapy:** All: 22.3±7.0; No AKI: 21.2±6.8; AKI: 25.8±6.6; (Early AKI: 27.2±5.1; Late AKI: 24.1±7.8) **24 h:** All: 19.7±8.5; No AKI: 18.7±7; AKI: 22.5±9.6; (Early AKI: 24.5±7.8; Late AKI: 20.2±11.1)	Not described	Not described	Daily at 8:00 am	All: 4 (3-6); No AKI: 4 (3-6); AKI: 5 (3-9); (Early AKI: 5 (3-7); Late AKI: 5 (4-9))
Covajes [73]	15 mg/kg (TBW)	20-30 mg/kg/d; VCM level <20 mg/L: Bolus (500-1000 mg) + increase of daily dose by 500-1000 mg/d; VCM level >30 mg/L: Stop for 4-8 h + reduction of daily dose by 500-1000 mg/d	16.4±6.4 mg/kg	**24 h:** 23.5 ± 8.1 mg/kg/d; **48 h:** 23.2 ± 7.4 mg/kg/d; **72 h:** 23.3 ± 11.0 mg/kg/d	20-30	Not described	**24 h:** 24.7±9.0; **48 h:** 26.0±8.1; **72 h:** 27.7±9.3	Not described	**24 h:** 51 %; **48 h:** 56 % ; **72 h:** 67 %; *Subtherapeutic*: **24 h:** 29 %; **48 h:** 22 % ; **72 h:** 8 %; *Supratherapeutic*: **24 h:** 20 %; **48 h:** 21 % ; **72 h:** 26	Daily at 8:00 am	4 (3-7)
Cristallini [67]	35 mg/kg (4 h)	According to renal function >150 mL/min: 45 mg/kg/d; 120-150 mL/min: 40 mg/kg/d; 80-119 mL/min: 30 mg/kg/d; 50-69 mL/min: 25 mg/kg/d; 25-50 mL/min: 14 mg/kg/d; <25 (anuria): 7 mg/kg/d; VCM level <20 mg/L: Bolus (500-1000 mg) + increase of daily dose by 25 %/d; VCM level >30 mg/L:	2650 mg	2112 mg/d	20-30	Not described	**12 h:** 25 (21-32); **24 h:** 22 (19-28); **48 h:** 26 (22-30)	771 (664-905)	**12 h:** 56 %; **24 h:** 54 %; **48 h:** 73 %	First: End of LD; 12 h, 24 h, 48 h after initiation of CI Regular: Daily at 8:00 am	Not described

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
		Stop for 4 h + reduction of daily dose 25 %/d									
Di Filippo [77] **Excluded due to number of patients <30 and time course of only 7 months**	*500 mg (10 min)*	*2000 mg/d*	*Not described*	*Not described*	*30-40*	*Not described*	***24 h:*** *13.88±5.7;* ***48 h:*** *17.76±7.6;* ***72 h:*** *24.3±3.9*	*Not described*	*Not described*	*First: 2 h, 48 h, 96 h after initiation of CI; Regular: Not described*	*6.14±1.37*
Duszynska [44] **Excluded due to number of patients <30**	*500 mg*	*30 mg/kg/d (TBW); VCM level <15 mg/L: Bolus (500 mg) + increase of daily dose by 25 %/d; VCM level >20 mg/L: Reduction of daily dose by 25 %/d*	*500 mg*	*29.6±5.5 mg/kg/d; 2219±476 mg/d; Total: 17.7±5.2 g*	*15-20*	*≥400*	*Time to target: 72 h (24-120)*	*316 (123-577); MIC: 2 (1-2); AUC24/MIC: All: 195 (133-343); Clinical cure: 194 (134-389); Microbiological eradication: 162 (116-389); AUC96/MIC: All: 1112 (650-1414)*	*Css: 71.4 % Subtherapeutic: 19 %; Supratherapeutic: 10 % AUC24/MIC: 23.8 %; AUC96/MIC: 24 %*	*First: Immediately + 30 min after LD; 24 h, 48 h, 96 h after initiation of CI; Regular: Not described*	*7 (7-8)*
Eldemiry [53] **Excluded due to number of patients <30**	*none*	*Rate of infusion (g/d) = [0.0205 CrCl + 3.47] * (Css) * (24/1000)*	*Not described*	*Total: 9.93±2.21 g*	*15-20*	*Not described*	***Overall therapy:*** *18.13±14.15*	*Not described*	*40 %; Subtherapeutic: 30 %; Supratherapeutic: 30 %*	*Not described*	*5.05±0.99*
Hanrahan [87]	Not described	Not described	Not described	1700 mg/d (1200-2100); Total: 9.0 g (6.0-14.4)	Not descri bed	Not described	**Overall therapy:** 18.4 (15.6-21.2)	Not described	Not described	First: ≥18 h after dose change; Regular: Not described	5.3 (3.4-10.3)
Hong [39] **Excluded due to time course of only 9 months**	*20 mg/kg (1 g/h)*	*According to renal function ≥90 mL/min: 40 mg/kg/d; 50-90 mL/min: 30 mg/kg/d; 20-50 mL/min: 15 mg/kg/d; (Dose adjustment via ratio method (current total daily dose x desired Css = new total daily dose x current Css) or pharmakokinetic equation: Css = (dose/24 h)/clearance)*	*19.9±3 mg/kg*	*Achieving goal: 33±10.6 mg/kg/d; 2572±784 mg/d*	*20-30*	*>400*	***24 h:*** *28±9.2* *Time to target: 1.96 d; Time within target: 55 %*	*671.5±219.9*	***24 h:*** *40 %; Subtherapeutic: 21.5 % Supratherapeutic: 38.5 % AUC24/MIC (S. aureus, 11/15): MIC=0.5: 100 % (2/2); MIC=1: 88.9 % (8/9); MIC=2: 0 % (0/0) Population-based: MIC=0.5: 100 % (65/65); MIC=1: 92.3 % (60/65); MIC=2: 27.7 % (18/65)*	*First: 24 h after initiation of CI; CrCl <50 mL/min: 36-48 h after initiation of CI; Regular: not described*	*10.4±7.8*
Hutschala [46]	20 mg/kg (1 h)	36 mg/kg/d (0.025 mg/kg/min)	Not described	1935±688 mg/d (352-3411)	20-25	Not described	**Overall therapy:** 25.0±4.0 (7-30); Time to target: 16±8 h	529±98	Not described	Daily at 7:00 am	9±6 (3-19); Time between surgery and start of therapy: 4.9±1.8
Lin [45] **Excluded due to number of patients <30**	*25 mg/kg*	*1500 mg/d (60 mg/h)*	*26.65±3.06 mg/kg; 2232.14±385.61 mg*	***Overall therapy:*** *15.66±6.26 mg/kg/d;* ***24 h:*** *1329.85±335.61 mg/d;* ***48 h:*** *1339.28±348.17 mg/d;* ***72 h:*** *1428.57±301.09 mg/d; Total dose prior to first 24 h level: 3625±497.5 mg*	*15-25*	*Not described*	***24 h:*** *20.35±2.78;* ***48 h:*** *20.8±2.66;* ***72 h:*** *19.25±2.01; Time to target: 24±0.56 h*	*Not described*	***24 h:*** *100 %*	*First: 24 h after initiation of CI; Regular: Daily, but no further monitoring, when two consecutive serum concentrations within target range and no change in CVVH flow rate*	*6.57±3.25*
Lin [57]	25-30 mg/kg	According to renal function ≥60 mL/min:	Obese: 24.8±2.05 mg/kg; 2894±525 mg;	Obese: 24.8±12.7 mg/kg/d; 2885±1450 mg/d;	15-25	Not described	**24 h:** All: 20.32±3.72; Obese: 20.3±3.81;	Obese: 488±91.5; Non-obese: 480.9±91.04; CVVH:	**24 h:** Obese: 92.3 %; Non-obese: 88.5 %	First: 24 h after initiation of CI;	Obese: 6.88±3.02; Non-obese:

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
		2000 mg/d; max. 4.25 g/d; Concomitant CVVH: Initial dose 1500 mg/d; VCM level <15 mg/L: Bolus (500-1000 mg) + proportional increase of daily dose; VCM level >25 mg/L: Stop for 4-6 h + proportional reduction of daily dose	Non-obese: 25.6±1.66 mg/kg; 1923±345 mg; CVVH: Obese: 25.3±0.744 mg/kg; 2722±441 mg; Non-obese: 25.4±1.49 mg/kg; 1833±280 mg; Preserved renal function: Obese: 24.6±2.47 mg/kg; 2985±555 mg; Non-obese: 25.9±1.88 mg/kg; 1941±370 mg	Non-obese: 41.9±20 mg/kg/d; 3039±1313 mg/d; CVVH: Obese: 13.3±4.73 mg/kg/d; 1389±39 7 mg/d; Non-obese: 21.7±8.33 mg/kg/d; 1500±375 mg/d; Preserved renal function: Obese: 30.8±11.3 mg/kg/d; 3676±1131 mg/d; Non-obese: 53.4±13.7 mg/kg/d; 3882±674 mg/d			Non-obese: 20.03±3.79; CVVH: Obese: 19.8±3.05; Non-obese: 21.6±3.02; Preserved renal function: Obese: 20.6±4.21; Non-obese: 19.6±4.41	Obese: 474±73.2; Non-obese: 517±48.6; Preserved renal function: Obese: 496±101; Non-obese: 471±106	CVVH Obese: 100 %; Non-obese: 100 %	Regular: Every 24 h until 2 serum concentrations within target range	6.5±3.06
Ma [52] Excluded due to inclusion of ICU and non-ICU patients in analysis	*Not described*	*Not described*	*Not described*	*Inital: 2047±466 mg/d (1000-3750); Final: 2098±766 mg/d (600-4000)*	*15-20[a]; BJI: 12-20*	*Not described*	*Initial: 13±5 (2-27); Final: 16±3 (7-46)*	*402±118; Nephrotoxic risk: 535±233; No nephrotoxic risk: 360±116*	*78 %*	*At steady state*	*46±31*
Mohammedi [85]	A: 500 mg; B: 15 mg/kg (1 h)	0.227 * CrCl + 5.67 (according to Rodvold 1988 [31])	A: 500 mg; 7.54±1.52 mg/kg; B: 1147±317 mg; 15 mg/kg	Not described	20	Not described	**24 h:** A: 14.9±5.4; B: 18.5±6.4	Not described	Not described	First: 1 h after end of LD; Regular: Not described	Not described
Ocampos-Martinez [33]	15 mg/kg (1-1.5 h)	According to renal function >80 mL/min: 30 mg/kg/d; 50-80 mL/min: 20-30 mg/kg/d; <50 mL/min: 10-20 mg/kg/d; VCM level <20 mg/L: Bolus (500 mg) + increase of daily dose by 500-1000 mg/d; VCM level >30 mg/L: Stop for ≥4 h + reduction of daily dose by 500-1000 mg/d	16.2±5.4 mg/kg; 1199±366 mg	**24 h:** 26.8±8.1 mg/kg/d; 1975±507 mg/d; **48 h:** 28.7±10.1 mg/kg/d; 2103±636 mg/d; **72 h:** 29.7±13.9 mg/kg/d; 2232±688 mg/d	20-30	Not described	**24 h:** 20.4±8.9; **48 h:** 24.1±9.1; **72 h:** 25.5±10.1; Time to target: 2 d (1-3)	Not described	**24 h:** 47 %; **48 h:** 67 %; **72 h:** 86 %; *Subtherapeutic:* **24 h:** 42 %; **48 h:** 14 %; **72 h:** - %; *Supratherapeutic:* **24 h:** 11 %; **48 h:** 19 %; **72 h:** - %	First: ≥16 h after initiation of CI; Regular: daily at 8:00 am	4 (3-7)
Omuro [75]	1000 mg	2000 mg/d; VCM level <20 mg/L: Bolus (500-1000 mg)	Not described	2374 mg/d (2168-2764); Total: 14 g (9.3-18.5)	20-40	Not described	**Overall therapy:** 20.03 (15.67-26.25)	Not described	Not described	Not described	6 (4-7)
Perin [63]	1000-1500 mg according to	Not described	15.6 mg/kg (12.5-20.8); 1000 mg	**24 h:** 27.5 mg/kg/d (21.3-31.9);	20-25	Not described	**24-48 h:** 19.8 (16-25.1)	Not described	**24-48 h:** 24 %	First: 24-48 h after initiation of CI	4 (2-7) (max. 14 d due to

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
	physician's choice		(1000-1500)	2000 mg/d (1600-2000); **48 h**: 28.4 mg/kg/d (23.8-34.8); 2000 mg/d (2000-2500)						Regular: Daily	protocol)
Ricard [118] Excluded due to number of patients <30 and unspecified length of time course	*15 mg/kg*	*60 mg/kg/d*	*Not described*	*Not described*	*Not described*	*Not described*	***Overall therapy:*** *25.5±7.1 (20.9-31.0); Died: 31.9±2.82 (30.2-33.65) (3/14); Survived: 23.76±6.88 (19.1-26.7) (11/14)*	*612.03±169.72 (502.2-744.6); **AUC24/MIC:** 1257.5±699.0 (746.4-1448.7) (12/14); Died: 1627.7±1037.5 (905.6-2100.8) (3/14); Survived: 1134.15±481.5 (768.0-1363.2) (9/14)*	*Not described*	*Not described*	*Not described*
Saugel [69] Excluded due to time course of only 9 months	*20 mg/kg (TBW) (3 h) (max 2 g)*	*According to renal function 20-30 mg/kg; max. 2-3 g; VCM level <20 mg/L: Bolus (500 mg) + increase of daily dose by 500 mg/d; VCM level >30 mg/L: Stop for 4 h + reduction of daily dose by 500 mg/d; VCM level >40 mg/L: Stop for 12 h + reduction of daily dose by 1000 mg/*	*1750 mg (1400-2000)*	***24 h:** 3120 mg/d (2596-3980); **48 h:** 1584 mg/d (1271-1817); **72 h:** 1171 mg/d (832-1392); **96 h:** 645 mg/d (396-1218); **120 h:** 480 mg/d (180-960); **144 h:** 504 mg/d (152-1124); **168 h:** 873 mg/d (408-1500)*	*20-30*	*Not described*	***Overall therapy:*** *29.0 (25.2-33.2)*	*Not described*	***24 h:** 48 %; **48 h:** 39 %; **72 h:** 33 %; **96 h:** 26 %; **120 h:** 43 %; **144 h:** 57 %; **168 h:** 69 % Subtherapeutic: **24 h:** 16 %; **48 h:** 10 %; **72 h:** 6%; **96-169 h:** 11 %, 14 %, 24 %, 15 %; Supratherapeutic: **24 h:** 36 %; **48 h:** 52 %; **72 h:** 61; **96-169 h:** 63 %; 39 %; 19 %; 15 %*	*Daily*	*7 (5-9)*
Saugel [69]	1000-1250 mg (depending on BW+renal function)	60 mg/h (=1.440 mg/d); Renal impairment: 40 mg/h (=960 mg/d)	1400 mg	960 mg/d (526-1723)	15-25	Not described	**Overall therapy:** 19.8 (9.8-29.4)	Not described	*Subtherapeutic:* **24 h:** 44 %; **48 h:** 29 %; **72 h:** 23 %	Not routinely and only after discretion of treating ICU physician	6 (2-21)
Schmelzer [60] Excluded due to number of patients <30 and unspecified length of time course	*20 mg/kg*	*According to renal function 0.9-2.4 mg/kg/h (TBW unless BW was ≥30 % than IBW --> ABW)*	*Not described*	*Not described*	*15-25*	*Not described*	***Overall therapy:*** *19.8±6.13*	*Not described*	*57.1 % Subtherapeutic: 21.5 % Supratherapeutic: 21.4 %*	*First: 48 h after LD; Regular: Every 7 d*	*Not described*
Sin [56]	25 mg/kg	Nomogram based on CVVH intensity: CVVH intensity 10-15 mL/kg/h: 1000 mg/d; 15.1-20 mL/kg/h: 1250 mg/d; 20.1-25 mL/kg/h: 1500 mg/d; 25.1-30 mL/kg/h: 1750 mg/d; >30 mL/kg/h: 2000 mg/d	24±1.9 mg/kg; 2125±294.6 mg	**24 h:** 16.1±6.1 mg/kg/d; 1355.7±272.7 mg/d; **48 h:** 15.3±5.2 mg/kg/d; 1324.3±311 mg/d; **72 h:** 14.4±4.7 mg/kg/d; 1267.8±311.2 mg/d	15-25	Not described	**24 h:** 20.1±4.7; **48 h:** 20.7±3.7; **72 h:** 21.9±3.5	Not described	**24 h:** 82.7 %; **48 h:** 81.8 %; **72 h:** 75 %; Subtherapeutic: **24 h:** 3.8 %; **48 h:** 6.1 %; **72 h:** 8.3 %; Supratherapeutic **24 h:** 13.5 %; 48 h: 12.1 %; **72 h:** 16.7 %	First: 24 h after LD; Regular: Every 24 h	4.9±3.4

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
Spadaro [58]	≤65 kg: 1000 mg (1 h); >65 kg: 1500 mg (1.5 h)	According to renal function (CrCl) >50 mL/min: 2000 mg/d; 20-50 mL/min: 1500 mg/d; 10-20 mL/min: 1000 mg/d; <10 mL/min: 500 mg/d	CrCl >50 mL/min: 16.7±4.8 mg/kg; CrCl ≤50 mL/min: 18±2 mg/kg	Total (0-48 h): CrCl >50 mL/min: 5.4±0.3 g; CrCl ≤50 mL/min: 3.6±0.8 g	15-25	>400	Not described	CrCl >50 mL/min: AUC/MIC: 468±79; CrCl ≤50 mL/min: AUC/MIC: 490±84	**24 h:** >50 mL/min: 44 %; ≤50 mL/min: 57 %; **48 h:** >50 mL/min: 41 %; ≤50 mL/min: 40 % **72 h:** >50 mL/min: 41 %; ≤50 mL/min: 41 %	Every 48 h at 7:30 am	>50 mL/min: 9±1.1; ≤50 mL/min: 9.1±1.6
Spapen [61]	15 mg/kg (1 h)	30 mg/kg/d VCM level <15 mg/L: Increase of daily dose by 500 mg/d; VCM level >25 mg/L: Reduction of daily dose by 500 mg/d; VCM level >30 mg/L: Stop for 6 h	Not described	Not described	15-25	Not described	**Overall therapy:** VCM level <25 mg/L: No AKI: 95.6 % (65/68) (71.4 %,65/91); AKI: 4.4 % (3/68) (7.9 %, 3/38); VCM level 25-30 mg/L: No AKI: 69.0 % (20/29) (22.0 %, 20/91); AKI: 31.0 % (9/29) (23.7 %, 9/38); VCM level >30 mg/L: No AKI: 18.8 % (6/32) (6.6 %, 6/91); AKI: 81.3 % (26/32) (68.4 %, 26/38)	Not described	Not described	Daily at 8:00 am	AKI: 14.9±9.8; No AKI: 9.2±4.9
Stepan [62]	≤65 kg: 1000 mg (1 h); >65 kg: 1500 mg (1.5 h)	According to renal function SCr <1.4 mg/dL: 1.5 g/d; SCr >1.4 mg/dL: 1 g/d; VCM level <15 mg/L: Increase of daily dose by 500 mg/d; VCM level >25 mg/L: Reduction of daily dose by 500 mg/d; VCM level >30 mg/L: Stop for 6 h + reduction of daily dose by 500 mg/d	Not described	1500±620 g/d; Total 12.9±6.9 g	15-25	Not described	**Overall therapy:** 19.0±4.3	Not described	Not described	Daily at 5:00 am	9 (7-10)
Tiede [119] *Excluded due to number of patients <30*	*1000 mg (1 h)*	*Nomogram based on kidney function (According to Pea. 2012 [122] and Minichmayr, 2018 [123])*	*1000 mg/d*	*57.2 mg/kg KG/d (41.2-68.6); 4250 mg/d (3500-7000)*	*20-30*	*>400*	***24 h:*** *24.5±4.04 (22.5-25.7)*	*Not described*	*Not described*	*First: 24 h, 72 h after initiation of CI Regular: Not described*	*13 (8-18)*
Tuon [86]	30 mg/kg	60 mg/kg/d	Not described	Not described	Not described	Not described	**Overall therapy:** 34.9 (21.47-42.1)	838 (515-1010)	Not described	First: ≤48 h after initiation of CI; Regular: Not described	10-14
Udy [72]	15 mg/kg (TBW)	15 mg/kg/d; VCM level <20 mg/L:	16.4±5.5 mg/kg	**24 h:** 23.7±8.1 mg/kg/d	20-30	Not described	**24 h:** 24.6±9.2	Not described	**24 h:** 69.1 %;	Not described	Not described

Reference	Planned		Measured		Target definition		Measured			TMD	Duration of Therapy [days]
	Loading Dose (LD)	Maintenance Dose (MD)	Loading Dose (LD)	Maintenance Dose (MD)	Css [mg/L]	AUC24/ MIC	Css [mg/L] (mean/median)	AUC24 [mg*h/L] (mean/median)	Target attainment [%]		
		Bolus (500-1000 mg) + increase of daily dose by 500-1000 mg/d; VCM level >30 mg/L: Stop for 4-8 h + reduction of daily dose by 500-1000 mg/d							*Subtherapeutic:* 8.6 %; *Supratherapeutic:* 22.2 %		
van de Vijsel [54] *Excluded due to number of patients <30*	*1500 mg*	*1000-1500 mg/d (42-62 mg/h)*	*Not described*	*Not described*	*15-20*	*≥400*	*Not described*	*403 (89-792)*	*71 %*	*Not described*	*15.2±14.6 (2-52)*
van den Heever [55] *Excluded due to number of patients <30*	*15 mg/kg*	*30 mg/kg/d (without renal impairment)*	*1100±214 mg (750-1500)*	*3282 mg/d*	*15-20*	*≥360*	*24 h: 15* *Time to target: 21 h*	*Not described*	*50 % after 21 h; 100 % within 33 h*	*First:* *1 h after LD;* *Regular:* *Every 6 h*	*Not described*
Vazquez [65] *Excluded due to number of patients <30*	*Not described*	*3000 mg/d*	*Not described*	*2400±640 g/d (2000-3000)*	*20-25*	*Not described*	*Overall therapy:* *19.5 (14.9-24.8)* *24 h:* *15.1 (12.4-19.2);* *48 h:* *19.5 (15.5-25.7)* *72 h:* *22.8 (16.8-29.0)* *Clinical condition:* *Serious:* *11.3 (10.4-13.8) (7/25);* *Worse:* *12.1 (10.8-13.5) (2/25);* *Improvement:* *23.5 (22.0-27.3) (16/25=;* *Apyretic:* *43.2 (41.7-44.8) (2/25)*	*Not described*	*Mean:* *20.7 %* *24 h:* *16.0 %* *48 h:* *20.0 %* *72 h:* *22.2 %*	*Routinely*	*Not described*
Wysocki [47]	15 mg/kg (adjustment according to nomogram (Moellering, 1984 [10]))	30 mg/kg/d; VCM level <20 mg/L: Increase daily dose by 500 mg; VCM level >25 mg/L: Decrease daily dose by 500 mg	Not described	Not described	20-25	Not described	**Overall therapy**: 24±8; Success: 23±4; Failure: 25±5 Time to target: 36±31 h	577±120 Failure: 685±260; Success: 596±159	Not described	Daily at 7:00 am until two consecutive VCM levels in target range, afterwards sampling only if 10 % change in BW or SCr	13±5
Wysocki [120] *Excluded due to number of patients <30*	*15 mg/kg*	*30 mg/kg/d*	*Not described*	*24±14 mg/kg/d*	*20-30*	*Not described*	*Overall therapy: 24±6* *Time to target: 2.3±1.5 d*	*Not described*	*Not described*	*Daily at 7:00 am*	*16±10*
Yamada [42] *Excluded due to number of patients <30*	*30 mg/kg*	*30 mg/kg/d*	*Not described*	*Not described*	*15-25*	*Not described*	*12 h:* *19.6 (14.4-23.7)* *24 h:* *23.59 (14.52-28.97);* *36 h:* *21.5 (12.2-30.0);* *48 h:* *18.28 (10.6-27.125)*	*530.2 (108-958.4)*	*Not described*	*First:* *1 h after LD;* *Regular:* *12 h, 24 h, 36 h, 48 h after initiation of CI*	*Not described*

a: pneumonia, meningitis, endocarditis, ABW: adjusted body weight, AUC: area under the curve, AUC24/MIC: area under the curve of drug concentration during the first 24 hours
of therapy divided by the minimal inhibitory concentration, AUC24: area under the curve of drug concentration during the first 24 hours of therapy, AUC96/MIC: area under the
curve of drug concentration during the first 96 hours of therapy divided by the minimal inhibitory concentration, AUC96: area under the curve of drug concentration during the first
96 hours of therapy, BJI: bone and joint infection, (T)BW: (total) body weight, CI: continuous infusion of vancomycin, Css: concentration at steady state (12 h: Css about 12 hours
after initiation of CI or on the 1st day of CI, sometimes called "day 0" or "day 1" in publications; 24 h: Css about 24 hours after initiation of CI or on the 2nd day of CI, sometimes

called "day 1" or "day 2" in publications; 48 h: Css about 48 hours after initiation of CI or on the 3rd day of CI, sometimes called "day 2" or "day 3" in publications; 72 h: Css about 72
hours after initiation of CI or on the 4th day of CI, sometimes called "day 3" or "day 4" in publications), IBW: ideal body weight, LD: loading dose, MD: maintenance dose (24 h: MD
on the 1st day of CI (= D1) or within the 1st 24 hours of CI, 48 h: MD on the 2nd day of CI (= D2) or within 24-48 hours after initiation of CI, 72 h: MD on the 3rd day of CI (= D3) or
within 48-72 hours after initiation of CI), MIC: minimum inhibitory concentration, TDM: therapeutic drug monitoring, VCM: vancomycin.

Main findings Clinical and Microbiological Efficacy

Table S4: *Overview of the clinical and microbiological efficacy of continuously applied vancomycin. Thirty-five studies were identified in the initial full-text selection process that presented data of steady-state serum concentrations of continuously administered vancomycin (CI) and efficacy (clinical or microbiological success (e.g. cure) or failure (e.g. mortality)). Only eighteen studies made it into the final analysis. Studies excluded from the final selection because of an increased risk of bias (e.g. unspecified or time course of less than 12 months or a CI study population of less than 30 patients) are written in italics.*

Reference	Category	Therapy Failure Definition	Therapy Failure Results	Therapy Success Definition	Therapy Success Results	Independent predictors Univariate	Independent predictors Multivariate
Akers [64]	Clinical failure + success	Mortality (in-hospital, 14-day, 28-day)	**In-hospital mortality**: <u>All</u>: 32.2 % (29/90); <u>Non-CVVH</u>: 19.1 % (13/68); <u>Gram-positive bacteremia</u>: 16 %, 4/25 / 4.4 %, 4/90; <u>Sepsis without gram-positive bacteremia</u>: 70 %, 14/20 / 15.6 %, 14/90; <u>Pneumonia</u>: 35 %, 7/20 / 7.8 %, 7/90; **14-d mortality**: <u>All</u>: 10 % (9/90); **28-d mortality**: <u>All</u>: 18.9 % (17/90)	Not defined	Not defined	Not defined	Not defined
	Microbiological failure	Recurrence of gram-positive bacteremia after beginning of CI	<u>MSSA</u>: (2 of an unknown quantity); <u>MRSA</u>: (2 of an unknown quantity); <u>Enterococci</u>: (3 of an unknown quantity) <u>CI+II</u>: 17.5 % (10/57)	Not defined	Not defined	Not defined	Not defined
Albanèse [74] Excluded due to number of patients <30 and unspecified length of time course	*Clinical success*	*Not defined*	*Not defined*	*Cure; Recovery*	*100 %*	*Not defined*	*Not defined*
	Microbiological success	*Not defined*	*Not defined*	*Bacteriological cure*	*100 %*	*Not defined*	*Not defined*
Beumier [70]	Clinical failure + success	Mortality (ICU)	57 % (18/32)	Target attainment	**12 h**: 69 %; **24 h**: 63 %; *Subtherapeutic*: **12 h**: 3 %; **24 h**: 19 %; *Supratherapeutic*: **12 h**: 28 %; **24 h**: 19 %	<u>Target attainment</u>: Body weight; CRRT intensity	Not defined
Carricajo [76] Excluded due to number of patients <30 and unspecified length of time course	*Clinical success*	*Not defined*	*Not defined*	*Target attainment*	*<u>Css</u>: <u>All</u>: 27.3 %; <u>≥120 mL/min</u>: 0 %; <u><120 mL/min</u>: 42.9 %; Subtherapeutic: <u>All</u>: 59.1 %; <u>≥120 mL/min</u>: 100 %; <u><120 mL/min</u>: 35.7 %; Supratherapeutic: <u>All</u>: 13.6 %; <u>≥120 mL/min</u>: 0 %; <u><120 mL/min</u>: 21.4 %; <u>**AUC/MIC**</u>: <u>All</u>: 66.7 %;*	*Not defined*	*Not defined*

Reference	Category	Therapy Failure		Therapy Success		Independent predictors	
		Definition	**Results**	**Definition**	**Results**	**Univariate**	**Multivariate**
					≥120 mL/min: 25 %; *<120 mL/min: 87.5 %*		
Cianferoni [71]	Clinical failure	Mortality (ICU)	<u>All</u>: 23 % (48/207); <u>No AKI</u>: 18 % (28/157); <u>AKI</u>: 40 % (20/50); <u>(Early AKI</u>: 46 % (13/28); <u>Late AKI</u>: 32 % (7/22))	Not defined	Not defined	Not defined	Not defined
Covajes [73]	Clinical failure + success	Mortality (ICU)	59 % (50/85)	Target attainment	**24 h**: 51 %; **48 h**: 56 % ; **72 h**: 67 %; *Subtherapeutic*: **24 h**: 29 %; **48 h**: 22 % ; **72 h**: 8 %; *Supratherapeutic*: **24 h**: 20 %; **48 h**: 21 % ; **72 h**: 26 %	**24 h target attainment**: Age; Daily VCM dose (mg/kg); CRRT intensity	**24 h target attainment**: Age; Daily VCM dose (mg/kg); CRRT intensity
Cristallini [67]	Clinical failure + success	Mortality (ICU)	22 % (24/107)	Target attainment	**12 h**: 56 %; **24 h**: 54 %; **48 h**: 73 %	Not defined	**24 h**: BMI; Body weight; uCrCl
Di Filippo [77] **Excluded due to number of patients <30 and time course of only 7 months**	*Clinical success*	*Not defined*	*Not defined*	*Improvement* *(= Reduction in SOFA score; leukocytes; body temperature (T); tachycardia; tachypnea)*	*SOFA: -33.8 % (before initiation of CI: 6.62±2.2; end of therapy: 4.37±3.5);* *Leukocytes: -37.6 % (before initiation of CI: 17.24±12.84; end of therapy: 10.76±3.61);* *T: 100 % (11/11);* *Tachycardia: 100 % (11/11);* *Tachypnea: 100 % (11/11);* *(CI+II): Resolution of fever, tachycardia, tachypnea)*	*Not defined*	*Not defined*
	Microbiological success	*Not defined*	*Not defined*	*Cure* *(= Negative culture of the same type of biological sample)*	*100 % (25/25)*	*Not defined*	*Not defined*
Duszynska [44] **Excluded due to number of patients <30**	*Clinical failure + success (evaluation 24 h after end of CI)*	*Persistence or progression of clinical symptoms of infection;* *Initial recovery followed by deterioration;* *Change to broader spectrum antibiotic therapy (escalation);* *Increased radiological infiltrates/computer tomography (CT)-scan pathology;* *Worsening of laboratory data;* *Need for surgery source control;* *Catecholamines*	*Css:* *All: 19 % (4/21);* *Reaching target at least once: 17.6 % (3/17);* *No reaching of target: 25 % (1/4);* *AUC24/MIC:* *>400: 20 % (1/5);* *≤400: 18.7 % (3/16)*	*Cure* *(= Hemodynamic stabilization: resolution of clinical infection signs (body temperature < 37.5 °C);* *laboratory abnormalities (reduction of leukocytes, CRP, PCT concentration by more than 80 % compared to baseline); no further need for VCM)*	*Css:* *All: 81 % (17/21);* *Reaching target at least once: 82.4 % (14/17);* *No reaching of target: 75 % (3/4)* *AUC24/MIC:* *>400: 80 % (4/5);* *≤400: 81.3 % (13/16);* *Clinical cure: 194 (134-389)*	*Not defined*	*Not defined*
	Microbiological failure + success (evaluation 24 h after end of CI)	*Persistence colonization of new gram-positives or the same pathogen(s) in laboratory samples*	*Css:* *All: 19 % (4/21);* *Reaching target at least once: 23.5 % (4/17);* *No reaching of target: 0 % (0/4)* *AUC24/MIC:* *>400: 20 % (1/5);* *≤400: 18.7 % (3/16)*	*Microbiological eradication* *(= Negative culture from blood, intra-abdominal fluids, CSF, etc.)*	*Css:* *All: 81 % (17/21);* *Reaching target at least once: 76.5 % (13/17);* *No reaching of target: 100 % (4/4)* *AUC24/MIC:* *>400: 80 % (4/5);* *≤400: 81.3 % (13/16);* *Microbiological eradication: 162 (116-389)*	*Not defined*	*Not defined*
Eldemiry [53] **Excluded due to number of patients <30**	*Clinical failure + success*	*Mortality (15-day)*	*Not described*	*Improvement* *(= Reduction in BUN; leukocytes; pCO2; body temperature (T); APACHE II; increase in pO2; spO2)*	*BUN: (-23.1 %; 46.8±20.27/36±18.71);* *Leukocytes: -40.6 % (16.82±13.23/9.99±3.78);* *pCO2: -15.2 % (42.55±11.7/36.07±8.34);* *T: -3.1 % (reduction in 90 % of patients; 38.335±1.16/37.15±0.42);* *APACHE II: -30.3 % (14.2±4.6/9.9±5.54);* *pO2: +36.3 % (69.3±46.79/94.45±30.1);* *spO2: +22.2 % (76.94±17.8/94.01±11.03)*	*Not defined*	*Not defined*

Reference	Category	Therapy Failure		Therapy Success		Independent predictors	
		Definition	**Results**	**Definition**	**Results**	**Univariate**	**Multivariate**
	Microbiological success	-	-	*Cure*	*83.3 % (2/12)*	-	-
Hanrahan [87]	Clinical failure	Mortality (ICU all-cause; within 72 h of last recorded VCM dose)	ICU: 26.3 % (172/653); Within 72 h of last VCM: 19.9 % (130/653); Mortality or nephrotoxicity within 72 h of cessation: 38.7 % (253/653)	Not defined	Not defined	Not defined	Not defined
Hong [39] Excluded due to time course of only 9 months	*Clinical failure + success*	*Mortality (ICU)*	*15.4 % (10/65)*	*Target attainment*	*24 h: 40 %; Subtherapeutic: 21.5 % Supratherapeutic: 38.5 % AUC24/MIC (S. aureus, 11/15): MIC=0.5: 100 % (2/2); MIC=1: 88.9 % (8/9); MIC=2: 0 % (0/0) Population-based: MIC=0.5: 100 % (65/65); MIC=1: 92.3 % (60/65); MIC=2: 27.7 % (18/65)) Time to target: 1.96 d; Time within target: 55 %*	*Not defined*	*Not defined*
	Microbiological success	-	-	*Eradication*	*55.5 % (11/20)*	*Not defined*	*Not defined*
Hutschala [46]	Clinical failure + success	Mortality (ICU, in-hospital)	ICU: 21 % (25/119); In-hospital: 30.3 % (36/119); Timing of death in course of VCM administration: 9±3.3 d (1-20)	Improvement (= Reduction of CRP; leukocytes)	CRP: -66.4±41.6 % (before CS: 3.7±5.1 (0.5-25.1); at start of VCM: 22.64±10.1 (7.3-55); on 10th day of VCM: 7.6±5.69 (0.7-32.1))	Not defined	Not defined
Lin [45] Excluded due to number of patients <30	*Clinical failure + success*	*Mortality (in-hospital)*	*50 % (7/14)*	*Target attainment; Time to target*	*24 h: 100 % Time to target: 24±0.56 h*	-	-
Lin [57]	Clinical failure + success	Mortality (in-hospital)	Obese: 19.2 % (5/26); Non-obese: 15.4 % (4/26)	Target attainment	**24 h:** Obese: 92.3 %; Non-obese: 88.5 % CVVH Obese: 100 %; Non-obese: 100 %	Not defined	Not defined
Ma [52] Excluded due to inclusion of ICU and non-ICU patients in analysis	*Clinical failure + success*	*Mortality (infection-related, in-hospital)*	*Infection-related: 1 % (2/141); All: 2 % (3/141)*	*Target attainment*	*78 %*	*Not defined*	*Not defined*
				Cure (= Resolution of infection signs and symptoms)	*93 % (62/67)*	*Not defined*	*Not defined*
	Microbiological success	*Readmission within 14 d of discharge for infection recurrence; Initiation of a new antibiotic with a similar spectrum due to lack of response*	*7 % (3/40)*	*Cure (= Negative culture during/up to 14 d after discontinuing CI after initial positive culture)*	*93 % (37/40)*	*Not defined*	*Not defined*
Mohammedi [85]	Clinical failure + success	Mortality (ICU)	A (LD 500 mg): 50 % (10/20); B (LD 15 mg/kg): 35 % (7/20)	Cure (in patients with proven infection)	A (LD 500 mg): 56 % (10/18); B (LD 15 mg/kg): 93 % (14/15)	Not defined	Not defined
Ocampos-Martinez [33]	Clinical failure + success	Mortality (ICU)	29 % (77/261)	Target attainment	**24 h:** 47 %; **48 h:** 67 %; **72 h:** 86 %; *Subtherapeutic:* **24 h:** 42 %; **48 h:** 14 %; **72 h:** ND *Supratherapeutic:*	Target attainment: **24 h:** CrCl; Loading dose; SCr; **48 h:** CrCl; Gender (male);	Target attainment: **24-48 h:** CrCl; Gender (male)

Reference	Category	Therapy Failure		Therapy Success		Independent predictors	
		Definition	**Results**	**Definition**	**Results**	**Univariate**	**Multivariate**
					24 h: 11 %; **48 h**: 19 %; **72 h**: ND	SCr; SOFA	
Omuro [75]	Clinical failure	Mortality (ICU)	CI: 25.2 % (30/119); (VCM-AKI (CI+II): 48 %; Non VCM-AKI (CI+II): 16.8 %)	Not defined	Not defined	ICU Mortality: AKI	Not defined
Perin [63]	Clinical failure + success	Mortality (ICU, in-hospital, 28-day)	**28-day**: All: 26 % (46/178); D2/3 VCM level 20-25 mg/L: 19 % (8/42); D2/3 VCM level <>20-25 mg/L: 28 % (37/132)	Target attainment	**24-48 h**: 24 %	Target attainment: Prolonged ICU stay before initiation of CI; *Subtherapeutic*: AKI on d1/2; Prolonged ICU stay before initiation of CI	Target attainment: Prolonged ICU stay before initiation of CI; *Subtherapeutic*: AKI on d1/2
		Persistence or progression of baseline signs and symptoms of infection after ≥ 2 d of treatment, consistent with active infection Requirement for additional antibacterial treatment	Failure without identification: 13 % (23/179)	Cure (= Resolution of clinical signs and symptoms compared with baseline) (= No requirement for additional antibacterial treatment)	65 % (116/179) (test of cure could not be assessed in 13 % (23/179))		
	Microbiological failure + success	Relapse (= Finding of same pathogen); Reinfection (= Presence of another pathogen)	Relapse: 3 % (5/179); Reinfection 7 % (12/179);	Not defined	Not defined	Not defined	Not defined
Ricard [118] *Excluded due to number of patients <30 and unspecified length of time course*	*clinical failure + success*	*Mortality (ICU)*	*21.4 % (3/14)*	*Cure; Improvement (= Reduction of CSF leukocytes; CSF protein; CSF glucose);*	*Cure: 64.3 % (9/14); Improvement: 14.3 % (2/14); (Leukocyte: 1st lumbar puncture: 8±24; 2nd lumbar puncture: 0.7±0.11; Protein: 1st: 8.6±7.22; 2nd: 5.4±4.35; Glucose: 1st: 0.5±0.77; 2nd: 2.6±1.43)*	*Not defined*	*Not defined*
	Microbiological success	*Not defined*	*Not defined*	*Cure (= Eradication of pathogens in CSF)*	*Gram-positive cocci: 46 % (1st: 13; 2nd: 7/13); S pneumoniae: 100 % (1st: 12; 2nd: 0/12)*	*Not defined*	*Not defined*
Saugel [69] *Excluded due to time course of only 9 months*	*Clinical failure*	*Mortality (in-hospital; ICU)*	*ICU: 44 % (15/34); Hospital: 59 % (20/34)*	*Not defined*	*Not defined*	*Not defined*	*Not defined*
Schmelzer [60] *Excluded due to number of patients <30 and unspecified length of time course*	*Clinical success*	*Not defined*	*Not defined*	*Target attainment*	*57.1 % Subtherapeutic: 21.5 % Supratherapeutic: 21.4 %*	*Not defined*	*Not defined*
Sin [56]	Clinical failure + success	Mortality (in-hospital)	63.5 % (33/52)	Target attainment	**24 h**: 82.7 %; **48 h**: 81.8 %; **72 h**: 75 %; *Subtherapeutic*: **24 h**: 3.8 %; **48 h**: 6.1 %; **72 h**: 8.3 %; *Supratherapeutic* **24 h**: 13.5 %; 48 h: 12.1 %; **72 h**: 16.7 %	Not defined	Not defined

Reference	Category	Therapy Failure		Therapy Success		Independent predictors	
		Definition	Results	Definition	Results	Univariate	Multivariate
Spadaro [58]	Clinical failure + success	Mortality (ICU)	CrCl >50 mL/min: 21.4 % (45/210); CrCl ≤50 mL/min: 23.9 % (33/138)	Target attainment	**24 h:** CrCl >50 mL/min: 44 %; CrCl ≤50 mL/min: 57 %; **48 h:** CrCl >50 mL/min: 41 %; CrCl ≤50 mL/min: 40 % **72 h:** CrCl >50 mL/min: 41 %; CrCl ≤50 mL/min: 41 %	Not defined	Mortality: Subtherapeutic level at first VCM measurement (→ AUC/MIC was in therapeutic range); SAPS II score
Spapen [61]	Clinical failure	Mortality (no differentiation between "infection-related" or "AKI-induced")	AKI: 53 % (20/38); No AKI: 20 % (18/91)	Not defined	Not defined	Not defined	Not defined
Stepan [62]	Clinical failure + success	Mortality (infection-related)	18 % (6/33)	Cure (= Vanishing of all symptoms of an infection); Improvement (= Reduction of symptoms of infection; LOS; LOV; LOT; Reduction of leukocytes; Reduction of CRP)	Cure/improvement: 64 % (21/33); LOS:: 26 d (12.8-40.3); LOV: 25 d (10.5-39.3); LOT: 9 (7-10); Leukocytes: d0: 13.4 (9.7-18.9); end: 10.9 (8.6-17.9) (-18.7 %); CRP: d0: 192.0±98.1; end: 123±83.1 (-35.9 %)	Not defined	Not defined
		Persistence of symptoms; Increase of symptoms	Not described				
	Microbiological failure + success	Persistency; Superinfection; Relapse	Not described	Cure (=Eradication; Suspected eradication)	76 % (25/33)	Not defined	Not defined
Tiede [119] Excluded due to number of patients <30	*Clinical success (study not designed for efficacy evaluation)*	*Not defined*	*Not defined*	*Cure; Improvement (= Reduction of infection parameter within 7 d after initation of CI: CRP (serum), leukocyte (serum, CSF))*	*Cure: 100 % (9/9); CRP: 100 % (9/9); Leukocyte serum: overall decrease, but not in every patient; Leukocyte CSF: 100 % (9/9)*	*Not defined*	*Not defined*
Udy [72]	Clinical failure	Mortality (not specified)	58 % (47/81)	Not defined	Not defined	Not defined	Not defined
van de Vijsel [54] Excluded due to number of patients <30	*Clinical failure + success*	*Mortality (ICU, infection-related)*	*ICU: 92 % (20/22); Infection-related: 59 % (13/22)*	*Target attainment*	*71 %*	*Not defined*	*Not defined*
van den Heever [55] Excluded due to number of patients <30	*clinical failure + success*	*Mortality (ICU)*	*10 % (1/10)*	*Target attainment*	*50 % after 21 h; 100 % within 33 h*	*Not defined*	*Not defined*
Vazquez [65] Excluded due to number of patients <30	*Clinical failure + success*	*Worsening of clinical condition; Serious condition*	*Worsening: 8 % (2/25) Serious: 28 % (7/25)*	*Improvement of clinical condition; Afebrile*	*Improvement: 64 % (16/25); Apyretic: 8 % (2/25)*	*Not defined*	*Not defined*
Wysocki [47]	Clinical failure + success	Mortality (infection-related: 10-day; end of treatment; overall: 10-day; end of treatment; ICU)	**Infection-related**: D10: 8 % (5/61); End of treatment: 10 % (6/61); **Overall**: D10: 8 % (5/61); End of treatment: 18 % (11/61); ICU: 37 % (21/61)	Cure; Improvement	78.7 % (48/61)	Not defined	Not defined
		Persistency or impairment of clinical, laboratory, radiological statuses	D10: 21 % (13/61); End of treatment: 21 % (13/61)				
	Microbiological failure + success	Presence of *Staphylococcus spp.* or other species in specimen on day 5	*Staphylococcus*: 39 % (24/61); Other species: 15 % (9/61); Bacteremia: 28 % (17/61)	Cure (= Eradication of *Staphylococcus spp.* in	46 % (28/61)	Not defined	Not defined

Reference	Category	Therapy Failure		Therapy Success		Independent predictors	
		Definition	Results	Definition	Results	Univariate	Multivariate
				specimen on day 5)			
Wysocki [120] *Excluded due to number of patients <30*	*Clinical failure + success*	*Mortality (infection-related, overall)*	*Infection-related:* *15 % (0-33) (2/13)* *ICU: 38 % (11-65) (5/13)*	*Duration of fever (<38.5 °C)*	*3 d (1-8)*	*Not defined*	*Not defined*
	Microbiological success	*Not defined*	*Not defined*	*Duration of bacteremia*	*2 d (1-7)*	*Not defined*	*Not defined*
Yamada [42] *Excluded due to number of patients <30*	*Clinical failure*	*Mortality (not specified)*	*36 % (4/11)*	*Not defined*	*Not defined*	*Not defined*	*Not defined*

AKI: acute kidney injury, APACHE: Acute Physiology and Chronic Health Evaluation, BUN: blood urea nitrogen, BW: body weight, CI: continuous infusion of vancomycin, (u)CrCl:
creatinine clearance (measured on daily urine excretion), CRP: C-reactive protein, CRRT: continuous renal replacement therapy, CSF: cerebrospinal spinal fluid, LOS: length of
stay, LOT: length of therapy with vancomycin, LOV: length of ventilation, PCO2: partial pressure of carbon dioxide, PCT: procalcitonin, PO2: partial pressure of oxygen, SOFA:
sepsis-related organ failure, VCM: vancomycin.

Main findings Safety

Table S5: *Overview of the safety of continuously applied vancomycin. Twenty-seven studies were identified in the initial full-text selection process that presented data of steady-*
state serum concentrations of continuously administered vancomycin (CI) and safety (e.g. nephrotoxicity in the form of acute renal failure). Only sixteen studies made it into the
final analysis. Studies excluded from the final selection because of an increased risk of bias (e.g. unspecified or time course of less than 12 months or a CI study population of less
than 30 patients) are written in italics.

Reference	Definition	Incidence	Serum Creatinine [mg/dL]	Creatinine Clearance [mL/min]	Nephrotoxins (% of patients)	Independent Predictors		
						Univariate	Multivariate	Association
Akers [64]	Non-CVVH: Increase in SCr by ≥0.5 mg/dL or at least 50 % increase from start to end of vancomycin therapy CVVH: Urine output <0.3 mL/kg/d	**All (CVVH + Non-CVVH):** ≥ 50 % SCr increase: 7.8 % (7/90); ≥0.5 mg/dL SCr increase at end of therapy: 6.7 % (6/90); ≥0.5 mg/dL SCr increase at any time during therapy: 20 % (18/90); **Non-CVVH**: ≥ 50 % SCr increase: 10.4 % (7/68); ≥0.5 mg/dL SCr increase at end of therapy: 8.8 % (6/68); ≥0.5 mg/dL SCr increase at any time during therapy: 22.1 % (15/68)	Mean: 0.99±0.39	CrCl: 90.8±39.2	Not described	Not described	Not described	Not described
	Bone marrow toxicity: Difference in leukocytes, neutrophils and platelets at the beginning and end of CI	Leukocytes: Start of CI: 10.6 (8.4-17.5); End of CI: 12.2 (8.4-18.8) (not significant) Neutrophils: Start of CI: 9.1 (6.7-14.8); End of CI: 9.9 (6.4-16.5) (not significant) Platelets: Start of CI: 176 (101-271); End of CI VCM: 236 (108-417) (significant)						
Albanèse [74] Excluded due to number of patients <30 and unspecified length of time course	*No specific definition for nephrotoxicity mentioned ("no adverse effect")*	*0 % (no renal impairment detected despite high level of VCM in serum)*	*D1: 0.76±0.27; Last day of treatment: 0.63±0.21*	*Not described*	*Not described*	*Not described*	*Not described*	*Not described*
Baptista [68]	Increase in SCr by >0.3 mg/dL on ≥2 consecutive days; Red-man syndrome	A (MD 30 mg/kg/d): 6.3 %; B (MD nomogram): 4 %	A: 0.68±0.3; B: 0.68±0.3	CrCl: A: 125.1±66.5; B: 120.5±54.2; ARC on d1: A: 36.7 %; B: 40 %	Not described	Not described	Not described	Not described
Carricajo [76] Excluded due to number of patients <30 and unspecified length of time course	*No specific definition for nephrotoxicity mentioned*	*0 %*	*Not described*	*CrCl: 105.5±34.6 (50-178)*	*Not described*	*Not described*	*Not described*	*Not described*
Cianferoni [71]	Daily urine output <0.5 ml/kg/h and/or increase of SCr ≥0.3 mg/dl or 50-100 % increase from baseline (=VCM on first day of therapy) on at least two consecutive days during and within 72 h after VCM discontinuation	Total: 24 % (50/207); VCM level <15 mg/L: 6 % (2/34) 15-20 mg/L: 11 % (5/47) 20-25 mg/L: 30 % (18/60) 25-30 mg/L: 38 % (15/39) >30 mg/L: 37 % (10/27) Early AKI: 56 % (28/50)	Not described	CrCl (1.73 m²): All: 68 (31-108); No AKI: 72 (35-117); AKI: 44 (26-88);	At least 1 nephrotoxin (All: 74 %; no AKI: 69 %; AKI: 92 %; early AKI: 93 %; late AKI: 91 %); Number of nephrotoxins (1/patient (1-2)); ACEi/ARB (All: 15 %); Aminoglycosides (All: 8	Not described	AKI: Mean serum VCM (over d1-3); Duration of therapy; Early AKI: Bacteremia; Mean serum VCM (over d1-3); Mean dose/d (over d1-3); Late AKI: Diabetes;	AKI: Severity of illness (APACHE II, SOFA); SCr/CrCl at baseline

Reference	Definition	Incidence	Serum Creatinine [mg/dL]	Creatinine Clearance [mL/min]	Nephrotoxins (% of patients)	Independent Predictors		
						Univariate	Multivariate	Association
	Early AKI: Occurrence within first 2 days of therapy; Late AKI: Occurrence after 2 days of therapy; Severe AKI: Need for CRRT or HD within VCM therapy or 3 days after drug discontinuation	Late AKI: 44 % (22/50) CRRT: No AKI: 2 % (3/157 patients needing CRRT 9/11/13 d after VCM discontinuation); AKI: 18 % (9/50) during VCM therapy		(Early AKI: 36 (20-49); Late AKI: 85 (38-101))	%); Contrast, iv (All: 22 %); Diuretics (All: 37 %); Vasopressors (All: 33 %); Inotropes (All: 17 %); Others (All: 8 %, e.g. amphotericin B; calcineurin inhibitors; colistin; NSAIDs)		Duration of therapy	
Duszynska [44] Excluded due to number of patients <30	*AKIN [102] during VCM therapy until 72 h after drug discontinuation*	23.8 % (5/21)	1±0.6	CrCl: 94±47	*Aminoglycosides (0 %); Colistin (24 %); Contrast, iv (14 %); Diuretics (29 %); NSAIDs (19 %)*	*Not described*	*Not described*	*Not described*
Eldemiry [53] Excluded due to number of patients <30	*Allergy; Ototoxicity*	0 %	2.01±0.63	-	*Loop diuretics (10 %); Meropenem (15 %)*	*Not described*	*Not described*	*Not described*
Hanrahan [87]	AKI (RIFLE [117])	24.7 % (161/653) Nephrotoxicity or mortality within 72 h of cessation: 38.7 % (253/653)	Not described	Not described	(Inotropes)	Not described	Not described	Not described
Hong [39] Excluded due to time course of only 9 months	*Consensus Recommendation from AHSP/IDSA/SIDP on Therapeutic Monitoring of Vancomycin (2009) [50]*	15.4 % (10/65)	0.92±0.31	CrCl: 88.8±37.6	ACEi/ARB; aminoglycosides; amphotericin B; iv contrast dye; loop diuretics	*Not described*	*Not described*	*Not described*
Hutschala [46]	AKI (AKIN [102] and RIFLE [117])	Total: **RIFLE**: 37 % (44/119); RIFLE: R: 30.3 %; I: 4.2 %; F: 2.5 %; **AKIN**: 49.6 % (59/119); AKIN: 1: 29.4 %; 2: 11.8 %; 3: 8.4 %; RRT: 23.5 % (28/119) Necessity to administer diuretics (furosemide): 12.6 % (15/119)	Before surgery: 0.9±0.5 (0.5-1.5); Before VCM: 1.2±0.6 (0.6-4.3); Maximum during VCM: 1.5±0.7 (0.6-5.0)	CrCl: Before surgery: 119±21 (81-172); Before VCM: 54±40 (1-254); Minimum during VCM: 36±29 (1-146)	Aminoglycosides (12 %); Constrast, iv; Diuretics (13 %); Vasopressors	Not described	Not described	Not described
Lin [57]	Not requiring CVVH: Increase in SCr by 0.5 mg/dL or at least 50 % increase from baseline over two consecutive SCr values; Hemodialysis upon discharge from hospital; Hearing loss	AKI: 0 %; Hemodialysis: 0 %; Hearing loss: 0 %	Not described	Urine CrCl: Obese: 166±62.7; Non-obese: 168.1±59.1	Not described	Not described	Not described	Not described
Ma [52] Excluded due to inclusion of ICU and non-ICU patients in analysis	*AKI (RIFLE [117])*	*Nephrotoxic risk: 12 % (16/129) Renal injury: 3 % (4/129) Need for RRT: 0 % (0/129)*	*Initial: 0.76±0.25; Final: 0.8±0.37; Highest up to 2 weeks after completing VCM: 0.89±0.42*	CrCl: 130±65.6	*ACEi/ARB (23 %); Aminoglycosides (0 %); Contrast, iv (19 %); Diuretics (20 %); NSAIDs (50 %); Piperacillin/Tazobactam (11 %) PPI (27 %); Cisplatin; drugs of abuse (cocaine, heroin, ketamine, methadone, methamphetamine); gold therapy; methotrexate; pamidronate; pentamidine; quinine; iv voriconazole; zoledronate*	*Not described*	*Bivariate: Risk: Dose modality at time of highest SCr; VCM duration at time of highest SCr; Concomitant piperacillin/tazobactam; Concomitant gram-negative bacteria infection; Concomitant diuretics; Concomitant nephrotoxin; Injury: Dose modality at time of highest SCr; VCM duration at time of highest SCr Concomitant piperacillin/tazobactam; Concomitant gram-negative bacteria infection*	*Not described*

Reference	Definition	Incidence	Serum Creatinine [mg/dL]	Creatinine Clearance [mL/min]	Nephrotoxins (% of patients)	Independent Predictors		
						Univariate	Multivariate	Association
Mohammedi [85]	Alterations in renal function	0 %	Not described	Not described	Not described	Not described	Not described	Not described
Omuro [75]	AKI (AKIN [102])	20.2 % (eventually higher rate of AKI in medical patients (CI/II: surgical: 25.7 %; medical: 42.6 %))	Initiation of VCM (mean): 0.9 (0.73-1.5)	-	Number of nephrotoxins (3/patient); ACEi/ARB (35 %); Aminoglycosides (13 %); Contrast, iv (60 %); Diuretics (94 %); Piperacillin/tazobactam (65 %); Vasopressors (94 %) (Inotropes (19 %)	ICU mortality	Not described	Inotropics; Medical ICU; Vasopressors; VCM therapy
Perin [63]	AKI (KDIGO [103]) (measured on D1-4; D10; D15)	During VCM administration: 60 % (107/179), With RRT: 27 % (49/179); VCM ≥25 mg/L at d2/3: 77 % (34/44), With RRT: 36 % (16/44); VCM <25 mg/L at d2/3: 55 % (72/131), With RRT: 25 % (33/131)	Baseline: 0.77 (0.67-0.97); Advanced: 1.18 (0.81-1.83)	**CKD-EPI**: 62 (34-88); augmented renal clearance at d1/2: 4 %	ACEi (20 %); Aminoglycosides (79 %); ARB (10 %); Chemotherapy (4 %); Contrast; Diuretics (20 %); NSAIDs (9 %); Others (12 %)	Not described	Not described	Not described
Ricard [118] Excluded due to number of patients <30 and unspecified length of time course	*Alteration of renal function (that could be specifically related to treatment)*	*0 %*	*Mean: 0.95*	*Not described*	*Not described*	*Not described*	*Not described*	*Not described*
Saugel [59]	Start of RRT	7.3 %	Not described	Not described	Not described	Not described	Not described	Not described
Schmelzer [60] Excluded due to number of patients <30 and unspecified length of time course	*50 % increase of SCr from baseline*	*3.6 %*	*0.72±0.2*	*-*	*ACEi; ARB; aminoglycosides; amphotericin B; calcineurin inhibitors; NSAIDs; iv contrast*	*Not described*	*Not described*	*Not described*
Sin [56]	Infusion reaction; Ototoxicity	0 %	Not described	Not described	Not described	Not described	Not described	Not described
Spadaro [58]	AKI (Consensus Recommendation from AHSP/IDSA/SIDP on Therapeutic Monitoring of Vancomycin (2009) [50])	CrCl >50 mL/min: 2.4 %; CrCl ≤50 mL/min: 9.4 %; VCM level 25-30 mg/L: 0 %; VCM level >30 mg/L: <8 %	Baseline: CrCl >50 mL/min: 1.0±0.4; CrCl ≤50 mL/min: 2.3±1.4	CrCl: Baseline: >50 mL/min: 106.4±40.7; ≤50 mL/min: 37±16.2	ACEi (>50 mL/min: 19.5 %; ≤50 mL/min: 15.2 %); Aminoglycosides (>50 mL/min: 5.7 %; ≤50 mL/min: 6.5 %); Vasopressors (>50 mL/min: 15.2 %; ≤50 mL/min: 18.1 %)	Not described	CrCl at ICU admission	No correlation between nephrotoxicity and VCM within or over target range; No association with concomitant vasopressor therapy, aminoglycosides, ACEi
Spapen [61]	AKI (AKIN [102] 1)	Total: 29.5 % (38/129); Distribution according to VCM level: VCM level <25 mg/L: 7.9 % (3/38); VCM level 25-30 mg/L: 23.7 % (9/38); VCM level >30 mg/L: 68.4 % (26/38); VCM level <25 mg/L: No AKI: 95.5 % (65/68) (71.4 %, 65/91); AKI: 4.5 % (3/68) (7.9 %, 3/38);	AKI: 0.9±0.19; No AKI: 0.8±0.35	Not described	ACEi/ARB (no AKI: 19 %; AKI: 18 %); Aminoglycosides (no AKI: 43 %; AKI: 32 %); Immunosuppressants (no AKI: 2 %; AKI: 0 %); NSAIDs (no AKI: 4 %; AKI: 3 %),	Diabetes mellitus; Shock	VCM level (especially >30 mg/L); (Lean) Body weight; SAPS 3 score	Duration of therapy; No relationship between type of infection and incidence of AKI; No relationship between nephrotoxic medication and incidence of AKI

Reference	Definition	Incidence	Serum Creatinine [mg/dL]	Creatinine Clearance [mL/min]	Nephrotoxins (% of patients)	Independent Predictors		
						Univariate	Multivariate	Association
		VCM level 25-30 mg/L: No AKI: 69 % (20/29) (22 %, 20/91); AKI: 31 % (9/29) (23.7 %, 9/38); VMC level >30 mg/L: No AKI: 18.8 % (6/32) (6.6 %, 6/91); AKI: 81.3 % (26/32) (68.4 %, 26/38); Return of SCr to baseline at discharge (surviving): 66 % (12/18)			Vasopressors (Nephrotoxins considered only relevant when present during VCM infusion and before increase in SCr)			
Stepan [62]	Increase of SCr; Reduction of CrCl	0 %	D0: 1.1 (0.83-1.5); End of therapy: 0.93 (0.73-1.55)	MDRD: D0: 60 (39.6-60.0); End of therapy: 60 (42-60.0)	Not described	Not described	Not described	Not described
Tiede [119] *Excluded due to number of patients <30*	*No specific definition for nephrotoxicity mentioned ("renal impairment")*	*0 %* *(no renal impairment detected despite high-dose of VCM therapy)*	*Not described*	*> 100*	*Not described*	*Not described*	*Not described*	*Not described*
Tuon [86]	AKI (AKIN [102])	21 % (7/33); AKIN 1: 3 % (1/33); AKIN 2: 6 % (2/33); AKIN 3: 12 % (4/33)	0.66 (0.5-0.92)	Not described	Not described	Not described	Not described	Not described
Wysocki [47]	50 % increase of SCr from D0 until end of treatment; Initiation of Dialysis	Increase of SCr: 16.4 % (10/61); Dialysis: 9.8 % (6/61); Phlebitis/fever: 3 % (2/61); Risk factor for nephrotoxicity: Diabetes: 12 % (7/61); Diuretics: 35 % (18/61); iv contrast: 3 % (2/61); Aminoglycosides: 26 % (6/61)	Baseline (mean): 1.11±0.46; D10: 1.21±0.8; End of treatment: 1.36±0.89	CrCl: Baseline (mean): 77±41; D10: 73±34; End of treatment: 68±36	Aminoglycosides (26 %); Contrast, iv (3 %); Diuretics (35 %); Immunosuppression	Not described	Not described	Not described
Wysocki [120] *Excluded due to number of patients <30*	*Baseline SCr <3 mg/dL: Increase of SCr ≥ 0.5 mg/dL over baseline (= highest level or within 48 h of therapy); Baseline SCr ≥3 mg/dL: Increase of SCr ≥ 1 mg/dL over baseline (= highest level or within 48 h of therapy) (according to Smith, 1980 [124])*	*15.4 %*	*Baseline: 1.28±0.93; Later: 1.28±0.66*	*Not described*	*Not described*	*Not described*	*Not described*	*Not described*
Yamada [42] *Excluded due to number of patients <30*	*AKI (AKIN [102])*	*AKIN 1: 9 %; AKIN 2: 0 %; AKIN 3: 0 %*	*Not described*	*CrCl: 118.45 (111.2-119.7)*	*Aminoglycosides (9 %)*	*Not described*	*Not described*	*Not described*

ACEi: angiotensin-converting enzyme inhibitor, AKI: acute kidney injury, AKIN: Acute Kidney Injury Network, CrCl: creatinine clearance,
CRRT: continuous renal replacement therapy, D0: Start of vancomycin therapy, D1: Day 1 of vancomycin therapy, DM2: diabetes mellitus type 2, HD: hemodialysis, NSAID:
nonsteroidal anti-inflammatory drugs, RIFLE: Risk, Injury, Failure, Loss of kidney function and End-stage kidney disease, SAPS II: Simplified Acute Physiology Score II, SCr: serum
creatinine, VCM: Vancomycin.

Table S 6: *Characteristics of studies included in the forest plot analysis comparing the influence of vancomycin steady-state serum concentration below or above 25 mg/L on*
nephrotoxicity (= acute kidney injury) (n=3).

Reference	Patients (n)		Age (years) (mean)		Male sex (n)		ICU Type (n)		Target Css	LD (median)		MD (median)		Css (mean)		Duration of Therapy (days) (median)		ICU Mortality (n)		Nephrotoxicity (n)				
	AKI	No AKI	AKI	No AKI	AKI	No AKI	AKI	No AKI		AKI	No AKI	AKI	No AKI	AKI	No AKI	AKI	No AKI	AKI	No AKI			<25 mg/L		≥25 mg/L
Cianferoni 2013 [71]	50	157	61	60	32	98	Medical: 31 Surgical: 18	Medical: 92 Surgical: 65	20-30 mg/L	1000 mg 13 mg/kg	1000 mg 13 mg/kg	2000 mg/d 25 mg/kg/d	1940 mg/d 25 mg/kg/d	C24: 22.5 mg/L Cmean: 25.8 mg/L	C24: 18.7 mg/L Cmean: 21.2 mg/L	5	4	20	28	Other	Increase in SCr level of ≥0.3 mg/dL or 50-100 % increase frome baseline, whichever was greater (on at least two consecutive days); daily urine output <0.5 ml/kg/h	25/141	18%	25/66	38%
Perin 2020 [63]	107	72	67		119		ND	ND	20-25 mg/L	1000 mg 15.6 mg/kg		2000 mg/d 27.5 mg/kg/d		C24: 20.3 mg/L		4		46		KDIGO	Increase in SCr level of ≥0.3 mg/dL or 50-100 % increase from baseline, whichever was greater (on at least two consecutive days); daily urine output <0.5 mg/kg/h for 6-12 h	72/131	55%	34/44	77%
Spapen 2011 [61]	38	91	63	61	23	36	ND	ND	15-25 mg/L	ND	ND	ND	ND	Cmean: ND	Cmean: ND	15	9	20	18	AKIN	Increase in SCr level of ≥0.3 mg/dL or 50-100 % increase from baseline, whichever was greater (on at least two consecutive days); no measurement of urine output due to concerns about dependency on uncontrolled "extrarenal" events (e.g. volume status, loop diuretics, vasoactive agents)	3/68	4%	35/61	57%

835 AKI: acute kidney injury, C24: mean vancomycin steady-state serum concentration 24 h after initiation of therapy, Cmean: mean vancomycin steady-state serum concentration
836 during the entire duration of therapy or at least three days of therapy, Css: vancomycin steady-state serum concentration, ICU: intensive care unit, LD: loading dose, MD:
837 maintenance dose, ND: not described, SCr: serum creatinine.

839 **Table S 7**: *Comparison of the influence of vancomycin steady-state serum conc*
on the rate of acute kidney injury (AKI) (n=3 studies representing 515 patients
confidence interval 0.432-0.622; z = -5.745; p = <0.0001).

Reference	RR	Lower limit	Upper limit	Z-value	P-value	
Cianferoni 2013 [71]	0.468	0.292	0.750	-3.159	0.0016	841
Perin 2020 [63]	0.711	0.569	0.889	-2.995	0.0027	842
Spapen 2011 [61]	0.077	0.025	0.237	-4.460	<0.0001	843
Summary	**0.535**	**0.432**	**0.662**	**-5.745**	**<0.0001**	844

846 RR: relative risk, RR <1 indicates a lower rate of acute kidney injury at a vancomycin serum concentration of <25 mg/L in contrast to >25 mg/L. P-value <0.05 was considered
847 significant. Calculations according to Altmann 2011 [84]
848

Quality Assessment

850 ***Table S8***: *Quality assessment of the non-randomized studies using the Newcastle-Ottawa Scale (NOS). A star*
851 *system described the suitability of the selection of the study groups (S1-S4) (max. four stars), the comparability of*
852 *the groups (C1) (max. two stars) and the ascertainment of the exposure or outcome of interest (E1-E3) (max.*
853 *three stars). The total number of stars was interpreted as "good quality" at 8-9 stars, "fair quality" at 6-7 stars,*
854 *"questionable quality" at 4-5 stars, "poor quality" at 2-3 stars and "serious risk of bias" at 0-1 stars.*

Reference	S1	S2	S3	S4	C1	E1	E2	E3	Total	Evaluation
Akers 2012 [64]	SG	*	*	ND	**	*	ND	ND	5	Questionable quality
Baptista 2014[68]	SG	*	*	*	-	*	ND	ND	4	Questionable quality
Beumier 2013 [70]	SG	NA	ND	*	NA	ND	*	ND	2	Poor quality
Cianferoni 2013 [71]	SG	*	*	*	*	*	*	*	7	Fair quality
Covajes 2013 [73]	SG	NA	*	*	NA	*	*	-	4	Questionable quality
Cristallini 2016 [67]	SG	NA	ND	*	NA	ND	*	*	3	Poor quality
Hanrahan 2014 [87]	*	*	*	*	**	*	ND	*	8	Good quality
Hutschala 2009 [46]	SG	*	*	ND	**	*	*	*	7	Fair quality
Lin 2016 [57]	SG	*	*	ND	**	*	-	*	6	Fair quality
Mohammedi 2006 [85]	SG	*	ND	ND	**	ND	-	*	4	Questionable quality
Ocampos-Martinez 2012 [33]	SG	NA	*	*	NA	*	*	ND	4	Questionable quality
Omuro 2021 [75]	*	*	*	ND	**	*	ND	ND	6	Fair quality
Perin 2020 [63]	*	NA	*	*	NA	*	*	ND	5	Questionable quality
Saugel 2013 [59]	*	*	*	*	*	*	-	ND	6	Fair quality
Sin 2018 [56]	SG	NA	ND	ND	NA	ND	*	*	2	Poor quality
Spadaro 2015 [58]	SG	*	*	ND	**	*	ND	*	6	Fair quality
Spapen 2011 [61]	*	*	*	*	*	*	ND	*	7	Fair quality
Tuon 2021 [86]	SG	NA	ND	ND	NA	ND	ND	ND	0	Serous risk of bias
Udy 2013 [72]	SG	NA	*	*	NA	*	*	*	5	Questionable quality

*: award of one star within the selection (S1-4) and exposure (E1-3) categories and maximum of two stars in the
comparability (C1) category when an item was positively rated, -: no star could be awarded when an item was
negatively rated, C1: comparability of cohorts on the basis of design or analysis, E1: assessment of outcome, E2:
was follow-up long enough for outcome to occur?, E3: adequacy of follow up of cohorts, NA: not applicable, ND:
not described, S1: representativeness of the exposed cohort, S2: selection of the non-exposed cohort, S3:
ascertainment of exposure, S4: demonstration that outcome of interest was not present at start of study, SG:
selected group, Total: sum of stars in the row.

Table S9: *Quality assessment of the randomized trials using the revised Cochrane risk of bias tool (RoB 2). The*
overall bias "some concerns" was interpreted as "questionable quality" in the summary of the quality assessment
results.

Reference	Randomization Process	Effect of assignment to interventions	Effect of adhering to interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall Bias	Evaluation
Stepan 2009 [62]	Some concerns	Some concerns	Some concerns	Low risk	Some concerns	Some concerns	Some concerns	Questionable quality
Wysocki 2001 [47]	Low risk	Some concerns	Some concerns	Low risk	Some concerns	Some concerns	Some concerns	Questionable quality

869 **Efficacy**

870 ***Table S10***: Overview of the clinical failure rates other than mortality, the clinical success rates and the
871 microbiological failure and success rates in comparison to the vancomycin steady-state serum concentrations
872 presented in the eighteen studies included in the efficacy analysis of continuously administered vancomycin.

Clinical failure				Clinical success							
Persistence/Progression				Cure				Improvement			
Study	C24	Cmean	AUC24	Study	C24	Cmean	AUC24	Study	C24	Cmean	AUC24
				Mohammedi 2006 (LD 500 mg)	14.9 mg/L 56 %						
				Mohammedi 2006 (LD 15 mg/kg)	18.5 mg/L 93 %						
Perin 2020	20.3 mg/L 13 %			Perin 2020	20.3 mg/L 65 %						
				Stepan 2009		19.0 mg/L 64 %		Stepan 2009		19.0 mg/L 64 %	
Wysocki 2001		24.0 mg/L 21 %	577 mg*h/L 21 %	Wysocki 2001		24.0 mg/L 79 %	577 mg*h/L 79 %	Wysocki 2001		24.0 mg/L 79 %	577 mg*h/L 79 %

Microbiological failure								Microbiological success			
Persistence				Relapse (Reinfection)				Cure			
Study	C24	Cmean	AUC24	Study	C24	Cmean	AUC24	Study	C24	Cmean	AUC24
				Akers 2012		20.0 mg/L 18 %					
				Perin 2020	20.3 mg/L 3 % (7 %)						
								Stepan 2009		19.0 mg/L 76 %	
Wysocki 2001		24.0 mg/L 54 %	577 mg*h/L 54 %					Wysocki 2001		24.0 mg/L 46 %	577 mg*h/L 46 %

AUC24: area under the curve of serum concentration versus time for 24 h, C24: steady-state concentration 24 h
after initiation of therapy, Cmean: mean vancomycin steady-state serum concentration during the entire duration
of therapy or at least three days of therapy, (clinical) cure: resolution of clinical infection signs (e.g. body
temperature <37.5 °C) and symptoms, (microbiological) cure: negative cultures of the same type of biological
sample (e.g. blood, intra-abdominal fluids, cerebrospinal fluid (CSF), etc.), full eradication (e.g. on day 5),
negative cultures during or up to 14 days after discontinuing the continuous vancomycin infusion after an initial
positive culture, no requirement for antibiotic escalation or additional antibacterial treatment and shorter duration
of bacteremia, improvement: reduction of symptoms of infection, decrease of leukocytes, length of stay, length of
ventilation, duration of therapy, (clinical) persistence/progression: persistence or progression of baseline signs
and symptoms of infection after two or more days of treatment that were consistent with the active infection,
impairment of laboratory and radiological statuses, (microbiological) persistence: expansion of colonization of new
gram-positives or the same pathogens in laboratory samples, the elongation of *Staphylococcus spp.* or other
species in the specimen on day five, relapse: recurrence of gram-positive bacteremia after initiation of continuous
vancomycin use, readmission within 14 days of discharge because of recurrence of infection, detection of the
same pathogen or presence of another pathogen.

Table S 11: *Overview of the clinical and microbiological failure and success parameters and frequency ranges*
presented in the eighteen studies included in the efficacy analysis of continuously administered vancomycin.

Parameter		Definition	Range	Reference
Clinical failure	**Mortality**	Intensive care unit (ICU)	21-59 %	[33, 46, 47, 58, 63, 70, 71, 73, 75, 98, 100]
		In-hospital	17-63 %	[46, 47, 56, 57, 63, 64]
		X-Day (10-day, 14-day, 28-day, within 72 h of last recorded vancomycin dose)	8-26 %	[47, 63, 64, 100]
		Infection-related	8-18 %	[47, 62]
	Persistence or progress	Persistence or progression of baseline signs and symptoms of infection after two or more days of treatment that were consistent with the active infection, impairment of laboratory and radiological statuses	13-21 %	[47, 62, 63]
Clinical success	**Cure**	Resolution of clinical infection signs (e.g. body temperature <37.5 °C) and symptoms	64-93 %	[46, 47, 62, 63, 98]
	Improvement	Reduction of symptoms of infection, decrease of leukocytes, length of stay (LOS), length of ventilation (LOV), duration of therapy (LOT)		
Microbiological failure	**Persistence**	Expansion of colonization of new gram-positives or the same pathogens in laboratory samples and the elongation of *Staphylococcus spp.* or other species in the specimen on day five	3-54 %	47, 63, 64
	Escalation	Initiation of a new antibiotic with a similar spectrum to vancomycin due to lack of response and superinfection		
	Relapse	Recurrence of gram-positive bacteremia after initiation of continuous vancomycin use, readmission within 14 days of discharge because of recurrence of infection, detection of the same pathogen or presence of another pathogen		
Microbiological success	**Cure**	Negative cultures of the same type of biological sample (e.g. blood, intra-abdominal fluids, cerebrospinal fluid (CSF), etc.) or during or up to 14 days after discontinuing CI after an initial positive culture, full eradication (e.g. on day 5), no requirement for antibiotic escalation or additional antibacterial treatment and shorter duration of bacteremia	46-91 %	[47, 62, 63]

891
892

Additional Plots

Figure S1: *Scatterplots of the mortality rate plotted against the rate of acute kidney injury (AKI) (= nephrotoxicity) for studies in which mean vancomycin serum levels measured approximately 24 h after initiation of therapy with continuous infusion of vancomycin (C24) were reported (n=4 studies representing 478 patients). **a)** Differentiation according to the type of mortality. **b)** Differentiation according to the AKI definition.*

Filled black triangle: ICU mortality, bordered cross: in-hospital mortality, X: 28-day mortality, filled black diamond: AKIN, filled black square: KDIGO, squared triangle: other definition of AKI, non-filled triangle: RRT
AKI: acute kidney injury, AKIN: Acute Kidney Injury Network, ICU: intensive care unit, KDIGO: Kidney Disease Improving Global Outcomes, RRT: renal replacement therapy, X-Day: 28-day.

Figure S2: *Scatterplots of the mortality rate plotted against the rate of acute kidney injury (AKI) (= nephrotoxicity) for studies in which mean vancomycin serum levels calculated from the average of the levels obtained during the entire duration of therapy with continuous infusion of vancomycin or at least three days of therapy (Cmean) were reported (n=7 studies representing 1,282 patients). **a)** Differentiation according to the type of mortality. **b)** Differentiation according to the AKI definition.*

Filled black circle: mortality at the end of treatment with vancomycin, filled black triangle: ICU mortality, bordered cross: in-hospital mortality, non-filled square: infection-related mortality, X: 28-day mortality, filled black diamond: AKIN, squared triangle: other definition of AKI, star: RIFLE, non-filled triangle: RRT, non-filled diamond: Rybak2009
AKI: acute kidney injury, AKIN: Acute Kidney Injury Network, ICU: intensive care unit, KDIGO: Kidney Disease Improving Global Outcomes, RIFLE: Risk, Injury, Failure, Loss, End Stage Renal Disease, RRT: renal replacement therapy, Rybak2009: Consensus Recommendation from AHSP/IDSA/SIDP on Therapeutic Monitoring of Vancomycin (2009) (AHSP: American Society of Health-System Pharmacists, IDSA: Infectious Diseases Society of America, SIDP: Society of Infectious Diseases Pharmacists).

Figure S3: *Scatterplots of the mortality rate plotted against the rate of acute kidney injury (AKI) (= nephrotoxicity)*
for studies in which the mean vancomycin areas under the serum concentration vs. time curve for 24 h during
therapy with continuous infusion of vancomycin (AUC24) were reported (n=4 studies representing 580 patients).
a) Differentiation according to the type of mortality. b) Differentiation according to the AKI definition.

Filled black circle: mortality at the end of treatment with vancomycin, filled black triangle: ICU mortality, bordered
cross: in-hospital mortality, non-filled square: infection-related mortality, X: x-day mortality (e.g. 10-day, 28-day,
30-day), filled black diamond: AKIN, squared triangle: other definition of AKI, star: RIFLE, non-filled triangle: RRT,
non-filled diamond: Rybak2009
AKI: acute kidney injury, AKIN: Acute Kidney Injury Network, ICU: intensive care unit, KDIGO: Kidney Disease
Improving Global Outcomes, RRT: renal replacement therapy, RIFLE: Risk, Injury, Failure, Loss, End Stage
Renal Disease, RRT: renal replacement therapy, Rybak2009: Consensus Recommendation from
AHSP/IDSA/SIDP on Therapeutic Monitoring of Vancomycin (2009) (AHSP: American Society of Health-System
Pharmacists, IDSA: Infectious Diseases Society of America, SIDP: Society of Infectious Diseases Pharmacists).

Figure S4: *a) Scatterplot of studies in which a mean vancomycin level measured approximately 24 h after*
initiation of therapy with continuous infusion of vancomycin (C24), a target attainment rate and a mortality rate
were reported (n=8 studies representing 768 patients). b) Scatterplot of studies in which a C24, a target
attainment rate and a rate of acute kidney injury (= nephrotoxicity) were reported (n=3 studies representing 335
patients).

Filled black triangle: ICU mortality, bordered cross: in-hospital mortality, non-filled circle: type of mortality was not
reported, X: x-day mortality (e.g. 10-day, 28-day, 30-day), filled black diamond: AKIN, filled black square: KDIGO,
squared triangle: other definition of AKI, non-filled triangle: RRT, * target range, ** C24

AKI: acute kidney injury, AKIN: Acute Kidney Injury Network, aLD: applied average loading dose, aMD: applied
average maintenance dose, APACHE II: Acute Physiology And Chronic Health Evaluation II score, C24: mean
vancomycin level measured approximately 24 h after initiation of therapy with continuous infusion of vancomycin,
CVVH: continuous veno-venous hemofiltration, ICU: intensive care unit, KDIGO: Kidney Disease Improving
Global Outcomes, LOT: length of therapy, RIFLE: Risk, Injury, Failure, Loss, End Stage Renal Disease, (C)RRT:
(continuous) renal replacement therapy, Rybak2009: Consensus Recommendation from AHSP/IDSA/SIDP on
Therapeutic Monitoring of Vancomycin (2009) (AHSP: American Society of Health-System Pharmacists, IDSA:
Infectious Diseases Society of America, SIDP: Society of Infectious Diseases Pharmacists), SAPS II: Simplified
Acute Physiology Score II, SOFA: Sepsis-related Organ Failure Assessment score.

Figure S5: **a)** *Scatterplot of studies in which a mean vancomycin steady-state serum level during the entire*
duration of continuously administered vancomycin or at least three days of therapy (Cmean), a target attainment
rate and a mortality rate were reported (n=4 studies representing 488 patients). **b)** *Scatterplot of studies in which*
a Cmean, a target attainment rate and a rate of acute kidney (= nephrotoxicity) injury were reported (n=1 study
representing 90 patients).

Filled black triangle: ICU mortality, bordered cross: in-hospital mortality, X: x-day mortality (e.g. 14-day, 28-day),
non-filled diamond: Rybak2009, * target range, ** Cmean
AKI: acute kidney injury, AKIN: Acute Kidney Injury Network, aLD: applied average loading dose, aMD: applied
average maintenance dose, APACHE II: Acute Physiology And Chronic Health Evaluation II score, Cmean: mean
vancomycin steady-state serum level during the entire duration of continuously administered vancomycin or at
least three days of therapy, ICU: intensive care unit, KDIGO: Kidney Disease Improving Global Outcomes, LOT:
length of therapy, RIFLE: Risk, Injury, Failure, Loss, End Stage Renal Disease, (C)RRT: (continuous) renal
replacement therapy, Rybak2009: Consensus Recommendation from AHSP/IDSA/SIDP on Therapeutic
Monitoring of Vancomycin (2009) (AHSP: American Society of Health-System Pharmacists, IDSA: Infectious
Diseases Society of America, SIDP: Society of Infectious Diseases Pharmacists).
963

Figure S6: **a)** *Distribution of studies for the mean vancomycin serum levels measured approximately 24 hours*
after initiation of therapy with continuously administered vancomycin (C24) (n=11 studies representing 1,200
patients). **b)** *Distribution of studies for the mean vancomycin steady-state serum levels during the entire duration*
or at least three days of therapy with continuously administered vancomycin (Cmean) (n=12 studies representing
1,877 patients). **c)** *Distribution of studies for the mean vancomycin area under the serum concentration-time*
curve for a period of 24 hours (AUC24) (n=7 studies representing 752 patients).

971 **Acknowledgment, Funding, Transparency declaration, Author contributions,**
972 **Supplementary data**

973 **Acknowledgments**

974 We acknowledge Viola Fuchs for her support in supervising the research project and we

975 thank Daniel Mai for providing the R Statistical Software, Alexander and Renate Viertel for

976 assistance with data analysis and Andreas Ismair for basic help in the writing process of the

977 manuscript.

978 **Funding**

979 This research received no external funding.

980 **Transparency declaration**

981 None of the other authors has any conflict of interest to declare.

982 **Author contributions**

983 K.V. and F.M. conceived of the presented idea. K.V. conducted the study selection and data

984 extraction. M.S. extracted data from a sample of eligible studies, good agreement was

985 achieved with the data extracted by K.V.. K.V. and F.M. analysed the data. K.V. wrote the

986 manuscript with support and critical revision from F.M., T.A., E.F. and M.S.. F.M. supervised

987 the project. All authors reviewed and contributed to the final manuscript. All authors have

988 read and agreed to the published version of the manuscript.

989 **Supplementary data**

990 Tables S1 to S10 and Figures S1 to S6 are available as supplementary data at JAC Online.

991

References

1. Vincent JL, Sakr Y, Singer M et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. *Jama* 2020; **323**: 1478-87.
2. European Centre for Disease Prevention and Control (ECDC). Healthcare-associated infections in intensive care units - Annual Epidemiological Report for 2017. *Stockholm: ECDC* 2019.
3. Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology* 2017; **36**: 1999-2006.
4. Rello J, Molano D, Villabon M et al. Differences in hospital- and ventilator-associated pneumonia due to Staphylococcus aureus (methicillin-susceptible and methicillin-resistant) between Europe and Latin America: a comparison of the EUVAP and LATINVAP study cohorts. *Medicina intensiva* 2013; **37**: 241-7.
5. Geffers C, Zuschneid I, Sohr D et al. Erreger nosokomialer Infektionen auf Intensivstationen: Daten des Krankenhaus-Infektions-Surveillance-Systems (KISS) aus 274 Intensivstationen. *Anästhesiol Intensivmed Notfallmed Schmerzther* 2004; **40**: 15-9.
6. Nationales Referenzzentrum für Surveillance von nosokomialen Infektionen (NRZ). Infektionssurveillance im Modul ITS-KISS, Referenzdaten - Berechnungszeitraum: Januar 2017 bis Dezember 2020. *KISS Krankenhaus-Infektions-Surveillance-System* 2021.
7. Anderson RC, Worth HM, Harris PN et al. Vancomycin, a new antibiotic. IV. Pharmacologic and toxicologic studies. *Antibiotics annual* 1956: 75-81.
8. Rybak MJ, Rotschafer JC, Rodvold KA. Vancomycin: over 50 years later and still a work in progress. *Pharmacotherapy* 2013; **33**: 1253-5.
9. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2011; **52**: e18-55.
10. Moellering RC, Jr. Vancomycin: a 50-year reassessment. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2006; **42 Suppl 1**: S3-4.
11. Levine DP. Vancomycin: a history. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2006; **42 Suppl 1**: S5-12.
12. Buckman SA, Turnbull IR, Mazuski JE. Empiric Antibiotics for Sepsis. *Surgical infections* 2018; **19**: 147-54.
13. Rello J, Sole-Violan J, Sa-Borges M et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. *Critical care medicine* 2005; **33**: 1983-7.
14. Sandiumenge A, Diaz E, Bodí M et al. Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy". *Intensive care medicine* 2003; **29**: 876-83.
15. Rybak MJ, Le J, Lodise TP et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *American Journal of Health-System Pharmacy* 2020; **77**: 835-64.
16. Howden BP, Ward PB, Charles PG et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2004; **38**: 521-8.
17. Sakoulas G, Gold HS, Cohen RA et al. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. *The Journal of antimicrobial chemotherapy* 2006; **57**: 699-704.
18. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. *Critical care medicine* 2009; **37**: 840-51; quiz 59.

19. Moise-Broder PA, Forrest A, Birmingham MC et al. Pharmacodynamics of
vancomycin and other antimicrobials in patients with Staphylococcus aureus lower
respiratory tract infections. *Clinical pharmacokinetics* 2004; **43**: 925-42.
20. Roberts JA, Abdul-Aziz MH, Lipman J et al. Individualised antibiotic dosing for
patients who are critically ill: challenges and potential solutions. *The Lancet Infectious*
diseases 2014; **14**: 498-509.
21. Lodise TP, McKinnon PS, Swiderski L et al. Outcomes analysis of delayed antibiotic
treatment for hospital-acquired Staphylococcus aureus bacteremia. *Clinical infectious*
diseases : an official publication of the Infectious Diseases Society of America 2003; **36**:
1418-23.
22. Jamal JA, Roger C, Roberts JA. Understanding the impact of pathophysiological
alterations during critical illness on drug pharmacokinetics. *Anaesthesia, critical care & pain*
medicine 2018; **37**: 515-7.
23. Udy AA, Roberts JA, Lipman J. Clinical implications of antibiotic pharmacokinetic
principles in the critically ill. *Intensive care medicine* 2013; **39**: 2070-82.
24. Case J, Khan S, Khalid R et al. Epidemiology of acute kidney injury in the intensive
care unit. *Critical care research and practice* 2013; **2013**: 479730.
25. Koeze J, Keus F, Dieperink W et al. Incidence, timing and outcome of AKI in critically
ill patients varies with the definition used and the addition of urine output criteria. *BMC*
nephrology 2017; **18**: 70.
26. Clermont G, Acker CG, Angus DC et al. Renal failure in the ICU: comparison of the
impact of acute renal failure and end-stage renal disease on ICU outcomes. *Kidney*
international 2002; **62**: 986-96.
27. Hoste EA, Bagshaw SM, Bellomo R et al. Epidemiology of acute kidney injury in
critically ill patients: the multinational AKI-EPI study. *Intensive care medicine* 2015; **41**: 1411-
23.
28. Hsu SI. Biopsy-proved acute tubulointerstitial nephritis and toxic epidermal necrolysis
associated with vancomycin. *Pharmacotherapy* 2001; **21**: 1233-9.
29. Matthews Z. Vancomycin continuous infusion: a cohort of 23 intensive care unit
patients. *The Australian Journal of Hospital Pharmacy* 2001; **31**: 108-10.
30. Belen C, Budhiraja P, Bracamonte E et al. Biopsy-proven acute tubular necrosis
associated with vancomycin in an adult patient. *Renal failure* 2012; **34**: 502-5.
31. Rodvold KA, Blum RA, Fischer JH et al. Vancomycin pharmacokinetics in patients
with various degrees of renal function. *Antimicrob Agents Chemother* 1988; **32**: 848-52.
32. Rotschafer JC, Crossley K, Zaske DE et al. Pharmacokinetics of vancomycin:
observations in 28 patients and dosage recommendations. *Antimicrob Agents Chemother*
1982; **22**: 391-4.
33. Ocampos-Martinez E, Penaccini L, Scolletta S et al. Determinants of early inadequate
vancomycin concentrations during continuous infusion in septic patients. *Int J Antimicrob*
Agents 2012; **39**: 332-7.
34. Hanrahan T, Whitehouse T, Lipman J et al. Vancomycin-associated nephrotoxicity: A
meta-analysis of administration by continuous versus intermittent infusion. *Int J Antimicrob*
Agents 2015; **46**: 249-53.
35. Hao JJ, Chen H, Zhou JX. Continuous versus intermittent infusion of vancomycin in
adult patients: A systematic review and meta-analysis. *Int J Antimicrob Agents* 2016; **47**: 28-
35.
36. Cataldo MA, Tacconelli E, Grilli E et al. Continuous versus intermittent infusion of
vancomycin for the treatment of Gram-positive infections: systematic review and meta-
analysis. *The Journal of antimicrobial chemotherapy* 2012; **67**: 17-24.
37. Chu Y, Luo Y, Quan X et al. Intermittent vs. continuous vancomycin infusion for gram-
positive infections: A systematic review and meta-analysis. *Journal of infection and public*
health 2020; **13**: 591-7.
38. Flannery AH, Bissell BD, Bastin MT et al. Continuous Versus Intermittent Infusion of
Vancomycin and the Risk of Acute Kidney Injury in Critically Ill Adults: A Systematic Review
and Meta-Analysis. *Critical care medicine* 2020; **48**: 912-8.

39.   Hong LT, Goolsby TA, Sherman DS et al. Continuous infusion vs intermittent
vancomycin in neurosurgical intensive care unit patients. *Journal of critical care* 2015; **30**:
1153.e1-6.
40.   Tafelski S, Nachtigall I, Troeger U et al. Observational clinical study on the effects of
different dosing regimens on vancomycin target levels in critically ill patients: Continuous
versus intermittent application. *Journal of infection and public health* 2015; **8**: 355-63.
41.   Schlobohm CJ, Zhu E, Duby JJ. Continuous infusion versus intermittent infusion
vancomycin in a burn center intensive care unit. *Burns : journal of the International Society*
for Burn Injuries 2021; **47**: 1495-501.
42.   Yamada CH, Telles JP, Oliveira DDS et al. Comparison of intermittent versus
continuous-infusion vancomycin for treating severe patients in intensive care units. *The*
Brazilian journal of infectious diseases : an official publication of the Brazilian Society of
Infectious Diseases 2020; **24**: 356-9.
43.   Bissell BD, Riggi G, Morrison C. Evaluation of Continuous Infusion Vancomycin
Administration in a Critically Ill Trauma Population. *Journal of intensive care medicine* 2020;
35: 570-5.
44.   Duszynska W, Taccone FS, Hurkacz M et al. Continuous vs. intermittent vancomycin
therapy for Gram-positive infections not caused by methicillin-resistant Staphylococcus
aureus. *Minerva anestesiologica* 2016; **82**: 284-93.
45.   Lin H, Bukovskaya Y, De Moya M et al. Vancomycin continuous infusion versus
intermittent infusion during continuous venovenous hemofiltration: slow and steady may win
the race. *Annals of intensive care* 2015; **5**: 10.
46.   Hutschala D, Kinstner C, Skhirdladze K et al. Influence of vancomycin on renal
function in critically ill patients after cardiac surgery: continuous versus intermittent infusion.
Anesthesiology 2009; **111**: 356-65.
47.   Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of
vancomycin in severe Staphylococcal infections: prospective multicenter randomized study.
Antimicrob Agents Chemother 2001; **45**: 2460-7.
48.   Lin H, Levine A, Newman K et al. 681: Evaluation of a vancomycin nomogram with a
continuous infusion of vancomycin for ICU patients. *Critical care medicine* 2018; **46**: 327-.
49.   James JK, Palmer SM, Levine DP et al. Comparison of conventional dosing versus
continuous-infusion vancomycin therapy for patients with suspected or documented gram-
positive infections. *Antimicrob Agents Chemother* 1996; **40**: 696-700.
50.   Rybak MJ, Lomaestro BM, Rotschafer JC et al. Therapeutic monitoring of vancomycin
in adults summary of consensus recommendations from the American Society of Health-
System Pharmacists, the Infectious Diseases Society of America, and the Society of
Infectious Diseases Pharmacists. *Pharmacotherapy* 2009; **29**: 1275-9.
51.   Rybak MJ, Le J, Lodise TP et al. Validity of 2020 vancomycin consensus
recommendations and further guidance for practical application. *American journal of health-*
system pharmacy : AJHP : official journal of the American Society of Health-System
Pharmacists 2021; **78**: 1364-7.
52.   Ma NH, Walker SAN, Elligsen M et al. Retrospective multicentre matched cohort
study comparing safety and efficacy outcomes of intermittent-infusion versus continuous-
infusion vancomycin. *The Journal of antimicrobial chemotherapy* 2020; **75**: 1038-46.
53.   Eldemiry EM, Sabry NA, Abbassi MM et al. A specially tailored vancomycin
continuous infusion regimen for renally impaired critically ill patients. *SAGE open medicine*
2013; **1**: 2050312113507921.
54.   van de Vijsel LM, Walker SA, Walker SE et al. Initial vancomycin dosing
recommendations for critically ill patients undergoing continuous venovenous hemodialysis.
The Canadian journal of hospital pharmacy 2010; **63**: 196-206.
55.   van den Heever T. Therapeutic drug monitoring for continuous infusion of vancomycin
in critically ill patients. *Dissertation, Department Critical Care University of the Free State,*
Universitas and Pelonomi Hospital, Bloemfontein, Free State 2011.
56.   Sin JH, Newman K, Elshaboury RH et al. Prospective evaluation of a continuous
infusion vancomycin dosing nomogram in critically ill patients undergoing continuous
venovenous haemofiltration. *The Journal of antimicrobial chemotherapy* 2018; **73**: 199-203.

57.   Lin H, Yeh DD, Levine AR. Daily vancomycin dose requirements as a continuous infusion in obese versus non-obese SICU patients. *Critical care (London, England)* 2016; **20**: 205.

58.   Spadaro S, Berselli A, Fogagnolo A et al. Evaluation of a protocol for vancomycin administration in critically patients with and without kidney dysfunction. *BMC anesthesiology* 2015; **15**: 95.

59.   Saugel B, Nowack MC, Hapfelmeier A et al. Continuous intravenous administration of vancomycin in medical intensive care unit patients. *Journal of critical care* 2013; **28**: 9-13.

60.   Schmelzer TM, Christmas AB, Norton HJ et al. Vancomycin intermittent dosing versus continuous infusion for treatment of ventilator-associated pneumonia in trauma patients. *The American surgeon* 2013; **79**: 1185-90.

61.   Spapen HD, Janssen van Doorn K, Diltoer M et al. Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients. *Annals of intensive care* 2011; **1**: 26.

62.   Stepan M, Chytra I, Pelnar P et al. Continuous infusion versus intermittent administration of vancomycin in critically ill patients with Gram-positive infections resistant to beta-lactam antibiotics. *Anesteziologie a intenzivni medicina* 2009; **20**: 309-16.

63.   Perin N, Roger C, Marin G et al. Vancomycin Serum Concentration after 48 h of Administration: A 3-Years Survey in an Intensive Care Unit. *Antibiotics (Basel, Switzerland)* 2020; **9**.

64.   Akers KS, Cota JM, Chung KK et al. Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal replacement therapy. *Journal of burn care & research : official publication of the American Burn Association* 2012; **33**: e254-62.

65.   Vázquez M, Fagiolino P, Boronat A et al. Therapeutic drug monitoring of vancomycin in severe sepsis and septic shock. *International journal of clinical pharmacology and therapeutics* 2008; **46**: 140-5.

66.   Lacave G, Caille V, Bruneel F et al. Incidence and risk factors of acute kidney injury associated with continuous intravenous high-dose vancomycin in critically ill patients: A retrospective cohort study. *Medicine* 2017; **96**: e6023.

67.   Cristallini S, Hites M, Kabtouri H et al. New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients. *Antimicrob Agents Chemother* 2016; **60**: 4750-6.

68.   Baptista JP, Roberts JA, Sousa E et al. Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogram. *Critical care (London, England)* 2014; **18**: 654.

69.   Saugel B, Gramm C, Wagner JY et al. Evaluation of a dosing regimen for continuous vancomycin infusion in critically ill patients: an observational study in intensive care unit patients. *Journal of critical care* 2014; **29**: 351-5.

70.   Beumier M, Roberts JA, Kabtouri H et al. A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. *The Journal of antimicrobial chemotherapy* 2013; **68**: 2859-65.

71.   Cianferoni S, Devigili A, Ocampos-Martinez E et al. Development of acute kidney injury during continuous infusion of vancomycin in septic patients. *Infection* 2013; **41**: 811-20.

72.   Udy AA, Covajes C, Taccone FS et al. Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients? *Int J Antimicrob Agents* 2013; **41**: 564-8.

73.   Covajes C, Scolletta S, Penaccini L et al. Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy. *Int J Antimicrob Agents* 2013; **41**: 261-6.

74.   Albanèse J, Léone M, Bruguerolle B et al. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. *Antimicrob Agents Chemother* 2000; **44**: 1356-8.

75.   Omuro PK, Chackupurakal R, Fetz K et al. Impact of continuous vs. intermittent vancomycin treatment on kidney function of critically ill patients. *Anästhesiologie und Intensivmedizin* 2021; **62**: 375-84.

76. Carricajo A, Forgeot A, Morel J et al. [Dosage adjustment of vancomycin in
continuous infusion in critically ill-patients]. *Annales francaises d'anesthesie et de*
reanimation 2010; **29**: 55-7.
77. Di Filippo A, De Gaudio AR, Novelli A et al. Continuous infusion of vancomycin in
methicillin-resistant staphylococcus infection. *Chemotherapy* 1998; **44**: 63-8.
78. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews
and meta-analyses: the PRISMA statement. *Journal of clinical epidemiology* 2009; **62**: 1006-
12.
79. Wells GA, Wells G, Shea B et al. The Newcastle-Ottawa Scale (NOS) for Assessing
the Quality of Nonrandomised Studies in Meta-Analyses.
80. Zeng X, Zhang Y, Kwong JS et al. The methodological quality assessment tools for
preclinical and clinical studies, systematic review and meta-analysis, and clinical practice
guideline: a systematic review. *Journal of evidence-based medicine* 2015; **8**: 2-10.
81. Sterne JAC, Savović J, Page MJ et al. RoB 2: a revised tool for assessing risk of bias
in randomised trials. *Bmj* 2019; **366**: l4898.
82. Ryan R, Hill S, Prictor M et al. Cochrane Consumers and Communication group
Study Quality Guide (CCCG).
https://opal.latrobe.edu.au/articles/journal_contribution/Study_Quality_guide/6818903
(09.05.2022.
83. Wan X, Wang W, Liu J et al. Estimating the sample mean and standard deviation
from the sample size, median, range and/or interquartile range. *BMC medical research*
methodology 2014; **14**: 135.
84. Altman DG, Bland JM. How to obtain the P value from a confidence interval. *Bmj*
2011; **343**: d2304.
85. Mohammedi I, Descloux E, Argaud L et al. Loading dose of vancomycin in critically ill
patients: 15 mg/kg is a better choice than 500 mg. *Int J Antimicrob Agents* 2006; **27**: 259-62.
86. Tuon FF, Yamada CH, Cieslinski J et al. Cerebrospinal Fluid Penetration of
Vancomycin During Continuous Infusion Therapy in Patients With Nosocomial Ventriculitis.
Therapeutic drug monitoring 2021; **43**: 807-11.
87. Hanrahan TP, Harlow G, Hutchinson J et al. Vancomycin-associated nephrotoxicity in
the critically ill: a retrospective multivariate regression analysis*. *Critical care medicine* 2014;
42: 2527-36.
88. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine.
Nephron 1976; **16**: 31-41.
89. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular
filtration rate. *Annals of internal medicine* 2009; **150**: 604-12.
90. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular
filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal
Disease Study Group. *Annals of internal medicine* 1999; **130**: 461-70.
91. ACCP/SCCM. American College of Chest Physicians/Society of Critical Care
Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for
the use of innovative therapies in sepsis. *Critical care medicine* 1992; **20**: 864-74.
92. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS
International Sepsis Definitions Conference. *Critical care medicine* 2003; **31**: 1250-6.
93. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and
guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus
Conference Committee. American College of Chest Physicians/Society of Critical Care
Medicine. *Chest* 1992; **101**: 1644-55.
94. Singer M, Deutschman CS, Seymour CW et al. The Third International Consensus
Definitions for Sepsis and Septic Shock (Sepsis-3). *Jama* 2016; **315**: 801-10.
95. Saran R, Robinson B, Abbott K et al. US Renal Data System 2019 Annual Data
Report: epidemiology of kidney disease in the United States. *Am J Kidney Dis* 2020; **75**:
suppl 1.
96. Gawronski KM, Goff DA, Brown J et al. A stewardship program's retrospective
evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with

methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. *Clin Ther* 2013; **35**: 772-9.

97.   Kullar R, Davis SL, Levine DP et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2011; **52**: 975-81.

98.   Wang Y, Dai N, Wei W et al. Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older. *Clinical interventions in aging* 2021; **16**: 1023-35.

99.   Jager NGL, van Hest RM, Lipman J et al. Antibiotic exposure at the site of infection: principles and assessment of tissue penetration. *Expert review of clinical pharmacology* 2019; **12**: 623-34.

100.   Tsutsuura M, Moriyama H, Kojima N et al. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing. *BMC infectious diseases* 2021; **21**: 153.

101.   Ingram PR, Lye DC, Tambyah PA et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. *The Journal of antimicrobial chemotherapy* 2008; **62**: 168-71.

102.   Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Critical care (London, England)* 2007; **11**: R31.

103.   Eknoyan G, Lameire N, Eckardt K et al. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Official Journal of the International Society of Nephrology* 2012; **2**.

104.   Jeffres MN. The Whole Price of Vancomycin: Toxicities, Troughs, and Time. *Drugs* 2017; **77**: 1143-54.

105.   Minejima E, Choi J, Beringer P et al. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. *Antimicrob Agents Chemother* 2011; **55**: 3278-83.

106.   Carreno J, Smiraglia T, Hunter C et al. Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy. *Int J Antimicrob Agents* 2018; **52**: 643-50.

107.   Teng CB, Rezai K, Itokazu GS et al. Continuation of high-dose vancomycin despite nephrotoxicity. *Antimicrob Agents Chemother* 2012; **56**: 3470-1; author reply 2.

108.   Carreno JJ, Kenney RM, Divine G et al. Randomized Controlled Trial to Determine the Efficacy of Early Switch From Vancomycin to Vancomycin Alternatives as a Strategy to Prevent Nephrotoxicity in Patients With Multiple Risk Factors for Adverse Renal Outcomes (STOP-NT). *The Annals of pharmacotherapy* 2017; **51**: 185-93.

109.   Mehta RL, Awdishu L, Davenport A et al. Phenotype standardization for drug-induced kidney disease. *Kidney international* 2015; **88**: 226-34.

110.   Ampe E, Delaere B, Hecq JD et al. Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects. *Int J Antimicrob Agents* 2013; **41**: 439-46.

111.   Summerfield SG, Yates JWT, Fairman DA. Free Drug Theory - No Longer Just a Hypothesis? *Pharmaceutical research* 2022; **39**: 213-22.

112.   Tsuji BT, Leonard SN, Rhomberg PR et al. Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum. *Diagnostic microbiology and infectious disease* 2008; **60**: 441-4.

113.   Ackerman BH, Taylor EH, Olsen KM et al. Vancomycin serum protein binding determination by ultrafiltration. *Drug Intell Clin Pharm* 1988; **22**: 300-3.

114.   De Cock PA, Desmet S, De Jaeger A et al. Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board? *The Journal of antimicrobial chemotherapy* 2017; **72**: 801-4.

115.   Kees MG, Wicha SG, Seefeld A et al. Unbound fraction of vancomycin in intensive care unit patients. *Journal of clinical pharmacology* 2014; **54**: 318-23.

116.   Berthoin K, Ampe E, Tulkens PM et al. Correlation between free and total vancomycin
serum concentrations in patients treated for Gram-positive infections. *Int J Antimicrob Agents*
2009; **34**: 555-60.
117.   Bellomo R, Ronco C, Kellum JA et al. Acute renal failure - definition, outcome
measures, animal models, fluid therapy and information technology needs: the Second
International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.
Critical care (London, England) 2004; **8**: R204-12.
118.   Ricard JD, Wolff M, Lacherade JC et al. Levels of vancomycin in cerebrospinal fluid of
adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a
prospective multicenter observational study. *Clinical infectious diseases : an official
publication of the Infectious Diseases Society of America* 2007; **44**: 250-5.
119.   Tiede C, Chiriac U, Dubinski D et al. Cerebrospinal Fluid Concentrations of
Meropenem and Vancomycin in Ventriculitis Patients Obtained by TDM-Guided Continuous
Infusion. *Antibiotics (Basel, Switzerland)* 2021; **10**.
120.   Wysocki M, Thomas F, Wolff MA et al. Comparison of continuous with discontinuous
intravenous infusion of vancomycin in severe MRSA infections. *The Journal of antimicrobial
chemotherapy* 1995; **35**: 352-4.
121.   Roberts JA, Taccone FS, Udy AA et al. Vancomycin dosing in critically ill patients:
robust methods for improved continuous-infusion regimens. *Antimicrob Agents Chemother*
2011; **55**: 2704-9.
122.   Pea F, Viale P, Cojutti P et al. Dosing nomograms for attaining optimum
concentrations of meropenem by continuous infusion in critically ill patients with severe
gram-negative   infections: a   pharmacokinetics/pharmacodynamics-based   approach.
Antimicrob Agents Chemother 2012; **56**: 6343-8.
123.   Minichmayr IK, Roberts JA, Frey OR et al. Development of a dosing nomogram for
continuous-infusion meropenem in critically ill patients based on a validated population
pharmacokinetic model. *The Journal of antimicrobial chemotherapy* 2018; **73**: 1330-9.
124.   Smith CR, Lipsky JJ, Laskin OL et al. Double-blind comparison of the nephrotoxicity
and auditory toxicity of gentamicin and tobramycin. *The New England journal of medicine*
1980; **302**: 1106-9.

1351